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Breast cancer is the most frequently diagnosed cancer in women, with over 1 million 
new cases in the world each year. Recently, in addition to genetic mutations, 
numerous studies have found that epigenetics plays a direct role in the etiology of 
breast cancer. The PADIs are a family of epigenetic enzymes that catalyze 
citrullination, with previous work in our lab showing that PADIs can convert both 
protein and histone arginine to citrulline, leading to the disruption of protein-protein 
interactions, as well as direct transcriptional downregulation. Previous research has 
suggested a potential oncogenic role for PADI2 in breast cancer, though no formal 
analysis existed. The studies herein investigate the potential role of PADI2 as a novel 
oncogene and therapeutic target in the treatment of breast cancer in vitro and in vivo.  
First, using an in vitro model of breast cancer progression (MCF10AT), we 
show that PADI2 is upregulated upon the malignant transformation of cells, especially 
in MCF10DCIS cells, which recapitulate the highly invasive comedo-like ductal 
carcinoma in situ (DCIS) tumors seen in humans. Secondly, using RNA-seq, we show 
that PADI2 is highly correlated with HER2/ERBB2 overexpression across 57 breast 
cancer cell lines. We concluded this study by validating the use of our first-generation 
PADI inhibitor, Cl-amidine, as a therapeutic agent for the treatment of breast cancer 
both in vitro and in vivo.  
Following this, we further investigated the functional relationship between 
PADI2 and HER2 expression. Interestingly, PADI2 appears to function both upstream 
 and downstream of HER2, potentially indicating a role in an oncogenic positive-
feedback loop with HER2. Previous evidence from our lab established that PADI2 
functions as an ER co-activator via the citrullination of histone H3 arginine 26 
(H3R26) at ER-target gene promoters. We show here that PADI2 can bind to the 
HER2 promoter and downstream ERE; thus, suggesting that the epigenetic regulation 
of HER2 gene expression by PADI2 occurs via similar mechanisms to ER-target 
genes. Moreover, we were able to validate our highly potent next-generation PADI 
inhibitor, BB-Cl-amidine, in the treatment of breast cancer cells in vitro.  
Lastly, using a mouse model of PADI2 overexpression (MMTV-FLAG-
PADI2), we found that 20% of mice developed skin lesions after five months. These 
tumors express high levels of transgenic human PADI2 and display markers of 
increased inflammation and invasiveness-EMT. Furthermore, a subset of these tumors 
showed via histopathological analysis to have undergone malignant progression to 
highly invasive squamous cell carcinomas.  
Collectively, these studies provide functional and mechanistic evidence 
establishing PADI2 as a potential novel oncogene and target for cancer therapy.
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CHAPTER ONE 
INTRODUCTION 
  
2 
 
1.1 Breast cancer 
1.1.1 Origin of breast cancer molecular subtypes 
In the United States, around 25% of all deaths are due to cancer 
1
, which translates to 
~600,000 deaths per year. Among women, breast cancer is the most commonly 
diagnosed cancer (~29%), and is second only to lung and bronchial cancers for cancer-
related deaths (~14%) 
1
. While there has been a decrease in overall breast cancer 
incidence, largely due to enhanced screening and awareness, breast cancer is still the 
leading cause of death among women ages 20-59 
1
. There are many risk factors 
associated with the development of breast cancer, including, but not limited to: genetic 
predisposition (e.g. BRCA1 and BRCA2 
2, 3
), high mammary tissue density, early 
menarche, late menopause, age at first pregnancy, parity, breast-feeding, and many 
additional environmental risk factors 
4
. Interestingly, some of these risk factors have 
recently been linked to the intrinsic breast cancer subtypes, with the majority of 
traditional breast cancer risk factors associated with luminal A tumors, the most 
common subtype 
5
. In addition, weight gain (i.e. increased mammary tissue density) is 
more strongly associated with luminal B tumors, age at menopause was significantly 
associated with the human epidermal growth factor receptor-2 (HER2)-type, and 
hormonal treatment (estrogen + progestin) is strongly associated with basal-like 
tumors 
4
. Interestingly, increased parity was found to be associated with a reduced risk 
of luminal A tumors; however, there was an increased risk of more malignant basal-
like tumors 
5, 6
. While early detection and targeted therapies have greatly reduced the 
incidence of mortality, the prognosis for women with locally advanced and metastatic 
breast cancer remains poor. Until recently, the predominant method of determining 
breast cancer prognosis has been via histological type, tumor grade, and lymph node 
involvement. Breast cancer is a highly heterogeneous disease, and while these 
histological parameters might be clinically useful, they offer little insight into the 
3 
 
molecular mechanisms behind this pathological diversity. Over the past decade, with 
improved sequencing and other genomics-based technologies, several groups have 
worked toward the molecular classification of breast cancer subtypes 
7, 8
. Perou et al. 
first used microarray-based analysis of invasive breast tumors to define a list of ~500 
“intrinsic genes”, whose expression varied in the tumors from different patients 7. 
Following up that study,  Sorlie et al. further refined this gene expression pattern, 
indicating the existence of four molecular “intrinsic” subtypes of breast cancer 
(Luminal A, Luminal B, HER2-enriched, and Basal-like), establishing a molecular 
foundation for the distinct tumor subtypes.  These four core “intrinsic” subtypes, in 
addition to the more recently identified Claudin-low and Normal breast-like groups, 
have repeatedly been observed across different studies 
9
, including recent data from 
the full genome and exome sequencing of primary breast tumors 
10
. These studies have 
also translated to the clinic, as multiple prognostic gene signature tests are currently in 
use to predict the likelihood of relapse, including the 70-gene prognostic gene 
signature (MammaPrint), the Oncotype DX, and the Genomic Grade Index 
11-15
. 
Remarkably, the different gene expression profiles correlate well with patient survival, 
with luminal A tumors having the most favorable prognosis, followed by luminal B 
tumors, while patients with HER2-positive and basal-like subtypes have the shortest 
survival time (Table 1.1). The ability to identify a patient’s tumor subtype greatly 
increases the chance of successful treatment using targeted therapies for those breast 
cancers. Unfortunately, the use of gene-expression profiling is not as widespread in 
clinical settings as it should be; however, in an effort to correlate clinical parameters 
with gene-expression driven subtypes, five immunohistochemical (IHC) makers have 
been used as surrogates to define the different subtypes: estrogen receptor alpha 
(ESR1 or ER), progesterone receptor (PR), human epidermal growth factor receptor-2 
(HER2 or ERBB2), cytokeratin 5/6 (CK5/6) and epidermal growth factor receptor  
4 
 
Table 1.1: Prevalence of breast cancer subtypes and current targeted therapies 
(% statistics from Susan G. Komen)  
Subtype  
ER/HER2 
Status  
Prevalence  Notes  Targeted Therapies  
Luminal A 
ER+ and 
HER2-  
42-59% 
Most common 
and best 
prognosis 
Tamoxifen (SERMs), 
SERDs, AIs  
Luminal B 
ER+ and 
HER2+ 
6-19% 
Slightly worse 
prognosis 
Tamoxifen (SERMs), 
SERDs, AIs, and anti-
HER2 mAb inhibition 
(e.g. Herceptin)  
HER2-
enriched  
ER- and 
HER2+ 
14-20% 
Often poor 
prognosis 
Anti-HER2 (Herceptin, 
Lapatinib) 
Basal-
like/Triple-
negative 
ER- and 
HER2-  
7-12% 
Often 
aggressive, 
worst prognosis  
EGFR inhibitors 
(Cetuximab), PARP or 
MEK inhibitors  
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(EGFR) 
16
. These IHC marker defined phenotypes have been shown to be associated 
with clinical characteristics similar to those seen in gene expression defined subtypes. 
In addition, these IHC markers are able to identify distinct biological characteristics 
associated with the differences between short and long-term outcomes 
17-19
. Recently, 
the PAM50 breast cancer subtype test has shown concordance with these standard 
clinical molecular markers, more specifically, with ER and HER2. In the absence of 
gene expression profiling, these two clinical markers have shown high agreement 
between protein biomarker scoring via IHC and gene expression 
20
. This current 
attempt to compare and incorporate new genomic assays with old and new molecular 
markers, especially with regard to patient treatment and/or selection for clinical trials, 
remains highly challenging; however, consensus recommendations have recently been 
made regarding the incorporation of these parameters in the management of breast 
cancer therapy 
21
. 
 
1.1.2 Luminal-like breast cancer subtype 
The luminal-like breast cancer subtype(s) have an expression pattern reminiscent of 
normal epithelial cells of the mammary gland and account for nearly 70% of all breast 
cancers 
22
. In particular, these cancers are estrogen receptor (ER) and progesterone 
receptor (PR)-positive, and often have higher expression of genes associated with ER 
signaling. The luminal-like subtype (Table 1.1) can be further divided into luminal A, 
which is usually low-grade and has the best prognosis, and luminal B, which is 
commonly of higher histological grade, more proliferative, and has a significantly 
worse prognosis 
8
. Furthermore, in addition to being ER- and PR- positive, the luminal 
B tumors have been shown in several studies to be HER2-positive 
17-19, 23, 24
. The most 
common target of therapy for luminal breast cancers is the estrogen receptor, which 
belongs to the steroid hormone receptor family (reviewed in Xu et al. 
25
), which also 
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includes retinoic acid, vitamin D, and the thyroid hormone receptor. While there are 
two ER genes, ERα and ERβ, each with its own tissue distribution 26, ERα has been 
shown to act as an oncogene in the mammary gland, while ERβ may act as a tumor 
suppressor and regulator of ERα activity 27. For the purposes of this work, I will only 
refer to ERα, herein called ER. ER signaling is required for the development of many 
tissues; however, there has been much work establishing a role for ER in the 
mammary gland development 
28
. Interestingly, mammary glands from genetically 
modified mice harboring a deletion of ER (ERKO) do not undergo ductal 
morphogenesis or alveolar development. This disrupted signaling results in reduced 
estrogen-responsive gene products in the mammary gland, in addition to reduced 
mammotropic hormones, both of which contribute to the ERKO mammary phenotype 
29-31
. ER functions as a ligand-activated transcription factor, and exists as a monomer 
when not ligand-bound. As a monomer, ER associates with co-repressor heat shock 
proteins (HSPs) such as Nuclear Receptor Co-Repressor (NCoR), Histone Deacetylase 
(HDAC) and Metastasis Associated Antigen-1 (MTA-1) 
32
. The endogenous ligand for 
ER is 17β-estradiol (E2), a cholesterol derivative under the control of the 
hypothalamic-pituitary-gonadal endocrine axis 
33
. Upon ligand binding, ER undergoes 
a conformation change, which allows the release of co-repressors and the recruitment 
of co-activators like Steroid Receptor Co-activator-1 (SRC1), Amplified in Breast 
Cancer (AIB1), or p300 and CBP-Associated Factor (PCAF) 
32
. The activation of ER 
leads to receptor dimerization, enabling importation into the nucleus where it is able to 
bind specific DNA sequences or estrogen response elements (ERE) in the promoters 
of target genes leading to the increase in gene expression of ER-target genes (Figure 
1.1). ER rarely binds to chromatin directly, and the loading of ER onto the promoter 
regions requires the presence of pioneer factors, such as the Forkhead Box Protein A1, 
(FOXA1). ER target genes subsequently regulate many cellular processes including  
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Figure 1.1: The ERBB2/HER2 and estrogen receptor signaling pathways in 
breast cancer signaling. The ERBB or HER family consists of four closely related 
type 1 transmembrane tyrosine kinase receptors: EGFR, also known as ERBB1, 
ERBB2 (also known as HER2), ERBB3, and ERBB4. The role of ERBB4 in cancer is 
not clear, therefore not represented here. HER2 is an orphan receptor; however, it is 
the preferred heterodimer partner. Ligand binding leads to the dimerization of ERBB 
proteins and trans- or auto-phosphorylation at tyrosine residues, which can then serve 
as docking sites for adaptor molecules. Two key signaling pathways are the MAPK 
pathway, which stimulates proliferation, and the PI3K-AKT pathway, which promotes 
tumor cell survival. The estrogen receptor, upon binding of estrogen, dimerizes and is 
transported to the nucleus, where it can bind directly to the ERE and drive 
transcription of target genes, or bind to transcription factors at the promoter (e.g. AP1, 
SP1, NFκB).  
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proliferation, cell cycle, invasion and metastasis (angiogenesis) 
34-38
. These activated 
ER complexes have also been shown to act as co-activators of other transcription 
factors via protein-protein interactions, including Fos/Jun and AP-1 (activator protein-
1) or SP-1(specificity protein-1), and Nuclear factor-κB (NFκB), thus affecting the 
transcription of genes that do not harbor EREs by indirect DNA binding 
39-42
. This 
non-classical transcriptional regulation accounts for almost 1/3
rd
 of the genes regulated 
by ER 
32
. The estrogen receptor also possesses the capacity for rapid (seconds to 
minutes after E2 stimulus) signaling via extranuclear mechanisms that are independent 
of its transcriptional activity 
43
.  For example, the rapid activation of components 
downstream of Growth Factor Receptors or Receptor Tyrosine Kinases (RTK), such 
as Insulin-like Growth Factor-1 Receptor (IGF1R), EGFR, and HER2, is thought to 
occur by ligand-dependent activation of membrane-bound ER 
44, 45
. Membrane-bound 
ER can regulate the expression of various components of growth factor signaling 
cascades via activation of MAPK and PI3K 
43
. On the other hand, growth factor 
signaling via the same pathways (IGF1R, EGFR, and HER2) can activate ER and 
promote transcription of ER target genes in a ligand-independent manner 
46-51
. This 
signaling is thought to occur via activation of downstream genes that ultimately leads 
to the phosphorylation and activation of ER 
48
. This cross-talk between ER and growth 
factor signaling has implications for resistance to hormone therapy, as this signaling 
increases ER co-activator expression, ultimately resulting in tamoxifen-induced ER 
transcription activity 
52
.  
There are currently three classes of drugs used to target estrogen signaling: (1) 
selective estrogen receptor modulators (SERMs), (2) selective estrogen receptor 
downregulators (SERDs), and (3) aromatase inhibitors (AIs). Tamoxifen and 
raloxifene are two of the most commonly prescribed SERMs, and tamoxifen has 
proven effective in treating most luminal subtype breast cancers. In addition, studies 
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have shown that SERMs, such as tamoxifen and raloxifene, may also be beneficial in 
long-term preventative treatment of patients with increased breast cancer risk factors 
53
. SERMs function antagonistically by binding to ER and preventing estrogen 
binding, while also holding ER in an inactive conformation, thereby preventing the 
recruitment of co-activators and inhibiting ER-mediated transcription 
54
. Moreover, 
tamoxifen bound ER actually mimics ER-bound to co-repressor complexes 
55
. There is 
some thought that SERMs might have tissue-specific pharmacology, due to the cell-
type specific profile of ER co-regulators 
56
. The second class of ER antagonists used to 
treat luminal-like cancers, SERDs, acts by binding ER and preventing receptor 
dimerization, thereby inhibiting DNA binding. In addition, SERDs, such as fulvestrant 
(ICI 182,780; Faslodex), also act by inducing down-regulation of ER via receptor 
degradation 
57
. More recently, aromatase inhibitors (AIs), such as letrozole, inhibit the 
enzyme aromatase, which catalyzes the conversion of testosterone to estradiol. 
Letrozole has been shown to be more effective in treating luminal-like cancers than 
Tamoxifen, and has been approved for the treatment of ER-positive breast cancers in 
post-menopausal women 
58-60
. 
Tamoxifen is currently the most widely used therapy for luminal-like breast 
cancers, and has been recommended for ER-positive breast cancers in high-risk pre- 
and post-menopausal women, in addition to treatment for metastatic luminal-like 
cancers 
61
. Interestingly, while tamoxifen is normally an antagonist to ER in the 
mammary gland, it has been found to be agonistic in other tissues (e.g. endometrium 
of the uterus), and its use is associated with a 2-fold increase in the rates of uterine 
cancer 
61, 62
. Furthermore, many women do not respond to tamoxifen treatment due to 
de novo resistance, and many more eventually relapse due to acquired resistance. One 
of the most commonly documented mechanisms of resistance is overexpression of 
growth factor receptors, particularly EGFR and HER2 
50, 51, 63
. In addition, the 
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expression of co-activator proteins, such as SRC1, AIB1, and Polyomavirus Enhancer 
Activator-3 (PEA3), have been shown to correlate with endocrine resistance in breast 
cancer 
64
. Particularly, the AIB1 gene has been shown to be critical in the development 
of tamoxifen resistance via ER/HER2 cross-talk 
50, 65
, and the role of AIB1 in breast 
cancer has been reviewed extensively elsewhere 
66
. MCF7 breast cancer cells (ER+ 
luminal A) overexpressing HER2 (MCF-7/HER2-18 
67
) that were treated with 
tamoxifen showed cross-phosphorylation and activation of ER and EGFR/HER2 
receptors. This was coincident with the phosphorylation and activation of the signaling 
molecules AKT and MAPK, as well as AIB1. Shou et al. have shown that tamoxifen 
treated MCF7/HER2-18 cells recruit co-activator complexes (ER, AIB1, CBP, p300) 
to the canonical ER-regulated gene, pS2, or Trefoil Factor-1 (TFF1). Conversely, 
tamoxifen treatment recruited co-repressor complexes to the control MCF7 cells that 
were not overexpressing HER2. Interestingly, Shou et al. were able to reverse the 
activating effects of tamoxifen by treating the cells first with Gefitinib, an EGFR 
inhibitor. This result has been repeated, albeit more effectively, using lapatinib, a dual 
EGFR/HER2 inhibitor 
68
.  Hurtado et al. have elucidated the mechanism behind this 
tamoxifen resistance, showing AIB1 outcompetes PAX2 for binding to a novel ERE in 
intron 4 of HER2/ERBB2, directly resulting in increased HER2 expression via 
chromatin looping back onto the HER2 promoter 
65
. This cooperative action of 
different growth factor receptors, especially EGFR/HER2, and other intracellular 
signaling pathways (e.g. AIB1) in the luminal-like breast cancer subtype, especially 
endocrine resistance cells, suggests that targeting multiple pathways along with the ER 
might be a more effective treatment.  Currently, there are multiple trials testing the 
efficacy of both HER2 and EGFR inhibitors along with tamoxifen, though this 
demonstrates the need for further research towards the discovery of novel genes 
involved in ER and EGFR/HER2 signaling and cross-talk. 
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1.1.3 HER2/ERBB2-amplified breast cancer subtype 
The HER2 gene, also known as Erythroblastic Leukemia Viral Oncogene Homolog-2 
(ERBB2), is a member of the EGFR/HER family of tyrosine kinases. This family 
consists of four members, commonly referred to as EGFR (HER1, or ERBB1), HER2 
(ERBB2, HER2/neu), HER3 (ERBB3), and HER4 (ERBB4). HER4 is the only gene 
that has not been clearly linked to cancer pathogenesis, though recent work has 
implicated a role for HER4 as a tumor suppressor 
69
. The EGFR/HER family proteins 
are type I transmembrane growth factor receptors that function to activate intracellular 
signaling pathways in response to extracellular signals. These membrane-spanning 
receptors consist of an extracellular ligand-binding domain, a transmembrane domain, 
and an intracellular tyrosine kinase domain (Figure 1.1). Unlike other members of the 
EGFR/HER family, HER2 is an orphan receptor, in that it lacks the capacity to bind a 
ligand. However, HER2 is the preferred dimerization partner, as it has the strongest 
catalytic kinase activity, and HER2-containing dimers have the strongest signaling 
functions 
70, 71
. This increased kinase activity has been attributed to the fact that HER2 
constitutively maintains an active conformation, normally achieved upon ligand 
binding in other family members 
72, 73
. In addition, heterodimers containing HER2 are 
characterized by slow rates of ligand dissociation and slow receptor endocytosis 
70, 74
. 
Conversely, HER3 lacks a functional kinase domain and is catalytically inactive 
75
. 
Interestingly, although individually both HER2 and HER3 are incomplete signaling 
molecules, HER2/HER3 dimers form the most active signaling heterodimer of the 
family, and are essential for many biological and developmental processes, in addition 
to being implicated in many breast cancers 
76
. EGFR/HER2 dimers are also important 
in mammary tumorigenesis, conferring both proliferative and invasive functions via 
prolonged activation of downstream mitogen-activated protein kinase (MAPK) 
signaling 
77
. While EGFR/HER2 dimers signal through the MAPK pathway, the 
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HER2/HER3 dimers primarily signal downstream via the phosphatidylinositol 3-
kinase (PI3K)-AKT pathway. HER2 lacks binding sites for the p85 subunit of PI3K; 
however, HER3 contains seven p85-docking sites 
78
. HER2 tumors have been shown 
to require both alleles of AKT1 for increased proliferation and migration 
79
, and mutant 
PIK3CA accelerates HER2-driven transgenic mammary tumors, while also inducing 
resistance to combination anti-HER2 therapies 
80
. The PI3K-AKT pathway has been 
shown to regulate cell growth and proliferation, survival, and translation via the 
proliferation gene cyclin D1, nuclear receptor co-activators SRC1 and AIB1, and 
transcription factors such as NFκB, PEA3, and COX2. There are a large number of 
genes downstream of HER2 signaling, including, but not limited to, JAB1 
81, 82
, PEA3 
83, 84
, FOXAI 
85
, FOXMI 
86, 87
, and GRB7 
88
. HER2 has also been found to signal often 
in positive feedback loops, including genes such as ADAM12 
89
, ERα36 90, BEX2 91, 
MED1 
92
, and the inflammatory gene, IL6 
93
. These signaling loops enhance the 
oncogenic signaling of HER2 and drive tumorigenesis, and in the case of MED1, 
tamoxifen resistance.  
 HER2 protein overexpression or gene amplification (17q12 amplicon) 
accounts for approximately 25-30% of all breast carcinomas 
94
. Tumors that are of the 
HER2 subtype are associated with poor prognostic factors, including highly 
proliferative and large tumors, higher grade, and nodal involvement 
17, 18
. In addition 
to very aggressive clinical characteristics, these HER2-positive tumors have also been 
shown to have a high rate of recurrence 
8
. While the majority of HER2-positive tumors 
are hormone receptor negative, some are ER-positive and usually cluster with the 
luminal B subtype. While amplification of the HER2 region is the most common cause 
of HER2 overexpression, there are many tumors still described by the HER2-positive 
subtype with no apparent gene amplification 
95
. This is most likely due to the large 
number of downstream targets of HER2 that can be upregulated upon increased HER2 
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protein expression, even in the absence of amplification; thus, driving signaling that is 
the signature of HER2-amplified breast cancers. Current therapeutic options for 
HER2-positive breast cancers include standard cytotoxic chemotherapy, combined 
with trastuzumab (Herceptin), a monoclonal antibody that binds to the extracellular 
domain of HER2. Trastuzumab has led to the improvement of patient outcome, 
including overall survival, especially in the adjuvant treatment of metastatic breast 
cancer 
96
. However, despite these great achievements, greater than 60% of HER2-
positive tumors do not respond to trastuzumab monotherapy, with initial responders 
developing resistance within 1 year 
94, 97
. The currently defined methods of 
trastuzumab resistance include: (1) the inability of trastuzumab to bind the 
constitutively active truncated form of HER2 receptor that is found in up to 60% of 
HER2-positive tumors, as well as the masking of the HER2 epitope by Mucin-4 
(MUC4) 
98
 or CD44/hyaluronan complexes 
99
; (2) alternative signaling through the 
insulin-like growth factor-1 receptor (IGFR1) 
100
; (3) upregulation of downstream 
signaling pathways, like SRC 
101, 102
 and/or AKT 
103
; (4) increase in the number of 
EGFR/HER3 heterodimers 
104
, and other receptors including c-Met and β-integrins 105; 
and (5) failure to trigger immune-mediate responses 
106
. Despite these problems, since 
the introduction of HER2-targeted therapy via trastuzumab, the prognostic 
stratification of breast cancer subtypes has shifted towards luminal B tumors having a 
decreased risk of recurrence when compared with luminal A tumors 
107
. This study has 
also shown that the luminal B tumors, which are ER+/HER2+, have a better response 
to trastuzumab than HER2-positive subtype (HER2+/ER-) tumors. This is most likely 
due to the different pathways involved in the signaling, as luminal B tumors are more 
likely to signal through the PI3K/AKT pathway, while HER2+/ER- tumors through 
EGFR/RAS/MAPK pathway, though more research is needed in this area to elucidate 
these differences. As previously mentioned, HER2 overexpression plays a key role in 
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the development of tamoxifen resistance, so those patients receiving treatment for both 
HER2 and ER might be predicted to have a greater response to therapy. For those 
HER2+/ER- tumors, lapatinib has been used with success more recently. O’Brien et 
al. have shown that while PI3K/AKT signaling in HER2+/ER- cell lines can confer 
resistance to trastuzumab, the cell lines were highly sensitive to lapatinib treatment 
108
. 
Overall, trastuzumab has been shown to reduce the risk of recurrence in patients by 
52%, and the risk of death by 33%, when compared to chemotherapy alone
109
. While 
trastuzumab is still the most widely used therapy for treating HER-positive breast 
cancers, there remains an incomplete understanding of the mechanisms behind the 
resistance to this drug. This has highlighted the pressing need to discover and validate 
novel targets of HER2-positive breast tumors, so that additional treatments may be 
used in combination with, or in the place of, trastuzumab as adjuvant therapy to 
cancers of the HER2-subtype. 
 
1.1.4 Basal-like breast cancer subtype 
Basal-like tumors, which account for 15-25% of all breast cancers, are a group of ER-
negative tumors named after their morphological and genetic relationship to normal 
basal/myoepithelial cells of the mammary gland. Tumors with the basal-like 
phenotype were initially described using IHC for cytokeratins (CK), as these tumors 
showed increased expression of CK5, 14, and 17, normally found in the basal cells of 
the mammary gland 
110
. While the majority of basal-like tumors are triple negative, in 
that they lack expression of ER, PR, and HER2, the two are not synonymous. In 
addition to being hormone receptor-negative, basal-like tumors are further described 
by the positive expression of EGFR and CK5/6 
17
. Despite a well-defined subtype that 
has been validated through microarray experiments 
7, 8
, and more recently through 
sequencing 
10
, the basal-like tumors tend to be rather heterogeneous. In addition, these 
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breast cancers have distinctive clinical presentations, varied histological features, and 
different responses and outcomes to chemotherapy 
8, 17, 111, 112
. Basal-like breast 
cancers are more likely to affect younger women (<50 years of age), and are more 
prevalent in African-American women 
113, 114
. Tumors of this subtype are usually high 
grade, more likely to metastasize, and have a higher risk of recurrence and death 
within five years of diagnosis 
115
. This aggressive clinical manifestation is evidenced 
by the pattern of metastases, as the primary tumor often spreads to the brain and lungs, 
making treatment much more difficult and worsening the prognosis 
116
. Unfortunately, 
due to the lack of druggable targets (e.g. ER and HER2), patients with basal-like 
tumors are often just treated with surgery and standard chemotherapy regimens. This 
absence of targeted therapies has increased the need for the identification of genes 
involved in the propagation of tumors of this subtype. Many different molecular 
pathways are implicated in aggressive basal-like cancers, with the hallmark of these 
tumors being an increase in genetic instability. These cancers frequently have DNA 
gains and losses, suggesting defective DNA repair pathways 
117
. There are currently a 
number of subtype specific markers being investigated, including EGFR, caveolin-1 
and -2, p-cadherin, osteonectin, and αβ-crystallin118-122. More recently, the sequencing 
of basal-like tumors has revealed a similarity of these cancers with high-grade serous 
ovarian tumors, including mutations in the tumor protein-53 (TP53 or p53), 
retinoblastoma protein-1 (RB1 or pRb), and both BRCA1 and BRCA2 (breast cancer 1 
and 2, early onset) 
10
. The loss of BRCA1 is highly associated with the risk of 
developing basal-like breast cancers, though these mutations are relatively rare in the 
general population (less than 1%). However, a woman carrying a BRCA1 inactivating 
mutation is estimated to have a ~65% increased risk of developing breast cancer by 
age 70, and ~30-40% risk for developing ovarian cancer 
123
. The BRCA1 gene acts as a 
tumor suppressor, and the loss of BRCA1 leads to increased chromosome instability; 
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ultimately, leading to the accumulation of additional deleterious mutations, often 
including p53 and pRb. These three genes are involved in the cell cycle and DNA 
damage response pathways; therefore, mutations in all three is mostly likely 
responsible for the high proliferation rates of basal-like tumors. For this reason, 
patients with this subset of basal-like tumors are often a good candidate for the newly 
developed poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors. 
PARP is a mediator of single strand DNA (ssDNA) break repair, and the inhibition of 
PARP results in the accumulation of ssDNA, which upon replication, is converted to 
double-strand breaks that are normally repaired by BRCA1. These double-strand 
breaks accumulate in the rapidly dividing cells and ultimately lead to cell death. While 
the outlook of PARP inhibitors sound promising, the two most advanced compounds 
in clinical trials, iniparib and olaparib, unfortunately did not make it past phase III and 
phase II respectively 
124
. Other drugs that are currently in pre-clinical and clinical 
testing for basal-like tumors include sunitinib malate, a multiple receptor tyrosine 
kinase (RTK) inhibitor (including targeting of PDGF and VEGF)
125
, and dasatinib, a 
c-Src inhibitor 
126, 127
. The relative paucity of agents currently being tested for basal-
like breast cancers only highlights the need for continued research towards the 
identification of novel therapeutic targets for these highly aggressive tumors. 
 
1.1.5 MCF10AT model of basal breast cancer progression 
The study of human breast cancer etiology is hampered by the lack of reproducible 
models that mimic the morphological events believed to be indicative of proliferative 
disease. The MCF10AT xenograft model of human breast cancer was developed in an 
attempt to meet this need (Figure 1.2) 
128-132
. The human cell line MCF10A originated 
from the spontaneous immortalization of non-malignant breast epithelium. 
Transfection with mutated T24 H-Ras allowed MCF10A to acquire the ability for  
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Figure 1.2: The MCF10AT model of basal breast cancer progression. Normal 
immortalized MCF10A cells were transformed with mutated T24 H-Ras (hRas), 
thereby acquiring the ability for xenograft growth in nude (nu/nu) mice. Pre-malignant 
lesions from xenografted MCF10AT cells were serially passaged in nude mice, 
leading to the isolation of further lesions that demonstrate a complex mix of 
morphological types and grades that recapitulate the morphological characteristics of 
the progression of human proliferative breast disease, including comedo-DCIS 
(MCF10DCIS) and invasive cancer (MCF10CA1a). 
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xenograft growth in immunodeficient (nude) mice. Serial passage of the H-Ras 
oncogene in transfected cells (MCF10AT) produces lesions in nude mice that 
demonstrate a complex of morphological types and grades that recapitulate the 
morphological characteristics of human proliferative breast disease, as well as, in a 
minority of mice, ductal carcinoma in situ or DCIS (MCF10DCIS.com), and invasive 
cancer (MCF10CA1a). Cell lines from this model encompass the entire range of 
human breast cancer progression, from benign normal tissue, to malignant/metastatic 
tumors. The majority of breast cancer originates as ductal hyperplasia, which 
eventually progresses to DCIS. The MCF10DCIS.com cell line, herein referred to as 
MCF10DCIS, has captured this stage of breast cancer progression, which is currently 
being diagnosed with high frequency. Furthermore, it represents the high-grade 
comedo-type DCIS, which is associated with a relatively high risk for subsequent 
development of invasive cancer 
133
. Comedo DCIS lesions are populated by larger and 
more pleomorphic neoplastic cells, with clinical histology featuring the presence of 
intraluminal necrosis. Comedo DCIS lesions often demonstrate microinvasion 
134
, 
higher proliferation 
135
, and are more frequently HER2-positive compared to non-
comedo lesions 
136
.  Therefore, the MCF10DCIS cell line might be the most 
appropriate target for chemoprevention regimens. The MCF10AT model, by the 
criteria of hormone receptor negativity and lack of amplification of the HER2 locus, as 
well as by clustering of the parental MCF10A cell line with the basal-like subtype by 
transcriptional profiling, most closely models the development of basal-like human 
breast cancers with very poor prognosis 
137
. This isogenic model of breast cancer is 
unique, in that it offers the opportunity to discover novel genes responsible for the 
progression of breast cancer. Furthermore, it allows for the investigation of these 
genes at specific stages during cancer development, in addition to testing and 
validating inhibitors to those genes, both in vitro and in vivo. 
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1.2 Peptidylarginine deiminase (PADI) enzyme family 
1.2.1 Background of the PADI family of enzymes 
The peptidylarginine deiminases (PADIs) are a family of calcium dependent post-
translational modification enzymes that convert positively charged arginine residues to 
neutral citrulline residues on target proteins 
138
 . This activity is termed citrullination 
(Figure 1.3a) or deimination, and has been shown to have wide-ranging effects on 
target protein structure, function, and protein-protein interactions (Figure 1.3b) 
139-142
. 
Furthermore, in addition to converting histone arginine residues to citrulline, PADI 
enzymes can also convert histone methylarginine to citrulline via "demethylimination" 
143
, leading to chromatin decondensation (Figure 1.4), which when occurring at gene 
promoters, can lead to an increase in gene expression 
144-146
. The PADI family consists 
of five well-conserved members (~55% amino acid identity in humans), each differing 
in its pattern of substrate specificity and tissue distribution.  Although there is some 
overlap, each PADI isozyme appears to target a unique set of cellular proteins. In 
particular, both PADI2 and PADI4 show expression in the mammary gland 
147
 and are 
regulated by estrogen in vivo 
148
. The PADIs are all arranged within a highly organized 
gene cluster on human chromosome 1p36.13 and on the orthologous region of mouse 
chromosome 4E1. Interestingly, the 1p36 region is often mutated and deleted in 
multiple cancers and likely contains novel tumor suppressor genes 
139-142
, suggesting 
that PADI genes and citrullination may play a role in tumorigenesis. Recently, the 
citrullination of proteins has been linked to a variety of human diseases 
149
 (Table 
1.2), including rheumatoid arthritis (RA) 
142, 150, Alzheimer’s disease (AD) 140, 151, 152, 
multiple sclerosis (MS) 
141, 153-156
, ulcerative colitis 
157
, psoriasis 
158
, chronic 
obstructive pulmonary disease (COPD) 
159
, lupus 
160
, glaucoma 
161, 162
, age-related 
macular degeneration (AMD) 
163
, and cancer (reviewed in Mohanan et al. 
164
).  
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Figure 1.3: The enzymatic activity of peptidylarginine deiminase (PADI) 
isozymes. (a) The different PADI isozymes catalyze the conversion of positively 
charged protein arginine residues to neutral citrulline in a process called deimination, 
or citrullination. (b) The change in charge of proteins can lead to conformational 
changes or loss of protein-protein interactions. (Figure obtained from Horibata et al., 
Jour. Repro. & Dev., 2012 
148
)   
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Figure 1.4: PADI-mediated histone tail citrullination leads to chromatin 
decondensation. PADI recruitment to target promoters by the relevant transcription 
factor is followed by deimination of N-terminal histone tails at specific residues, 
leading to a more open or “relaxed” chromatin architecture. This can have pronounced 
effects on gene expression of the target gene. (Figure obtained from Mohanan et al., 
Bio. Res. Int., 2012 
164
) 
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1.2.2 Peptidylarginine deiminase-1 (PADI1) 
PADI1 and PADI3 have been primarily characterized in the epidermis (basal to 
granular layer); with PADI3 being found to deiminate trichohyalin in hair follicles 
165, 
166
 and PADI1 deiminating keratin (K1 and K10) and filaggrin during epidermal 
differentiation 
167, 168
. It is thought that the deimination of keratin and filaggrin in the 
epidermis induces changes in the spatial organization of keratin intermediate filaments 
during keratinocyte maturation 
158
. This modification is important for maintaining the 
barrier function of superficial keratinized epidermal cell layers 
169-172
. The 
overexpression of PADI1 (potentially along with PADI2 and PADI3), which leads to 
abnormal levels of citrullinated keratin K1, has been reported in areas of the epidermis 
of psoriatic patients 
173
. In addition, the loss of PADI1 has been implicated in the 
development of Oral squamous cell carcinoma (OSCC), which is associated with 
substantial mortality and morbidity, with PADI1 being identified as a biomarker for 
the early detection of invasive OSCC. Gene expression analysis found expression of 
PADI1 to be downregulated in both dysplasia and OSCC, when compared with 
controls 
174
. The deimination of protein arginine residues in the keratinocytes of oral 
mucosa by PADI1 forms an epidermal barrier; therefore, the down-regulation of 
PADI1 may allow the growth, expansion, and movement of tumor cells. 
   
1.2.3 Peptidylarginine deiminase-2 (PADI2) 
PADI2, the ancestral isozyme of the PADI family, is widely distributed and is highly 
expressed in both muscle 
175, 176
 and brain 
152, 172
, and is often associated with the 
deimination of myelin basic protein (MBP) and vimentin 
177, 178
. The citrullination of 
MBP by PADI2 plays a key role in the pathogenesis of neurodegenerative disease, 
including MS 
153, 177
, while the citrullination of vimentin has been implicated in the 
development of AD
151, 152
. In addition, PADI2-mediated citrullination of the 
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intermediate filament vimentin in macrophages results in cytoskeletal disintegration 
and eventually apoptosis 
179
. PADI2 is implicated in various inflammatory diseases, 
such as RA and COPD
159
, and recent work has shown that PADI2 was linked to 
cytokine signaling during the immune-inflammatory response. For example, PADI2 
can citrullinate IKKγ in macrophages, leading to the suppression of NFκB activity 180. 
Additionally, PADI2 mediated citrullination of CXCL8 is also associated with 
modulation of the inflammatory response 
181
. In macrophages, both in vitro and in 
vivo, PADI2 has been shown to catalyze histone H4 arginine 3 (H4R3) 
hypercitrullination, and the formation of extracellular traps (ETs). Specifically, these 
macrophage ETs (METs) were also seen in “crown-like structures” (CLSs), which are 
infiltrating macrophages found in the adipose tissue of mammary glands from obese 
patients. CLSs are associated with increased levels of inflammatory mediators, and 
Mohanan et al. have shown that increased PADI2 driven METs in CLSs plays a key 
role in promoting inflammatory signaling 
182
. PADI2 is also abundantly expressed in 
the epithelium of the mammary gland, uterine endometrium, and in the pituitary gland 
183, 184
. Previous investigators have found that PADI2 expression and citrullination in 
reproductive tissues is strongly linked to the estrous cycle, with both expression and 
enzymatic activity reaching their peak during the secretory phase of the cycle 
148, 183-
185
. While PADI2 has historically been defined as a cytoplasmic protein, recent 
evidence from our lab shows that PADI2 can localize to the nucleus, as well as 
directly bind chromatin to influence target gene expression 
146, 186, 187
. In the canine 
mammary gland, estrous cycle regulated PADI2 expression in epithelial tissue 
correlates with citrulline levels, potentially indicating a role in gene expression. 
Recent evidence from our lab supports this prediction, as Zhang et al. have shown that 
PADI2 catalyzed citrullination of histone H3 arginine 26 (H3R26) facilitates ER target 
gene activation 
146
.  
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1.2.4 Peptidylarginine deiminase-3 (PADI3) 
PADI3 has been implicated in pancreatic cancer, with gene expression analysis of the 
highly metastatic human pancreatic cancer cell line (L3.6pl) showing PADI3 to be the 
most significant gene upregulated 
188
. Furthermore, analysis of PADI3 led to the 
identification of a PAD Intergenic Enhancer (PIE), an evolutionary conserved non-
coding segment located 86-kb from the PADI3 promoter. The PIE is a strong enhancer 
of the PADI3 promoter in Ca2+ differentiated epidermal keratinocytes, and requires 
bound Activator Protein-1 (AP-1) factors, namely c-Jun and c-Fos 
189
. The AP-1 
complex has a central role in multiple processes involved in tumorigenesis, including 
proliferation, migration, invasion and metastasis. The long-range control of PADI3 
expression via AP-1 implicates a potential role of deimination during tumorigenesis. 
As previously mentioned, PADI3 (potentially along with PADI1 and PADI2) driven 
citrullination has been reported to be found in the epidermis of psoriatic patients 
173
. 
 
1.2.5 Peptidylarginine deiminase-4 (PADI4) 
PADI4 was originally found to be expressed during retinoic acid-induced HL-60 
granulocyte differentiation and was originally thought to be the only PADI that 
localizes to the cell nucleus, likely via its distinct nuclear localization signal 
190
. 
Hagiwara et al., (2002) found that activation of HL-60 granulocytes induced extensive 
protein citrullination that was mainly limited to the histones H2A, H3, H4, and 
nucleophosmin. Regarding the role of PADI4 in gene regulation, a number of reports 
have validated our original finding that PADI4 regulates gene activity and can act as a 
transcriptional co-repressor. For example, Cuthbert et al., 
191
 found that PADI4 targets 
the endogenous VEGF-A promoter and represses hormone-mediated gene induction, 
while Balint et al., demonstrated that PADI4 attenuated retinoid-regulated gene 
expression 
192
. We have shown that in ER-positive MCF7 breast cancer cells, estrogen 
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stimulation enhances PADI4 binding and histone H4 citrullination at the canonical ER 
target gene TFF1, leading to transcriptional repression 
193
. More recently, Yanming 
Wang, a former postdoctoral fellow in the Coonrod lab, has published a series of 
studies elucidating the role of PADI4 in the regulation of p53 target gene expression 
145, 194-197
. More specifically, PADI4 serves as a p53 co-repressor to regulate histone 
arginine methylation at the p53-target gene p21/WAF1/CIP1 promoter 
195
. 
Furthermore, they show that histone arginine citrullination can coordinate with other 
histone modifications, HDAC2 in their case, to repress transcription 
194
. This work 
utilized the specific PADI inhibitor, Cl-amidine, to dissect the mechanisms of PADI4 
regulated gene expression. In addition, the combination of Cl-amidine with an HDAC 
inhibitor, suberoylanilide hydroxamic acid (SAHA), showed additive effects in 
inducing p21, GADD45, and PUMA expression, while inhibiting cancer cell growth in 
a p53-dependent manner. This important crosstalk between histone deacetylation and 
citrullination suggests that a combination of PADI4 and HDAC2 inhibitors serve as 
potential strategy for cancer treatment. Interestingly, a recent study found that 
citrullinated H4R3 (H4Cit3) levels are inversely correlated with p53 protein 
expression and with tumor size in non-small-cell lung carcinoma (NSCLC) tissues
197
, 
potentially indicating a tumor suppressor function for PADI4. Reinforcing the role for 
PADI4 as a tumor suppressor, recent results from our lab showed that the 
dysregulation of PADI4-mediated citrullination of nuclear GSK3β activates TGF-β 
signaling, thereby inducing epithelial-to-mesenchymal (EMT) transition in breast 
cancer cells. Conversely, our lab has recently shown using a genome-wide analysis of 
chromatin-bound PADI4 that PADI4 can function as a co-activator for a range of 
oncogenic transcription factors 
198
. Zhang et al. reported that the treatment of MCF7 
cells with EGF leads to PADI4-mediated citrullination of the ELK1 oncogene at the c-
Fos promoter. This PADI4-mediated citrullination facilitates the phosphorylation of 
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ELK1 by ERK1/2, which in turn, promotes the acetylation of histone H4 lysine 5 
(H4K5), leading to increased transcription of the immediate early c-Fos oncogene. In 
addition, recent evidence has shown that PADI4 is overexpressed in numerous 
malignant, but not benign tumor types 
139, 199, 200
. We have also shown that PADI4 
promotes hypercitrullination of histones (including H4R3, and H3R2, 8, 17, and 26) 
and global decondensation, which when occurring in neutrophils, leads to neutrophil 
ETs (NETs). Primarily, TNFα treated blood neutrophils resulted in the release of 
extracellular chromatin that was extensively citrullinated at H4R3. This extracellular 
chromatin has been shown to entrap and kill invading pathogens 
201-203
. Lastly, in 
addition to PADI4 functioning as a tumor suppressor and potential oncogene, the first 
PADI inhibitor, Cl-amidine (discussed in more detail later), was developed to treat 
disorders resulting from aberrant PADI4 expression. Interestingly, the treatment of 
several PADI4-expressing cancer cell lines with Cl-amidine elicited strong cytotoxic 
effects, while have no observable effect on non-cancerous lines, suggesting that 
PADIs may represent targets for new cancer therapies 
204
.  
 
1.2.6 Peptidylarginine deiminase-6 (PADI6) 
PADI6 is a maternal effect gene that is primarily expressed in oocytes and 
preimplantation embryos. We have shown using genetically modified mice (PADI6
-/-
) 
that PADI6 is essential for embryonic development beyond the 2-cell stage 
205
. 
Additionally, PADI6 localizes to poorly characterized cytoskeletal structures, termed 
cytoplasmic lattices, within oocytes and early embryos, and is required for lattice 
formation. Recent work from our lab has established that cytoplasmic lattices play a 
critical role in regulating microtubule-based activities during oocytes maturation and 
early development, as PADI6
-/- 
mice had defects in microtubule mediated organelle 
repositioning 
206, 207
. Interestingly, while this is the only isoform not specifically 
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implicated in having a potential role in cancer, a recent genome-wide association study 
(GWAS) in Icelanders shows a significant correlation between cutaneous basal cell 
carcinoma risk and mutations within the PADI4/PADI6 locus on chromosome 1p36 
208
. The role for PADI6 in reproductive and developmental biology has been 
extensively reviewed elsewhere 
148, 209, 210
 and will not be discussed further. 
 
1.2.7 PADI2 and potential links to cancer 
Given that there are several studies showing a link between PADI4 and cancer, and the 
high degree of similarity in both tissue expression and enzymatic activity (i.e. 
citrullination of mammary epithelium), we hypothesized that PADI2 might also play a 
role in cancer, specifically breast cancer. Interestingly, the first paper to report the 
cloning of full-length human PADI2 cDNA was by Ishigami et al., who found PADI2 
to be highly expressed in vitro in a skin cancer cell line, HSC-1, which is derived from 
a human cutaneous squamous carcinoma 
211. Using a zebrafish model of Ewing’s 
sarcoma (EWS-FLI1 fusion oncoprotein), Leacock et al. reported that PADI2 is one of 
six overlapping genes conserved between human and zebrafish EWS-FLI driven 
small-round-blue-cell tumor (SRBCT) tumors 
212
. Studies using mouse models of 
breast cancer have also shown a potential correlation between increased PADI2 levels 
and mammary tumors. Herschkowitz et al. identified PADI2 as one of 106 genes most 
commonly identified to be overexpressed between human and mouse mammary 
carcinomas 
213
. In addition, the MMTV-neu mouse model of HER2-positive breast 
cancer was shown to have elevated levels of PADI2 in both hyperplastic (~2-fold) and 
primary tumors (~4-fold) of the mammary gland, when compared to matched-normal 
mammary epithelium 
214
. In humans, PADI2 is one of the most upregulated genes in 
luminal subtype breast cancer cell lines compared to basal cell lines 
215, 216
. 
Additionally, gene expression profiling of 213 primary breast tumors with known 
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HER2/ERBB2 status identified PADI2 as one of 29 overexpressed genes in HER2-
positive tumors; thus, helping to define a HER2/ERBB2+ gene expression signature 
217
. Analyzing recent data from The Tumor Genome Atlas (TCGA) using the UCSC 
Cancer Genomics Browser, we see a correlation between PADI2 expression and 
tumors of the HER2-subtype; however, we also see that PADI2 is correlated with 
basal subtype tumors 
218
. Moreover, using the Memorial Sloan Kettering Cancer 
Center (MSKCC) cBio Cancer Genomics Portal, both basal and HER2 subtype tumors 
show decreased survival when PADI2 levels are increased 
219, 220
. These results are 
interesting, especially with regard to our recent data indicating a relationship between 
PADI2 and HER2 across the luminal subtype 
215, 216, 221
. However, these disparate 
results could potentially be attributed to differences in the tested samples, as well as 
experimental procedures, but there is no questioning that PADI2 expression correlates 
with mammary tumorigenesis. Recent genomics/proteomics based studies have shown 
PADI2 to be the fifth most correlated gene with breast cancer progression 
222
, a known 
interacting protein with the c-Myc oncogene 
223
, in addition to being one of the genes 
known to differentiate ER–positive and –negative tumors 224.  
These predictions and correlations between PADI2 and cancer have been 
supported by additional recent data from our laboratory. Comparative studies suggest 
that PADI2 nuclear expression in mammary carcinomas from human, canine, and 
feline, might be associated with tumor progression 
225
. Surprisingly, using canine 
mammary tumor cells (CMT25), Cherrington et al. have shown that EGF stimulation 
increases the transcription of PADI2, and subsequently the citrullination of histone H3 
arginine 2, 8, and 17. Furthermore, biochemical evidence in vitro shows definitively 
that PADI2 localizes to the nucleus of mammary epithelial cells, and that it associates 
with chromatin. Using truncation mutants, the motif responsible for nuclear 
localization was found to occur somewhere within the first 437 amino acids (aa) of the 
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PADI2 protein. Interestingly, the truncation of PADI2 from 665aa to 437aa, and then 
to 278aa, resulted in increasing proportions of PADI2 being targeted to the cell 
nucleus. Given that PADI2 does not contain a canonical nuclear localization signal 
(NLS), it is currently unclear how PADI2 gains entry to the nucleus. We hypothesize 
that PADI2 must contain a distinct nuclear directing motif or translocate to the nucleus 
via a protein-protein interaction with an additional NLS-containing protein. Both of 
these methods have been previously reported to occur in other proteins, such as ERKs, 
MEKs, and SMADs, which translocate to the nucleus via an NLS-independent 
mechanism 
226, 227
. In addition, protein-protein interactions, such as the one between 
tissue transglutaminase (tTG) and vascular endothelial growth factor receptor-2 
(VEGFR-2), facilitate nuclear importation upon stimulation 
228
. Having provided 
evidence that PADI2 can localize to the nucleus, associate with chromatin, and 
regulate gene expression, we wanted to expand our understanding of PADI2 target 
gene modulation in breast cancer. As previously mentioned, PADI2 is known to 
correlate with estrogen stimulation in vitro and in vivo, so we wanted to examine 
globally the role of PADI2 in breast cancer cells upon estrogen stimulation. Using 
estrogen receptor-positive MCF7 breast cancer cells, Zhang et al. have shown that 
PADI2 interacts with ER following estrogen treatment, thereby catalyzing the site-
specific citrullination of H3R26 (H3Cit26) at the promoters of nearly 200 ER target 
genes 
146
. The H3Cit26 modification promotes the formation of a more 
relaxed/decondensed chromatin architecture around the target promoters; thus, 
facilitating ER target gene activation. This work was followed by an examination of 
the role for PADI2 during breast cancer progression, using the previously mentioned 
MCF10AT model (see Chapter 2). PADI2 levels were highest in the transformed, 
HER2-positive, cell lines of the MCF10AT model, especially in the comedo-DCIS 
cells (MCF10DCIS). HER2-positive tumors account for about 25–30% of invasive 
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ductal carcinomas of the breast and have a significantly poorer outcome, increased risk 
of recurrent disease, and shorter overall survival 
94
. In ductal carcinoma in situ (DCIS) 
tumors, the incidence of HER2 overexpression/amplification is ≥ 60% 136, 229, 230, 
whereas benign and atypical breast lesions generally do not show any evidence of 
HER2 overexpression 
231
. Given the high incidence of HER2 alterations in high-grade 
DCIS associated with comedo necrosis, HER2 overexpression, and potentially PADI2 
overexpression, may confer a growth advantage to DCIS under ischemic conditions. 
We also examined the transcriptomic relationship between PADI2 and HER2 across a 
large number of breast cancer cell lines using RNA-seq, and reported that PADI2 and 
HER2 were highly correlated across the luminal subtype. Furthermore, we showed that 
PADI2 was one of the top genes correlating with HER2 expression in breast cancer 
cells 
221
.  This work suggests a functional relationship between these genes, which we 
now believe to occur via the same epigenetic mechanism as that seen in ER target 
genes. We ended this study by reporting the first successful use of our first-generation 
PADI inhibitor, Cl-amidine, to treat cancer cells both in vitro and in vivo. Specifically, 
Cl-amidine was able to significantly reduce the proliferation of breast cancer cells in 
2D- and 3D- culture, as well as reduce the size of xenografted MCF10DCIS tumors, 
most likely via S-phase induced apoptosis and cell cycle arrest 
221
.  
 
1.2.8 Peptidylarginine deiminase-inhibitors  
Due to increasing evidence that the PADI family is involved in multiple diseases, 
including cancer, PADI inhibitors have generated substantial research interest in 
recent years. Most work in this field has focused on creating inhibitors for PADI4, 
which is dysregulated in rheumatoid arthritis 
232, 233
. To date, Cl-amidine is the most 
potent PADI inhibitor and uses a chloroacetamidine warhead in place of the arginine 
substrate guanidinium group (Figure 1.5). This molecule irreversibly inhibits PADI  
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Figure 1.5: Chemical structure of both of the currently used small molecule pan-
PADI inhibitors, first-generation Cl-amidine, and next-generation BB-Cl-
amidine. The next-generation PADI inhibitor, BB-CLA, is more potent than its 
predecessor, Cl-amidine. This effect is likely due to the increased cellular permeability 
of the compound, which has increased hydrophobicity over Cl-amidine. 
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enzyme activity, is bioavailable, and preferentially targets the active form of these 
enzymes 
232, 233
. In addition to our recent report on the treatment of MCF10DCIS cells 
in vitro and in vivo, previous research has shown Cl-amidine to be effective in 
decreasing the growth of several cancer cell lines (e.g. HL-60, HT-29, U2OS, and 
MCF7 cells). We also have unpublished data (see Chapter 3) showing that Cl-
amidine (and BB-Cl-amidine) is effective at treating additional breast cancer cell lines, 
including BT-474, SKBR3, and MDA-MB-231cells. When administered in 
combination with other cancer drugs, such as doxorubicin or the HDAC inhibitor 
suberoylanilide hydroxamic acid (SAHA), Cl-amidine has a synergistic cytotoxic 
effect on cancer growth 
195, 234-236
. Cl-amidine is highly specific for all PADI enzymes, 
with dose-dependent cytotoxicity and little-to-no effect in non-cancerous cell lines 
(i.e. HL-60 granulocytes and NIH3T3 cells) 
236
. While we found that Cl-amidine 
suppressed tumor growth in vivo, the drug was well tolerated in our mice at a dose of 
50 mg/kg/day during the study. Similarly, previous work found that doses of Cl-
amidine up to 75 mg/kg/day in a mouse model of colitis 
157
, and up to100 mg/kg/day 
in a mouse model of RA 
237
, were well-tolerated without side effects. Our work using 
PADI inhibitors to target cancer in vivo was also validated by Wang et al., using a Cl-
amidine derivative with increased cell permeability, YW3-56, which significantly 
suppressed cancer cell growth and reduced tumor size in mouse xenograft models of 
sarcoma 
238
. This suggests that the development of new, more selective compounds, 
such as the second-generation PADI inhibitor, o-Cl-amidine, will help increase the 
effectiveness in future experiments 
239
. We have currently been employing the next-
generation PADI inhibitor, biphenyl-benzimidazole Cl-amidine (BB-Cl-amidine, 
Figure 1.5), which is ~3 fold more potent than Cl-amidine towards PADI2 in in vitro 
enzymatic assays, as well as over 100 fold more potent in decreasing cell growth in 
vitro in breast cancer cells (see Chapter 3). The increased potency of BB-Cl-amidine 
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over Cl-amidine is most likely due to its increased stability, in addition to increased 
cellular permeability, likely due to the higher hydrophobicity of the compound. While 
Cl-amidine (and more recently BB-Cl-amidine) has been important in numerous 
studies to help elucidate the role of PADIs in gene expression, the potential to develop 
this inhibitor into a novel epigenetic treatment of cancer, and specifically breast 
cancer, provides the impetus for our work. 
 
1.3 Statement of purpose 
Breast cancer is the most frequently diagnosed cancer in women, with over 1 million 
new cases in the world each year 
240
. Recently, in addition to genetic mutations, 
numerous studies have found that epigenetics plays a direct role in the etiology of 
breast cancer. To this end, the goal of my research was to outline the role of 
peptidylarginine deiminase-2 (PADI2) in the progression of breast cancer. The PADIs 
are a family of epigenetic enzymes that catalyze citrullination, with previous work in 
our lab showing that PADI4 can convert both protein and histone arginine to citrulline, 
leading to the disruption of protein-protein interactions, as well as direct 
transcriptional downregulation. While PADI4 is downregulated in multiple cancers, 
perhaps indicating a tumor suppressor role, previous studies suggested a potential 
oncogenic role for PADI2 in breast cancer. However, despite this evidence, a formal 
experimental analysis of this relationship had yet to exist. The studies herein outline 
the role of PADI2 as an oncogene, especially in the progression of breast cancer, both 
in vitro and in vivo, as well as the validation of PADI inhibitors as a novel therapeutic 
agent.  
In Chapter 2, we established a new line of evidence demonstrating that PADI2 
plays a role in the oncogenic progression of breast cancer using the basal-like 
MCF10AT model. Furthermore, we showed using RNA-seq, that PADI2 is highly 
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correlated with HER2/ERBB2 overexpression across 57 breast cancer cell lines. We 
concluded this study with the first preclinical evidence showing that the PADI 
inhibitor, Cl-amidine, could be utilized as a therapeutic agent for the treatment of 
tumors in vivo. Following this, we wanted to investigate the functional relationship 
between PADI2 and HER2 expression. Interestingly, PADI2 appears to function in a 
positive-feedback loop with HER2, as PADI2 expression is both up- and downstream 
of HER2 signaling (Chapter 3). While we have previously established a role for 
PADI2 as an ER co-activator via citrullination of H3R26 at target gene promoters, it 
appears that PADI2 regulation of HER2 expression may occur in the same fashion at 
both the HER2 promoter and downstream ERE. Moreover, we established that the 
next-generation PADI inhibitor, BB-Cl-amidine, is nearly 100X more potent than 
first-generation Cl-amidine in reducing the growth of cancer cells. Lastly, we wanted 
to examine the potential role of ectopically expressed human PADI2 in the 
development of carcinomas in mice (Chapter 4). Surprisingly, while the MMTV-
FLAG-PADI2 mice did not develop any mammary tumors, we discovered that 20% of 
the mice developed skin lesions after five months. These tumors expressed high levels 
of transgenic human PADI2 and displayed markers of increased invasiveness (i.e. 
EMT). Furthermore, a subset of these tumors showed via histopathological analysis to 
have undergone malignant progression to highly invasive squamous cell carcinomas. 
Collectively, these studies provide functional and mechanistic evidence 
establishing PADI2 as a potential novel oncogene and target for cancer therapy. 
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2.1 Summary 
Introduction:  
We have recently reported that the expression of peptidylarginine deiminase 2 
(PADI2) is regulated by EGF in mammary cancer cells and appears to play a role in 
the proliferation of normal mammary epithelium; however, the role of PADI2 in the 
pathogenesis of human breast cancer has yet to be investigated. Thus, the goals of this 
study were to examine whether PADI2 plays a role in mammary tumor progression, 
and whether the inhibition of PADI activity has anti-tumor effects.  
 
Methods: 
RNA-seq data from a collection of 57 breast cancer cell lines was queried for PADI2 
levels, and correlations with known subtype and HER2/ERBB2 status were evaluated. 
To examine PADI2 expression levels during breast cancer progression, the cell lines 
from the MCF10AT model were used.  The efficacy of the PADI inhibitor, Cl-
amidine, was tested in vitro using MCF10DCIS cells grown in 2D-monolayers and 
3D-spheroids, and in vivo using MCF10DCIS tumor xenografts. Treated MCF10DCIS 
cells were examined by flow-cytometry to determine the extent of apoptosis and by 
RT
2
 Profiler PCR Cell Cycle Array to detect alterations in cell cycle associated genes. 
 
Results: 
We show by RNA-seq that PADI2 mRNA expression is highly correlated with 
HER2/ERBB2 (p = 2.2x10
-6
) in luminal breast cancer cell lines. Using the MCF10AT 
model of breast cancer progression, we then demonstrate that PADI2 expression 
increases during the transition of normal mammary epithelium to fully malignant 
breast carcinomas, with a strong peak of PADI2 expression and activity being 
observed in the MCF10DCIS cell line, which models human comedo-DCIS lesions. 
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Next, we show that a PADI inhibitor, Cl-amidine, strongly suppresses the growth of 
MCF10DCIS monolayers and tumor spheroids in culture. We then carried out 
preclinical studies in nude (nu/nu) mice and found that Cl-amidine also suppressed the 
growth of xenografted MCF10DCIS tumors by more than 3-fold. Lastly, we 
performed cell cycle array analysis of Cl-amidine treated and control MCF10DCIS 
cells, and found that the PADI inhibitor strongly affects the expression of several cell 
cycle genes implicated in tumor progression, including p21, GADD45α, and Ki67.  
 
Conclusion: 
Together, these results suggest that PADI2 may function as an important new 
biomarker for HER2/ERBB2+ tumors and that Cl-amidine represents a new candidate 
for breast cancer therapy. 
 
Key words: Peptidylarginine deiminase, PAD2/PADI2, HER2/ERBB2, Breast 
Cancer, Luminal, Cl-amidine, Citrullination 
  
61 
 
2.2 Introduction 
PADIs are a family of posttranslational modification enzymes that convert positively 
charged arginine residues on substrate proteins to neutrally charged citrulline, and this 
activity is alternatively called citrullination or deimination. The PADI enzyme family 
is thought to have arisen by gene duplication and localizes within the genome to a 
highly organized cluster at 1p36.13 in humans. At the protein level, each of the five 
well-conserved PADI members shows a relatively distinct pattern of substrate 
specificity and tissue distribution 
1, 2
. Increasingly, the dysregulation of PADI activity 
is associated with a range of diseases, including rheumatoid arthritis (RA), multiple 
sclerosis, ulcerative colitis, neural degeneration, COPD, and cancer 
3-5
. While the 
presumptive function of PADI activity in most diseases is linked to inflammation, the 
role that PADIs play in cancer progression is not clear. We and others, however, have 
found that PADI4 appears to play a role in gene regulation in cancer cells via histone 
tail citrullination. For example, in MCF7 breast cancer cells estrogen stimulation 
enhances PADI4 binding and histone H4 citrullination at the canonical ER target gene, 
TFF1, leading to transcriptional repression 
6
. On the other hand, stimulation of MCF7 
cells with EGF facilitates activation of c-fos via PADI4-mediated citrullination of the 
ELK1 oncogene 
7
. Additionally, others have shown that citrullination of the p53 tumor 
suppressor protein affects the expression of p53 target genes p21, OKL38, CIP1 and 
WAF1 
8-10
. Interestingly, treatment of several PADI4-expressing cancer cell lines with 
the PADI inhibitor, Cl-amidine, elicited strong cytotoxic effects while having no 
observable effect on non-cancerous lines 
11
, suggesting that PADIs may represent 
targets for new cancer therapies. 
Our current study suggests that PADI2 may also play a role in cancer 
progression, and this prediction is supported by several previous studies. For example, 
a mouse transcriptomics study investigating gene expression in MMTV-neu tumors 
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found that PADI2 expression was upregulated ~2-fold in hyperplastic, and ~4-fold in 
primary neu-tumors, when compared to matched normal mammary epithelium 
12
. In 
humans, PADI2 is one of the most upregulated genes in luminal breast cancer cell 
lines compared to basal lines 
13, 14
. Additionally, gene expression profiling of 213 
primary breast tumors with known HER2/ERBB2 status identified PADI2 as one of 29 
overexpressed genes in HER2/ERBB2+ tumors; thus, helping to define a 
HER2/ERBB2+ gene expression signature 
15
. Given these previous studies, our goal 
was to formally test the hypothesis that PADI2 plays a role in mammary tumor 
progression. For the study, we first documented PADI2 expression and activity during 
mammary tumor progression, and then investigated the effects of PADI inhibition in 
cell cultures, tumor spheroids, and preclinical in vivo models of breast cancer.  
 
2.3 Materials and Methods 
Cell culture and treatment with Cl-amidine 
The MCF10AT cell line series (MCF10A, MCF10AT1kC1.2, MCF10DCIS.com, and 
MCF10CA1aC1.1) was obtained from Dr. Fred Miller (Barbara Ann Karmanos 
Cancer Institute, Detroit, MI, USA). This biological system has been extensively 
reviewed 
16, 17
 and culture conditions described 
18-20
. The MCF7, BT-474, SK-BR-3, 
and MDA-MB-231 cell lines were from obtained from ATCC (Manassas, VA, USA) 
and cultured according to manufacturer’s directions. All cells were maintained in a 
humidified atmosphere of 5% CO2 at 37
o
 C. For the experimental treatment of cell 
lines with Cl-amidine, cells were seeded in 6-well plates (2 x 10
4
) and collected by 
trypsinization 5d post-treatment. Counts were performed using a Coulter counter 
(Beckman Coulter, Fullerton, CA, USA) and are represented as mean fold difference 
in cell number after treatment. Cl-amidine was synthesized as previously described 
21
. 
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MMTV mice and the generation of MCF10DCIS xenografts and multicellular tumor 
spheroids 
Tissues from the MMTV-neu mouse were a generous gift from Dr. Robert S. Weiss, 
Cornell University, and the MMTV-Wnt-1 hyperplastic mammary glands and tumors 
were a gift of Dr. Louise R. Howe, Weill Cornell Medical College. MCF10DCIS 
xenograft tumors were generated by injecting 1 x 10
6
 cells in 0.1 mL Matrigel (1:1) 
(BD Biosciences, San Jose, CA, USA) subcutaneously near the nipple of gland #3 in 
6-week old female nude (nu/nu) mice (Taconic, Germantown, NY, USA). When the 
tumors reached ~200 mm
3
, intraperitoneal injections of Cl-amidine (50 mg/kg/day) or 
vehicle control (PBS) were initiated and carried out for 14 days. Tumor volume was 
calculated by the formula: (mm
3
) = (d
2
 × D)/2, where “d” and “D” are the shortest and 
longest diameters of the tumor, respectively. Tumor volume was measured weekly by 
digital caliper, and the differences between tumor volumes were evaluated by the non-
parametric Mann–Whitney–Wilcoxon (MWW) test. Results are reported as mean ± 
SD. After 14 days, tumors were removed and either snap-frozen, placed in RNAlater 
(Qiagen Inc., Valencia, CA, USA), or added to 10% buffered formalin. Seven mice 
per group were used for each treatment. All mouse experiments were reviewed and 
approved by the Institutional Animal Care and Use Committees (IACUC) at Cornell 
University. Multicellular tumor spheroids were generated using the liquid overlay 
technique as previously described 
22-24
. The spheroids were allowed to form over 48h 
and maintained up to 6–10 days for morphological analysis, then collected, rinsed with 
phosphate buffered saline, and fixed in 10% buffered formalin. 
 
Assay of PADI activity 
Cell lines were assayed for PADI activity as previously described 
25, 26
.  Briefly, 
citrulline levels were determined using BAEE (α-N-benzoyl-L-arginine ethyl ester) as 
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a substrate. After incubating lysates for 1h at 50°C with BAEE substrate mixture, the 
reaction was stopped by the addition of perchloric acid. The perchloric acid-soluble 
fraction was subjected to a colorimetric reaction with citrulline used as a standard and 
absorbance measured at 464 nm. 
 
Immunohistochemistry (IHC) and immunofluorescence (IF)  
IHC and IF experiments were carried out using a standard protocol as previously 
described 
27
.  Primary antibodies are as follows: anti-PADI2 1:100 (ProteinTech, 
Chicago, IL, USA), anti-ERBB2 (A0485) 1:100 (Dako, Carpentaria, CA, USA), anti-
Cytokeratin 1:100 (Dako), and anti-p63 1:100 (Abcam, Cambridge, MA, USA). 
Sections prepared for IHC were incubated in DAB chromagen solution (Vector 
Laboratories, Burlingame, CA, USA) according to the manufacturer’s protocol, 
washed, and then counterstained with hematoxylin.  The IF slides were incubated in 
streptavidin conjugated-488 (Invitrogen, Carlsbad, CA, USA), washed, and then 
mounted using Vectashield containing DAPI (Vector Laboratories).  Negative controls 
for both IHC and IF experiments were either rabbit or mouse IgG antibody at the 
appropriate concentrations. Tumor sections were examined for general morphological 
differences after hematoxylin and eosin (H&E) staining. Basement membrane 
integrity was determined using periodic acid-Schiff (PAS) stained slides, and was 
scored by SM on a scale of 0-3: 0- continuous with no breaching, 1- a few small 
interruptions, 2- several interruptions with breaching by tumor cells, 3- extensive loss 
of basement membrane with invasion of tumor cells over the breached area; 
observations were performed under 10X magnification. 
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Immunoblotting  
Immunoblotting was carried out as previously described 
27
. Primary antibodies were 
incubated overnight at 4
o
C using the following concentrations: anti-PADI2 1:1000 
(ProteinTech) and anti-ErbB2 1:5000 (Dako). To confirm equal protein loading, 
membranes were stripped and re-probed with anti-β-actin 1:5000 (Abcam). 
 
Quantitative Real-Time PCR (qRT-PCR) 
RNA was purified using the Qiagen RNAeasy kit, including on-column DNAse 
treatment to remove genomic DNA.  The resulting RNA was reverse transcribed using 
the ABI High Capacity RNA to cDNA kit according to the manufacturer’s protocol 
(Applied Biosystems, Foster City, CA, USA).  TaqMan Gene Expression Assays 
(ABI) for human PADI2 (Hs00247108_m1) and GAPDH (4352934E) were used for 
qRT-PCR. Data were analyzed by the 2 
-ΔΔ C(t)
 method 
28
. Data are shown as means ± 
SD from three independent experiments, and were separated using Student’s t-test. For 
the analysis of cell cycle gene expression, cDNA was synthesized (RT
2
 First Strand 
Kit, Qiagen) and samples analyzed for expression of 84 genes involved in cell cycle 
regulation by RT
2
 Profiler PCR Cell Cycle Array (PAHS-020A, Qiagen). For data 
analysis, the RT
2
 Profiler PCR Array software package was used and statistical 
analyses performed (n = 3). This package uses ΔΔ CT–based fold change calculations 
and the Student’s t-test to calculate two-tail, equal variance p-values. 
 
Flow-cytometry 
Monolayers of MCF10DCIS and MCF10A cells were seeded into 25 cm
2
 flasks (2 x 
10
6
 cells) and treated with either Cl-amidine (200 µM or 400 µM), or 10μg/mL 
tunicamycin (apoptosis positive control). BT-474, SK-BR-3, and MDA-MB-231 cell 
lines were treated as previously described for MCF10DCIS and MCF10A; however, 
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they were also treated with 100 µM Cl-amidine. Cells were harvested after 4d using 
Accutase (Innovative Cell Technologies, Inc, San Diego, CA, USA), fixed, then 
permeabilized, and blocked in FACS Buffer (0.1M Dulbecco’s phosphate buffered 
saline, 0.02% sodium azide, 1.0% bovine serum albumin, and 0.1% Triton X-100) 
containing 10% normal goat serum and stained (except the isotype controls) with 
rabbit anti-cleaved Caspase-3 antibody (Cell Signaling Technology, Inc, Danvers, 
MA, USA). Isotype controls were treated with normal rabbit IgG (Vector 
Laboratories) at 4 μg/mL. All samples were stained with secondary goat anti-rabbit 
IgG conjugated to Alexa-488 (Invitrogen) and DAPI (Invitrogen) according to the 
manufacturer’s instructions. Cells were analyzed on a FACS-Calibur (BD 
Biosciences) or a Gallios (Beckman Coulter) flow-cytometer and data analyzed for 
percent apoptotic cells (cleaved Caspase-3+) and cell cycle analysis with FlowJo 
software (TreeStar, Inc, Ashland, OR, USA). Data are shown as means ± SD from 
three independent experiments, and were separated using Student’s t-test. 
 
RNA-seq analysis of breast cancer cell lines 
Whole transcriptome shotgun sequencing (RNA-seq) was completed on breast cancer 
cell lines and expression analysis was performed with the ALEXA-seq software 
package as previously described 
29
. Briefly, this approach comprises (i) creation of a 
database of expression and alternative expression sequence ‘features’ (genes, 
transcripts, exons, junctions, boundaries, introns, and intergenic sequences) based on 
Ensembl gene models, (ii) mapping of short paired-end sequence reads to these 
features, (iii) identification of features that are expressed above background noise 
while taking into account locus-by-locus noise. RNA-seq data were available for 57 
lines (17 basal, 5 basal-NM, 6 claudin-low, 29 luminal). An average of 70.6 million 
(76bp paired-end) reads passed quality control per sample. Of these, 53.8 million reads 
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mapped to the transcriptome on average, resulting in an average coverage of 48.2 
across all known genes. Log2 transformed estimates of gene-level expression were 
extracted for analysis with corresponding expression status values indicating whether 
the genes were detected above background level. 
 
Statistical analysis 
All experiments were independently repeated at least three times unless otherwise 
indicated.  Values were expressed as the mean + the SD. Means were separated using 
Student’s t-test or by Mann-Whitney-Wilcoxon (MWW) test, with a p-value less than 
0.05 considered as significantly different. Subtype specific expression in the RNA-seq 
analysis was determined by Wilcoxon signed-rank test. Correlations were determined 
by Spearman rank correlation. Genes were considered significantly differentially 
expressed or correlated if they had a p-value less than 0.05. 
 
2.4 Results 
PADI2 is overexpressed in transformed cells of the MCF10AT model of breast cancer 
progression 
In order to investigate PADI2 expression during tumor progression, we first utilized 
TaqMan quantitative real-time PCR (qRT-PCR) to measure PADI2 mRNA levels in 
cells from the MCF10AT tumor progression series (Figure 2.1a). As shown 
previously, these cell lines closely model the progression from normal (MCF10A), to 
hyperplastic (MCF10AT), to ductal carcinoma in situ (DCIS) with necrosis 
(MCF10DCIS.com), and finally to invasive/metastatic (MCF10CA1) breast cancer 
16, 
17, 30
.  Results (Figure 2.1b) show that PADI2 mRNA expression is elevated in the 
transformed cell lines, with the highest levels found in the comedo-DCIS 
MCF10DCIS.com cell line (hereafter MCF10DCIS). Additionally, PADI2 protein 
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levels closely correlated with PADI2 mRNA levels across these lines, with the highest 
levels of PADI2 protein observed in the MCF10DCIS line. Given the previous 
microarray studies correlating PADI2 expression with HER2/ERBB2, we also probed 
this cell line series with a well-characterized HER2/ERBB2 antibody and found that 
HER2/ERBB2 levels were also elevated in the transformed cell lines compared to the 
more normal MCF10A line (Figure 2.1c). We also tested whether the increase in 
PADI2 expression correlated with PADI2 enzymatic activity, with results (Figure 
2.1d) showing that citrulline levels are, in fact, highest in the MCF10DCIS cell line; 
therefore, indicating a strong correlation between increased PADI2 expression and 
enzymatic activity. While these cell lines have been classified previously as basal-like 
31
, both MCF10A and MCF10DCIS have been shown to possess bipotential progenitor 
properties 
19, 32, 33
. Furthermore, the MCF10AT cells have been reported to show the 
same multipotent properties 
34
, but until recently, there has only been one other report 
showing that HER2/ERBB2 is upregulated in the transformed lines of this series 
35
. 
These data suggest that PADI2 activity may play a role in mammary tumor 
progression and that PADI2-mediated citrullination may be particularly relevant to 
comedo-DCIS biology. 
 
Levels of PADI2 correlate with the luminal breast cancer subtype and HER2/ERBB2 
overexpression 
To test whether PADI2 displays a restricted expression pattern with respect to breast 
cancer subtype, we next investigated PADI2 mRNA and protein expression in cell 
lines representing four common breast cancer subtypes: MCF7 (luminal A), BT-474 
(luminal B), SK-BR-3 (HER2/ERBB2+), and MDA-MB-231 (basal). At the protein 
level, PADI2 was observed in both BT-474 (ER+, PR+, HER2/ERBB2+) and SK-BR-
3 (ER-, PR-, and HER2/ERBB2 overexpressing) cell lines. Interestingly, the  
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Figure 2.1: PADI2 expression is highest in MCF10DCIS.com cells in the 
MCF10AT model of breast cancer progression. (a) The MCF10AT model is a 
series of cell lines that recapitulates the transition from normal epithelium to 
malignant carcinoma. (b and c) PADI2 mRNA and protein expression is increased in 
transformed cells of the MCF10AT model, with very high levels seen in MCF10DCIS 
cells. Total RNA was isolated and PADI2 mRNA levels were determined by qRT-
PCR (TaqMan) using MCF10A cells as a reference and GAPDH normalization. Data 
were analyzed using the 2 
-ΔΔ C(t)
 method and are expressed as the mean ± SD from 
three independent experiments (* p < 0.001). PADI2 expression levels were evaluated 
by subjecting whole cell lysates to SDS-PAGE and immunoblot analysis using an anti-
PADI2 antibody. HER2/ERBB2 expression levels, detected using an anti-HER2 
antibody, are also upregulated in the transformed cell lines when compared to the 
MCF10A levels. The blot was stripped and equal protein loading was determined by 
probing with a β-actin antibody. (d) Citrulline levels in the cell lines were determined 
by citrullination enzymatic assays, with the highest level of activity measured in the 
MCF10DCIS cells. Briefly, cell lysates were incubated with PADI substrate BAEE, 
and the reaction stopped with perchloric acid. The perchloric acid-soluble fraction was 
subjected to a colorimetric reaction with citrulline used as a standard and absorbance 
measured at 464 nm. 
 
  
70 
 
  
71 
 
comparison of PADI2 and HER2/ERBB2 protein levels across these four cell lines 
supports the hypothesis that these two proteins are coexpressed (Figure 2.2a). While 
the PADI2 protein expression is not observed in MCF7 cells in Figure 2.2a, a longer 
exposure of this film finds that PADI2 is weakly expressed in these cells (Figure 
2.3a). Analysis of PADI2 transcript levels in these lines finds that, as expected, PADI2 
mRNA is sharply elevated in the BT-474 line (Figure 2.2b), and is ~2 fold higher that 
that seen in the MCF10DCIS cells (Figure 2.3b) when compared to MCF10A cells. 
To test whether PADI2 expression is elevated in HER2/ERBB2 expressing cells in 
vivo, we next measured PADI2 mRNA in normal murine mammary epithelium and in 
primary mammary tumors collected from MMTV-neu mice. Results indicate PADI2 
mRNA levels are ~15-fold higher in the HER2/ERBB2 overexpressing tumors 
compared to normal mammary tissue from littermate controls (Figure 2.2c). The ~15-
fold increase in PADI2 expression found in our study, compared to the ~4-fold 
increase found in the previous study 
12
, may simply reflect technical differences 
between the studies as we utilized TaqMan qRT-PCR compared to microarray 
analysis.  We also investigated the level of PADI2 mRNA in MMTV-Wnt-1 mice, 
which is a basal mouse model of breast cancer 
36-38
. The MMTV-Wnt-1 model is 
unique in that it exhibits discrete steps in mammary tumorigenesis; the mammary 
glands are first hyperplastic, and then advance to invasive ductal carcinomas, finally 
culminating in fully malignant carcinomas that undergo metastasis 
39
. Interestingly, we 
see that PADI2 levels are higher in the hyperplastic mammary glands (Figure 2.2c) 
when compared to normal mammary glands; however, the levels are less than those 
seen in the MMTV-neu tumors and are further reduced in the fully malignant MMTV-
Wnt-1 tumors. 
To strengthen the hypothesis that PADI2 is primarily expressed in luminal 
breast cancer cell lines and is coexpressed with HER2/ERBB2, we next investigated  
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Figure 2.2: PADI2 expression is elevated in luminal B BT-474 cells, murine 
MMTV-neu tumors, and is correlated with the luminal subtype. (a) Four different 
breast cancer cell lines were selected to represent the common subtypes of breast 
cancer: MCF7 (luminal A), BT-474 (luminal B), SK-BR-3 (HER2/ERBB2+), and 
MDA-MD-231 (basal). Immunoblotting shows PADI2 protein expression is highest in 
both of the HER2/ERBB2 overexpressing cell lines, with the highest level seen in the 
luminal B BT-474 cells (ER+/PR+). (b) Relative PADI2 mRNA levels in the cell lines 
compared to MCF10A. (c) Tumors from MMTV-neu mice (luminal subtype) show a 
~15-fold increase in PADI2 compared to normal mammary tissue. Both MMTV-Wnt-1 
hyperplastic mammary tissue and tumors (basal subtype) show elevated levels of 
PADI2 compared to normal mammary tissue; however, PADI2 expression levels in 
MMTV-Wnt-1 tumors are ~10-fold less than those seen in the MMTV-neu tumors. 
PADI2 mRNA levels were determined by qRT-PCR (TaqMan) using MCF10A cells 
as a reference and GAPDH normalization. Expression levels were analyzed using the 2 
-ΔΔ C(t)
 method, and data are expressed as the mean ± SD from three independent 
experiments (* p < 0.05, ** p < 1 x 10
-6
). (d) RNA-seq analysis of 57 breast cancer 
cell lines shows that PADI2 expression is significantly higher in luminal lines versus 
basal (* p = 0.007) and higher in basal versus basal-NM/claudin-low (** p = 0.002). 
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Figure 2.3: Comparative expression levels of MCF10DCIS and HER2/ERBB2 
expressing BT-474 and SK-BR-3 cell lines. (a) Overexposure of image in Figure 2a, 
showing that there are low levels of PADI protein found in the MCF7 cell line. (b) 
MCF10DCIS PADI2 levels are about half that of BT-474 cells, with SK-BR-3 PADI2 
levels being about half of MCF10DCIS cells. These PADI2 levels recapitulate the 
relationship seen at the protein level. Total RNA was isolated from MCF10A, 
MCF10DCIS, BT-474, and SK-BR-3 cell lines and PADI2 mRNA levels were 
determined by qRT-PCR (TaqMan) using MCF10A cells as a reference and GAPDH 
normalization. Data were analyzed using the 2 
-ΔΔ C(t)
 method and are expressed as the 
mean ± SD from three independent experiments (* p < 0.005). 
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PADI2 mRNA levels by querying RNA-seq datasets collected from 57 breast cancer 
cell lines. A summary of PADI2 expression in these lines is shown in the Figure 2.4, 
with the most significant difference (p = 3.59 x 10
-5
) in PADI2 expression across 
subtypes being found when luminal lines were compared with all non-luminal 
subtypes (Figure 2.2d). We then quantified the correlation between PADI2 and 
HER2/ERBB2 expression across the 57 cell lines. Results show that the correlation 
between PADI2 and HER2/ERBB2 overexpression is highly significant across the 
luminal, basal-NM (non-malignant), and claudin-low cell lines (rho = 0.828, p = 2.2 x 
10
-16
) (Figure 2.5). Interestingly, a correlation between PADI2 and HER2/ERBB2 
expression was not observed across the basal cell lines. In contrast, a significant anti-
correlation was observed (rho = -0.495, p = 0.045), suggesting that the expression of 
these genes may be regulated by different mechanisms in these cell lines.  Lastly, we 
queried the RNA-seq dataset to determine which genes were best correlated with 
HER2/ERBB2 and PADI2 expression in the luminal, basal-NM, and claudin-low lines 
to assess the relative strength of their coexpression. Only a single gene (CCL17) was 
as correlated with PADI2 as HER2/ERBB2 (rho = 0.832, p = 2.2 x 10
-16
), and PADI2 
represented the 13th most highly correlated gene with HER2/ERBB2 (Table 2.1), thus 
suggesting co-regulation between HER2/ERBB2 and PADI2. 
 
Inhibition of PADI activity reduces cellular proliferation in breast cancer cell lines 
To investigate whether PADI2 expression is important for breast cancer cell 
proliferation, we next tested whether the pharmacological inhibition of PADI2 activity 
negatively affects the growth of tumor cells in vitro. We utilized the small molecule 
inhibitor Cl-amidine for this study because we have previously shown that this drug 
binds irreversibly to the active site of PADIs, thereby blocking activity in vitro and in 
vivo 
40
. Cl-amidine functions as a “pan-PADI” inhibitor as it blocks the activity of all  
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Figure 2.4: PADI2 gene-level expression compared to distribution of all genes 
across 57 breast cancer cell lines. Box-and-whisker plot of PADI2 mRNA 
expression levels across 57 breast cancer cell lines were measured by RNA-seq. 
PADI2 levels (black circles) are shown relative to all other genes in each cell line 
(interquartile range – colored boxes according to different subtype). PADI2 is most 
highly expressed in the luminal lines (26/29 above background – black circles located 
in the upper quartile). PADI2 levels are significantly different in luminal cell lines 
when compared to all non-luminal cell lines (p = 3.59 x 10
-5
). (open circles = outliers) 
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Figure 2.5: RNA-seq analysis of PADI2 expression across 57 breast cancer cell 
lines shows subtype specific expression and high correlation with HER2/ERBB2. 
The Spearman correlation between PADI2 and HER2/ERBB2 overexpression was 
highly significant across the luminal, basal-NM, and claudin-low cell lines (rho = 
0.828, p = 2.2 x 10
-16
). A significant anti-correlation between PADI2 and 
HER2/ERBB2 was observed across the basal cell lines (rho = -0.495, p = 0.045). 
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Table 2.1: Top genes that correlate with HER2/ERBB2 expression.  Genes 
identified by RNA-seq to be upregulated in HER2/ERBB2+ breast cancers were tested 
for correlation (Spearman’s rho) and the top 13 genes are ranked from top to bottom, 
with PADI2 exhibiting the 13
th
 strongest correlation with HER2/ERBB2 
overexpression. 
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active PADI family members (i.e. PADIs 1-4) with varying degrees of specificity 
41
. 
Cultures from the MCF10AT cell line series were treated with 10, 50, or 200 µM of 
Cl-amidine, and the effects of the inhibitor on cell proliferation were quantified. 
Results showed a dose-dependent decrease in the growth of all cell lines. Additionally, 
given that 200 µM Cl-amidine decreased the growth of MCF10DCIS cells by 75% 
(Figure 2.6a), this cell line appeared to be particularly affected by the inhibitor. Given 
the high level of PADI2 expression in the MCF10DCIS line, this finding suggests that 
PADI2 is likely playing an important role in the growth of MCF10DCIS cells. 
Importantly, while Cl-amidine also suppressed the growth of MCF10DCIS cells at 
lower concentrations, these doses did not inhibit the growth of the non-tumorigenic 
“normal” MCF10A line. These data suggest that Cl-amidine is not generally cytotoxic. 
In addition, citrulline levels in the Cl-amidine treated MCF10DCIS cells were 
significantly reduced, suggesting that the inhibitory effect of Cl-amidine was 
specifically due to the blockade of PADI activity (Figure 2.6b). In order to test the 
potential anti-tumor efficacy of Cl-amidine in a physiological model, we investigated 
the effects of this inhibitor on the growth of MCF10DCIS tumor spheroids. Spheroids 
grown from this cell line have been shown by others to form acinar-like structures that 
closely recapitulate the comedo-DCIS lesions that form in MCF10DCIS xenografts 
18, 
20, 42
.  Results from our studies found that Cl-amidine treatment significantly reduces 
tumor spheroid diameter (Figure 2.6c). Representative images of the effects of Cl-
amidine on the growth of MCF10DCIS monolayers and spheroids are shown in 
Figure 2.6d.  
 
Cl-amidine alters the expression of cell cycle associated genes and induces apoptosis 
The observed effects of Cl-amidine on cell proliferation suggested that this drug might 
affect tumor growth by altering the expression of genes involved in cell cycle  
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Figure 2.6: PADI inhibitor Cl-amidine inhibits proliferation in breast cancer cell 
lines grown in monolayer and spheroid cultures. (a) Relative mean fold difference 
in proliferation for the MCF10AT progression model cell lines at increasing 
concentrations of Cl-amidine after 5d treatment (n = 3, * p < 0.05, ** p < 0.005, *** p  
< 0.0005). (b) Citrulline levels for MCF10DCIS cells treated with 200 μM Cl-amidine 
were measured and compared to PBS control MCF10DCIS cells. Data represent (n = 
3, * p < 0.005) (c) Multicellular spheroids were treated with 200 μM Cl-amidine and 
the diameter was measured and recorded in microns (n = 3, * p < 0.05). (d) Phase 
contrast images (10X) of MCF10DCIS cells grown in monolayer (2D) or multicellular 
spheroids (3D) treated with either vehicle (PBS) or 200 μM of Cl-amidine (scale bar = 
100 µm). (e and f) MCF10A and MCF10DCIS cells were treated with different 
concentrations of Cl-amidine (0 µM, 200 µM, and 400 µM) and (f) 10μg/mL 
Tunicamycin, and analyzed by flow-cytometry. Data represent percent apoptotic cells 
(cleaved Caspase-3 positive) or percentage of cells in various phases of the cell cycle 
(DAPI), and are expressed as the mean ± SD from three independent experiments (* p 
< 0.005, ** p < 0.005). 
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progression. To test this hypothesis, mRNA from the Cl-amidine treated and control 
MCF10DCIS cells was examined for the expression of cell cycle associated genes 
using the RT
2
 Profiler PCR Cell Cycle Array via qRT-PCR. Using a threshold value 
of 2-fold expression change and a statistical significance of p < 0.05, we found that 
Cl-amidine affected the expression of a subset of genes (for the full unsorted list see 
McElwee et al., supplemental data 
43
), with the top 10-upregulated and -
downregulated genes presented in Table 2.2. Importantly, previous studies have 
shown that increased expression of GADD45α, the second most highly upregulated 
gene in our study, leads to cell cycle arrest and apoptosis in a range of cell types, 
including breast cancer cells 
44
.  This observation suggested that, in addition to 
affecting cell cycle gene expression (e.g. p21), Cl-amidine might also alter 
MCF10DCIS cell growth by inducing apoptosis. To test this hypothesis, we next 
treated MCF10A and MCF10DCIS cells with increasing concentrations of Cl-amidine 
for 4 days. Cells were fixed and labeled with anti-activated Caspase-3 antibody or 
DAPI, and then analyzed by flow-cytometry. Results show that Cl-amidine treatment 
significantly increased the percent of apoptotic MCF10DCIS cells in a dose-dependent 
manner (Figure 2.6e). In contrast, the MCF10A cells were largely unaffected. 
Furthermore, we also show that treatment of MCF10DCIS cells with Cl-amidine 
appears to induce cell cycle arrest in S-phase (Figure 2.6f). Lastly, we wanted to see 
whether the increase in apoptosis occurs earlier after treatment, so we tested the cells 
again following 2 days of treatment, but were unable to see any effect (Figure 2.8a). 
However, this was not surprising, as the effects of Cl-amidine are most pronounced 
after 3 days of treatment (data not shown). Taken together, it appears that Cl-amidine 
treatment after 4 days leads to  S-phase coupled apoptosis, which is an intrinsic 
mechanism that prevents DNA replication of a damaged genome in a mammalian cell 
45
. We also tested the effects of Cl-amidine on HER2/ERBB2 overexpressing cell lines  
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Table 2.2: Top 10 genes that are up- and down-regulated in MCF10DCIS cells 
after treatment with 200 μM Cl-amidine for 5 days. MCF10DCIS cells were 
treated with 200 μM Cl-amidine after seeding (5 x 104), and total RNA was collected 
5d post-seeding. The mRNA for each group was tested on the RT
2
 Profiler PCR Cell 
Cycle Array (SABiosciences Corporation, catalog number PAHS-020A). The PCR 
array was designed to study the profile of 84 human cell cycle related genes. Using a 
threshold value of 2-fold expression change and a statistical significance of p < 0.05, 
we found that Cl-amidine affected the expression of a subset of genes, with the top 10 
up- and down-regulated genes displayed here. 
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BT-474 and SK-BR-3. Again, we see a reduction in cell growth (Figure 2.7a) and an 
increase in apoptosis (Figure 2.7b) that is coupled to S-phase cell cycle arrest (Figure 
2.7c) for both BT-474 and SK-BR-3. These results show that Cl-amidine is effective 
in inhibiting the growth of luminal-HER2/ERBB2+ cell lines, BT-474 and SK-BR-3, 
and agree with previously reported data on Cl-amidine inhibition of growth in MCF7 
cells 
8, 9, 11, 46
. We wanted to test whether there would be any effect on a basal cell line, 
and chose MDA-MB-231 for comparison. Surprisingly, we see an effect on both cell 
growth and apoptosis (Figure 2.8b and c), albeit a smaller effect on apoptosis than we 
see in BT-474 and SK-BR-3. While this is interesting, and perhaps suggests the 
expression of a different PADI family member in this basal cell line, we have focused 
on PADI2 expressing cancers for this study, which are predominantly luminal and 
HER2/ERBB2 expressing. Taken together, these results suggest that Cl-amidine 
blocks the growth of MCF10DCIS cells by inducing cell cycle arrest and apoptosis. 
This prediction is supported by our previous finding that Cl-amidine can also drive 
apoptosis in lymphocytic cell lines in vitro 
3
. Importantly, the lack of an apoptotic 
effect on MCF10A cells suggests that Cl-amidine may primarily target tumor cells for 
killing. Consistent with this possibility is the fact that Cl-amidine did not affect the 
growth of non-tumorigenic NIH3T3 cells and HL60 granulocytes 
11
. 
 
PADI2 is highly expressed in the luminal epithelium of xenograft tumors derived from 
MCF10DCIS cells 
Given that PADI2 expression is elevated in the MCF10DCIS cell line, we investigated 
PADI2 expression and localization in primary tumors derived from MCF10DCIS-
injected mouse xenografts. Previous studies have shown that when MCF10DCIS cells 
are injected into the mammary fat-pad of immunodeficient nude (nu/nu) mice, tumors 
develop within 2-3 weeks. These tumors faithfully recapitulate the human comedo- 
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Figure 2.7: HER2/ERBB2 expressing cell lines BT-474 and SK-BR-3 show 
decreased proliferation after treatment with Cl-amidine. (a) BT-474 and SK-BR-3 
cell lines were treated with increasing concentrations of Cl-amidine (0 µM, 100 µM, 
200 µM, and 400 µM) over 4d and analyzed by flow-cytometry. Cell counts show a 
dose-dependent decrease in the growth of both BT-474 and SK-BR-3 (* p < 0.05, ** p 
< 0.001). (b) Apoptosis levels (cleaved Caspase-3 positive) significantly increase over 
the control in both BT-474 and SK-BR-3 cells after 200 µM and 400 µM of Cl-
amidine. Tunicamycin (10μg/mL) is shown as a control for apoptosis (* p < 0.05, ** p 
< 0.01, *** p < 0.001). (c) Cell cycle analysis of Cl-amidine treated cells (DAPI) 
indicates S-phase arrest occurs in both BT-474 and SK-BR-3 cell lines. Data are 
expressed as the mean ± SD from three independent experiments. 
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Figure 2.8: Flow-cytometry analysis of apoptosis in MCF10A and MCF10DCIS 
cell lines, and both proliferation/cell-growth and apoptosis in MDA-MB-231 cells. 
(a) MCF10A and MCF10DCIS cells were treated with different concentrations of Cl-
amidine (0 µM, 200 µM, and 400 µM) and 10μg/mL Tunicamycin, and analyzed by 
flow-cytometry. Data represent percent apoptotic cells (cleaved Caspase-3 positive) 
after 2d and are expressed as the mean ± SD from three independent experiments (* p 
< 0.05, ** p < 0.001). (b) MDA-MB-231 cells were treated with increasing 
concentrations of Cl-amidine (0 µM, 100 µM, 200 µM, and 400 µM) over 4d and 
analyzed by flow-cytometry. Cell counts (DAPI) show a dose-dependent decrease in 
the growth (* p < 0.001). (c) Apoptosis levels (cleaved Caspase-3 positive) 
significantly increase over the control only after treatment with 400 µM of Cl-
amidine. Tunicamycin (10μg/mL ) is shown as a control for apoptosis (* p < 0.01). 
Data are expressed as the mean ± SD from three independent experiments. 
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DCIS condition, with the basement membrane limiting duct-like structure being 
comprised of an outer myoepithelial layer, an inner layer of luminal epithelial cells, 
and a central necrotic lumen 
18, 19, 47, 48
. We chose to use subcutaneous injections 
instead of orthotopic or intraductal 
49
 methods, as previous work by Hu et al showed 
that the progression and phenotype of the MCF10DCIS tumors grown subcutaneously 
in the mammary fat pad were highly similar to human high-grade comedo-DCIS 
tumors 
19
. In our study, we found that PADI2 protein expression was restricted to the 
luminal epithelium of the duct-like structures in the MCF10DCIS xenografts, and was 
not observed in the stromal tissue or the necrotic core (Figure 2.9a, panel I and II). 
At the subcellular level, PADI2 appears to be expressed in both the cytoplasmic and 
nuclear compartments of luminal epithelial cells (Figure 2.9a, panel II). This 
observation supports our recent findings that PADI2 can be targeted to the nucleus of 
both human normal mammary tissue and breast cancer cells 
50
 and regulate gene 
activity via citrullination 
50, 51
.  
Next, we examined whether the observed correlation between PADI2 and 
HER2/ERBB2 expression also occurred in vivo. We found that both HER2/ERBB2 
and PADI2 were expressed within the luminal epithelium of MCF10DCIS tumors 
(Figure 2.9a, panel III and IV). Interestingly, a previous report by Behbod et. al. 
found low levels of HER2/ERBB2 in MCF10DCIS tumors that were grown 
intraductally. We predict that the disparity between this data and our data may be due 
to differences in the microenvironment. We then quantified PADI2 mRNA in the 
MCF10DCIS xenografts by qRT-PCR, and found that PADI2 levels were significantly 
higher in the tumors when compared to monolayer cultures (Figure 2.9b). We also 
carried out immunofluorescence (IF) analysis of these tumors to examine PADI2 
intratumoral localization. We found that PADI2 protein expression appears entirely 
limited to cytokeratin-positive luminal epithelial cells (Figure 2.9c, panel I and III,  
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Figure 2.9: PADI2 is expressed in MCF10DCIS xenograft tumors and localizes to 
the luminal epithelium. (a) MCF10DCIS cells (1 x 10
6
) were injected subcutaneously 
into female nude (nu/nu) mice (Charles River) and comedo-DCIS tumors formed after 
2 weeks. Tumor sections were probed with an (I, II) anti-PADI2 antibody (1:100) or 
(III, IV) anti-ERBB2 (1:100), and counterstained with hematoxylin. The black arrows 
indicate the luminal epithelium of the duct-like structures in DCIS tumors (I, III – 
20X, scale bar = 200 µm; II, IV – 100X, scale bar = 50 µm). While the HER2/ERBB2 
staining is predominantly cytoplasmic (IV), there are some nuclei staining positively 
for PADI2 (II). (b) Tumors were collected; two sections from each mouse were 
sampled and total RNA was isolated. PADI2 mRNA levels were determined by qRT-
PCR (TaqMan) using MCF10A cells as a reference and GAPDH normalization. 
PADI2 levels were higher in the tumor samples than normally found in the 
MCF10DCIS cells. Data were analyzed using the 2 
-ΔΔ C(t)
 method, and are expressed 
as the mean ± SD from three independent experiments (* p < 0.005). (c) 
Immunofluorescence staining (40X) shows that PADI2 is expressed in the luminal but 
not myoepithelium cells in MCF10DCIS tumors. Tumors were probed with anti-
PADI2 (II, III, V, VI – green fluorescent signal), anti-cytokeratin (I, III – luminal 
marker – red fluorescent signal), and anti-p63 (IV, VI – myoepithelial marker – red 
fluorescent signal). Nuclei were stained with DAPI (blue fluorescent signal). The 
dashed arrows delineate the luminal epithelium layer, while the dashed straight line 
delineates the myoepithelium layer, which is adjacent to the basement membrane. In 
the merged images, the co-localization of cytokeratin and PADI2 can be seen in the 
luminal epithelium (III), while in contrast, PADI2 is absent from the p63 stained 
myoepithelium (VI).  
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Figure 2.10: Immunofluorescence staining of MCF10DCIS xenografts for PADI2, 
luminal epithelium (pan-cytokeratin), and myoepithelium (p63). (A) MCF10DCIS 
cells (1 x 10
6
) were injected subcutaneously into female nude (nu/nu) mice (Charles 
River) and comedo-DCIS tumors formed after 2 weeks. Tumors were probed with 
anti-PADI2 (green fluorescent signal), anti-cytokeratin (luminal marker – red 
fluorescent signal), and anti-p63 (myoepithelial marker – red fluorescent signal). 
Nuclei were stained with DAPI (blue fluorescent signal). Immunofluorescence 
staining (63X) shows that PADI2 is expressed in the luminal but not myoepithelium 
cells in MCF10DCIS tumors. In addition, there is some evidence for PADI2 
expression in the nucleus. 
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and Figure 2.10), while no detectable PADI2 signal was observed in the p63 positive 
myoepithelial cells (Figure 2.9c, panel IV and VI, and Figure 2.10). 
 
Treatment of MCF10DCIS xenografts with Cl-amidine suppresses tumor growth 
Given the inhibitory effects of Cl-amidine on MCF10DCIS monolayer and spheroid 
growth, we next tested whether the treatment of mice with this inhibitor would 
suppress the growth of MCF10DCIS-derived tumors. For this study, mouse fat-pads 
were injected with MCF10DCIS cells (1 x 10
6
) and the tumors were allowed to 
establish and grow for ~2 weeks as described previously 
18-20, 47
.  Mice were randomly 
assigned into treatment or control groups and administered daily intra-peritoneal (IP) 
injections of either Cl-amidine (50 mg/kg/day) or vehicle (PBS). Note, that the choice 
of dose and route of administration were based on the previous demonstration that Cl-
amidine reduces disease severity in the murine collagen induced arthritis model of 
rheumatoid arthritis 
5
. Treatment continued for 14 days, at which point the tumors 
were harvested. Results from our xenograft study show that Cl-amidine treatment (n = 
7/group) caused a significant reduction in the size of the tumors (Figure 2.11a). 
Moreover, the analysis of tumor morphology by H&E and PAS staining showed that, 
while tumors from the sham-injected group displayed an advanced, potentially 
invasive, tumor phenotype (Figure 2.11b, panel II), tumors from the Cl-amidine 
treated group (Figure 2.11b, panel I) were much more benign in appearance. For 
example, the basement membrane of Cl-amidine treated tumors remained largely 
intact (Figure 2.11c) and had considerably less membrane breaching and leukocyte 
infiltration compared to the control group. These findings suggest that PADI2 plays an 
important role in comedo-DCIS progression and that the inhibition of PADI activity 
can suppress tumor progression in vivo. 
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Figure 2.11: Cl-amidine decreases the growth of MCF10DCIS tumors in a 
xenograft model of comedo-DCIS. (a) Average tumor volumes after 1, 7, and 14 
days of daily IP injections of Cl-amidine (50mg/kg/day) or PBS as vehicle control.  
MCF10DCIS cells (1 x 10
6
) were injected subcutaneously into female nude (nu/nu) 
mice (Charles River).  After 2 weeks of tumor growth (tumor volumes ~100-200 
mm
3
), mice were randomly treated with intraperitoneal injections of Cl-amidine at 50 
mg/kg/day (n = 7) or PBS as a vehicle control (n = 7). Tumor volume was measured 
weekly by digital caliper, and the differences between tumor volumes were evaluated 
by the non-parametric Mann–Whitney–Wilcoxon test (MWW). Results are reported as 
mean ± SD (Day 14, p = 0.002). (b) PAS stained sections (10X, scale bar = 200 µm) 
from representative treated (I) and control tumors (II), arrows in (I) show an intact 
basement membrane (BM), while the arrow in (II) shows breaching of the BM with 
infiltrating leukocytes. (c) BM integrity was scored on a scale from 1-3 by S.M., with 
values being expressed as the mean ± SD.  The treated tumors have a lower score, 
indicating a higher level of BM integrity (* p < 0.05 MWW).  
  
101 
 
 
 
 
 
 
 
102 
 
2.5 Discussion 
In this study, we show that PADI2 is specifically upregulated during mammary tumor 
progression and that the PADI inhibitor, Cl-amidine, is effective in inhibiting the 
growth of PADI2 overexpressing cell lines in both 2D and 3D cultures. In addition, we 
demonstrate here for the first time that Cl-amidine is successful in suppressing tumor 
growth in a xenograft mouse model of comedo-DCIS. Lastly, we document that 
PADI2 expression is highly correlated with HER2/ERBB2 overexpressing and 
luminal subtype breast cancers. 
Given the previous correlations between PADI2 and the HER2/ERBB2 
oncogene, the goal of this study was to carry out an initial test of the hypothesis that 
PADI2 plays a role in breast cancer progression. To accomplish this, we utilized the 
well-established MCF10AT model 
16, 17
 and found that PADI2 expression was highly 
upregulated in MCF10DCIS cells, a cell line that forms comedo-DCIS lesions that 
spontaneously progress to invasive tumors 
30, 47
.  Our finding that PADI2 expression is 
highest in comedo-DCIS lesions (defined by their necrotic centers) was perhaps not 
too surprising, given the close association of PADIs with inflammatory events. We are 
currently investigating the potential links between inflammatory signaling in these 
MCF10DCIS lesions and PADI2 activity.   
Interestingly, PADI2 expression in the MCF10AT series coincided with 
HER2/ERBB2 upregulation, which, again, was not entirely unexpected given previous 
reports correlating PADI2 expression with HER2/ERBB2 
15
. While we did find that 
HER2/ERBB2 and PADI2 protein expression correlated well across the MCF10AT 
cell lines, PADI2 protein levels are particularly high in the MCF10DCIS line, relative 
to HER2/ERBB2. We cannot currently explain this finding; however, it is possible 
that cell-line-specific factors are stabilizing the PADI2 transcript, thus allowing for 
increased protein expression 
52, 53
.  
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While our data show a potential relationship between PADI2 and 
HER2/ERBB2 in the MCF10AT model, we wanted to examine this correlation at 
higher resolution. To accomplish this we queried our RNA-seq dataset of 57 breast 
cancer cell lines with known subtype and HER2/ERBB2 status and found that: (a) 
PADI2 expression is highest in luminal cell lines and that (b) PADI2 expression is 
highly correlated with HER2/ERBB2+ across the basal-NM, claudin-low, and luminal 
lines. The observation that PADI2 is upregulated in the luminal subtype confirms 
previous gene expression data where PADI2 was identified as one of the top 
upregulated genes in luminal breast cancer lines compared to basal lines 
13, 14
. In order 
to test whether the observed correlation between PADI2 and HER2/ERBB2 would be 
retained at the protein level, we also tested a small sample of cell lines representing 
the four common breast cancer subtypes and found that PADI2 expression was only 
observed in the HER2/ERBB2+ BT-474 and SK-BR-3 lines. However, we did observe 
some discordance seen between PADI2 transcript and protein levels, but we predict 
this difference may be due to post-transcriptional regulatory mechanisms. This 
prediction is based, in part, upon the observation that PADI2 possesses a long 3’UTR 
54
 that contains several AU-rich elements 
55, 56
 that have been shown to bind the 
stabilizing regulatory factor HuR 
57
. HuR binding has been shown to enhance the 
stability of mRNAs involved in proliferation 
58-60
, while also playing a role in breast 
cancer, as cytoplasmic accumulation of HuR promotes tamoxifen resistance in BT-474 
cells 
61
 and the stability of HER2/ERBB2 transcripts in SK-BR-3 cells 
53
. Interestingly, 
from these studies, the level of HuR was reported to be high in both BT-474 and SK-
BR-3 cells, while it was relatively low in MCF7 cells. It is important to note that that 
while we observed low levels of PADI2 protein expression in MCF7 (Additional file, 
Figure S1a), recent work from our lab has confirmed the expression of PADI2 in 
MCF7 cells 
50, 51
. 
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We also examined two mouse models of mammary tumorigenesis, the luminal 
MMTV-neu and the basal MMTV-Wnt-1 and found that, as predicted, PADI2 levels 
are highest in the HER2/ERBB2 overexpressing MMTV-neu mice compared to 
normal mammary tissue and to hyperplastic and primary MMTV-Wnt-1 tumors. Taken 
together, these findings indicate that PADI2 is predominantly expressed in luminal 
epithelial cells, and that there appears to be a strong relationship between PADI2 and 
HER2/ERBB2 expression in breast cancer. Subsequent studies are now underway to 
test whether PADI2 plays a functional role in HER2/ERBB2 driven breast cancers, 
potentially by functioning as an inflammatory mediator. 
Previous studies have shown that the inhibition of PADI enzymatic activity by 
Cl-amidine is effective in decreasing the growth of several cancer cell lines (i.e. HL-
60, HT-29, U2OS, and MCF7 cells), and that administering the drug in combination 
with doxorubicin or the HDAC inhibitor SAHA can have synergistic cytotoxic effects 
on cells 
8, 9, 11, 46
.  Cl-amidine is highly specific for all PADI enzymes, with dose-
dependent cytotoxicity and little to no effect in non-cancerous cell lines (i.e. HL-60 
granulocytes and NIH3T3 cells) 
11
. Our studies expand on these previous results by 
showing that Cl-amidine suppresses the growth of the transformed lines of the 
MCF10AT model, especially the MCF10DCIS cell line, in both 2D and 3D cultures. 
In addition, we show for the first time that Cl-amidine is successful in treating tumors 
in vivo using a mouse model of comedo-DCIS from xenografted MCF10DCIS cells. 
Given that, the loss of basement membrane integrity is an important event during the 
progression of DCIS to invasive disease, it is significant that Cl-amidine treated 
xenografts maintain their basement membrane integrity and show reduced leukocytic 
infiltration across the basement membrane compared to the control group. These 
observations suggest that Cl-amidine treatment might enhance the ability of tumor 
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ductular myoepithelial cells to deposit continuous and organized basement 
membranes.  
While we chose the subcutaneous model of MCF10DCIS tumorigenesis, future 
studies on the effect of Cl-amidine could examine alternate methods of 
transplantation, such as the previously described intraductal method 
49
. In addition, 
different models of DCIS could be examined, such as xenografted SUM-225 cells, 
which show high HER2/ERBB2 and PADI2 levels (see Figure 3 for relative levels). Of 
note, we found that while Cl-amidine suppressed tumor growth, the drug was well 
tolerated by mice in this study. Similarly, our previous work found that doses of Cl-
amidine up to 75 mg/kg/day in a mouse model of Colitis 
3
, and up to100 mg/kg/day in 
a mouse model of RA 
5
, were well tolerated without side effects. Further work into 
studying the pharmacokinetics and biodistribution of Cl-amidine, or perhaps the 
development of an isozyme specific inhibitor of PADI2, will be an important step in 
helping to find a potent drug for the treatment of DCIS patients. 
The actual mechanisms by which Cl-amidine reduces cellular proliferation 
have yet to be fully elucidated, though evidence here suggests that PADI2 may play a 
role (direct or indirect) in regulating the expression of both cell cycle and tumor 
promoting genes. Previous reports have shown that Cl-amidine effectively upregulates 
a number of p53-regulated genes, including p21, PUMA, and GADD45 
8, 46
. Our qRT-
PCR cell cycle array results confirm that two of these genes, p21 and GADD45α, are 
upregulated after treatment of MCF10DCIS cells with Cl-amidine by 17.68- and 
13.53-fold, respectively. Furthermore, we have identified additional genes 
downregulated by Cl-amidine, including MKI67, MCM5, and MCM2, each with 
known functions in cancer progression. We have also quantitatively analyzed for 
apoptosis levels (Caspase-3) after Cl-amidine treatment via flow-cytometry, and see a 
dose-dependent decrease in proliferation and increase in apoptosis. Moreover, we also 
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show that the cells arrest in S-phase after Cl-amidine treatment, thus leading to S-
phase coupled apoptosis, which is a known response to DNA damage 
45
. Taken 
together, the observed inhibitory effects of Cl-amidine on tumor growth may be due to 
the suppression of genes involved in oncogenesis and the activation of genes involved 
in apoptosis, though additional work is needed to define the mechanisms behind these 
potential relationships.  
 
Conclusions 
In summary, we provide here an important new line of evidence demonstrating that 
PADI2 may play a role in the oncogenic progression of cancer and, in particular, 
breast cancer. Using the MCF10AT model, we show that PADI2 is highly upregulated 
following transformation at both the mRNA and protein level, with highest levels in 
the cell line that recapitulates human comedo-DCIS. Furthermore, we show that, 
across a wide array of breast cancer cell lines, PADI2 is specifically overexpressed in 
the luminal subtype, while also being highly correlated with HER2/ERBB2 
overexpression. This observation suggests that PADI2 may function as a biomarker 
for HER2/ERBB2+ lesions. Lastly, our preclinical mouse xenograft study suggests 
that the PADI inhibitor, Cl-amidine, could potentially be utilized as a therapeutic 
agent for the treatment of comedo-DCIS tumors. 
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CHAPTER THREE 
PADI2 AS A POTENTIAL THERAPEUTIC TARGET IN HER2/ERBB2-
POSITIVE BREAST CANCER 
 
 
 
 
 
 
 
 
 
 
 
* Manuscript from: John L. McElwee; Sachi Horibata; Xuesen Zhang; Sunish 
Mohanan; Josephine I. Chen; Dalton McLean; Lynne J. Anguish; Paul R. Thompson; 
and Scott A. Coonrod. PADI2 as a potential therapeutic target in HER2/ERBB2-
positive breast cancer. In preparation.  
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3.1 Summary 
Introduction:  
We have recently reported that the expression of peptidylarginine deiminase 2 
(PADI2) is correlated with HER2 expression in breast cancer cell lines and appears to 
play a role in the proliferation of mammary tumors in vitro and in vivo; however, the 
functional relationship between these two genes has yet to be investigated. Thus, the 
goals of this study were to examine the role of PADI2 in HER2-positive breast cancer, 
and to validate our next generation PADI inhibitor in the treatment of these tumors. 
 
Methods: 
Using molecular genetics approaches, we looked to identify whether PADI2 
expression was upstream or downstream of HER2. Lentiviral transduction of 
MCF10DCIS and BT474 cells was used to examine the role of PADI2 knockdown on 
HER2 signaling and cellular malignancy. Chromatin-immunoprecipitation (ChIP) was 
performed to identify whether PADI2 binds the HER2 promoter and/or upstream 
intronic ERE. Lastly, we used our next-generation PADI inhibitor, BB-Cl-amidine, to 
examine the role of PADI2 signaling on HER2-positive breast cancers. 
 
Results: 
We have previously shown a role for PADI2 in ER-target gene signaling via the 
citrullination of histone H3 arginine 26 (H3R26). This study shows that PADI2 
appears to play a role in HER2-signaling as part of an oncogenic positive-feedback 
loop. First, we show using MCF10DCIS and BT474 cells stably knocked-downed for 
PADI2, that HER2 expression levels are decreased. Next, we show that PADI2 binds 
the HER2 promoter and downstream ERE, and that reduced levels of PADI2 are 
concomitant with reduced levels of citrullinated H3R26 (H3Cit26).  The reduction in 
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PADI2 signaling has a negative effect on the expression of genes downstream of 
HER2 signaling, and these results can be replicated with our next-generation PADI 
inhibitor, BB-Cl-amidine. Interestingly, we also report that increased HER2 signaling 
can upregulate PADI2 expression.  Lastly, we established that the next-generation 
PADI inhibitor, BB-Cl-amidine, is nearly 100X more potent than first-generation Cl-
amidine in reducing the growth of cancer cells. 
 
Conclusion: 
Taken together, these results suggest an enhanced role for PADI2 in HER2 expressing 
breast cancers, and that the PADI inhibitor, BB-Cl-amidine, represents a potential 
novel therapy for the treatment of patients with HER2-positive mammary tumors.  
 
Key words: Peptidylarginine deiminase, PAD2/PADI2, HER2/ERBB2, Breast 
Cancer, BB-Cl-amidine, Citrullination, Histone H3 Arginine 26 
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3.2 Introduction 
Breast cancer is the most frequently diagnosed cancer in women, with over 1 million 
new cases in the world each year 
1
. Approximately 75% of breast cancers are ER-
positive, with anywhere between 15-20% of breast cancers positive for HER2 
amplification or overexpression 
2
. Between ER and HER2, the majority of breast 
cancers express at least one or both of these markers. While there are drugs targeting 
both of these hormone receptors, about ~30% of patients with ER-positive breast 
cancers fail to respond to treatments such as tamoxifen; in addition, the majority of 
those patients that do initially respond develop resistance over time 
3
. Interestingly, the 
most commonly documented mechanism of resistance to tamoxifen occurs via EGFR 
and HER2 overexpression 
4-6
. The same problem exists for patients with HER2-
positive tumors, as greater than 60% of patients fail to respond to trastuzumab 
monotherapy, with initial responders developing resistance within 1 year 
7, 8
. In 
addition, a significant portion of those patients treated with trastuzumab must 
discontinue treatment because of cardiotoxic side effects, owing to the role of HER2 
receptor signaling in the heart 
9
. This has highlighted the critical need to discover and 
validate novel targets for both ER- and HER2-positive tumors, so that additional 
treatments may be used in combination with, or in the place of, current therapies to 
overcome issues with de novo and acquired resistance. 
Recently, in addition to genetic mutations, numerous studies have found that 
epigenetics plays a direct role in the etiology of breast cancer 
10-12
. The PADIs are a 
family of posttranslational modification enzymes that convert positively charged 
arginine residues on substrate proteins to neutrally charged citrulline, and this activity 
is alternatively called citrullination or deimination. Protein citrullination has recently 
been implicated in many diseases, including cancer 
13-19
. PADI2 has historically been 
defined as a cytoplasmic protein; however, recent evidence from our lab shows that 
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PADI2 can localize to the nucleus and directly bind chromatin to influence target gene 
expression 
13, 14, 16
. In the canine mammary gland, estrous cycle regulated PADI2 
expression in epithelial tissue correlates with citrulline levels, potentially indicating a 
role in gene expression. Recent evidence from our lab supports this prediction, as 
Zhang et al. have shown that PADI2 catalyzed citrullination of histone H3 arginine 26 
(H3R26) facilitates ER target gene activation 
16
. PADI2-mediated citrullination of 
H3R26 likely facilitates transcriptional activation by creating an open, permissive, 
chromatin architecture around the EREs of E2-induced genes. Following this, we 
established a new line of evidence demonstrating that PADI2 plays a role in the 
oncogenic progression of breast cancer using the basal-like MCF10AT model. 
Furthermore, we showed using RNA-seq, that PADI2 is highly correlated with 
HER2/ERBB2 overexpression across 57 breast cancer cell lines. We concluded this 
study with the first preclinical evidence showing that the PADI inhibitor, Cl-amidine, 
could be utilized as a therapeutic agent for the treatment of tumors in vivo.  
These findings led to additional questions, mainly, what was the functional 
relationship between PADI2 and HER2 in breast cancer. In this study, we present an 
additional role for PADI2 in the expression of the HER2 oncogene. Interestingly, 
PADI2 appears to function both upstream and downstream of HER2, potentially 
indicating a role in an oncogenic positive-feedback loop with HER2. Since our 
previous evidence suggested that PADI2 could act as an ER co-activator via the 
citrullination of H3R26, we were curious whether PADI2 regulates HER2 expression 
using the same mechanism. Using both PADI2 shRNA and our next-generation PADI 
inhibitor BB-Cl-amidine, we show that the reduction of PADI2, as well as the 
inhibition of PADI2-mediated citrullination of H3R26 (BB-Cl-amidine), leads to 
decreased expression of HER2. Conversely, HER2 regulation of PADI2 gene 
118 
 
expression is most likely downstream of PI3K signaling. Lastly, we validate our next-
generation PADI inhibitor, BB-Cl-amidine, in the treatment of breast cancer cells. 
Taken together, these results suggest an enhanced role for PADI2 in HER2 
expressing breast cancers. Given the role of PADI2 in ER- and HER2-positive tumors, 
PADI2 inhibitors may have therapeutic value for over 85% of all breast cancers, thus 
potentially benefiting a large majority of patients.  
 
3.3 Materials and Methods 
The Cancer Genome Atlas (TCGA) data analysis  
Data are from the sequencing of mammary tumors as part of the TCGA project 
20
. 
User generated gene-based heat map was performed using the UCSC browser via the 
TCGA portal (https://genome-cancer.ucsc.edu/proj/site/hgHeatmap/) 
21
. Survivability 
data was generated using the cBio Cancer Genomics Portal (http://cbioportal.org), 
which is an open-access resource for exploration of the TCGA data sets 
22
.  
 
Cell culture and treatment with BB-Cl-amidine and small-molecule inhibitors 
Cell lines from the MCF10AT breast cancer progression model used were the non-
tumorigenic MCF10A, MCF10AT1kC1.2 (MCF10AT), and MCF10DCIS.com 
(MCF10DCIS) cells, and were obtained from Dr. Fred Miller (Barbara Ann Karmanos 
Cancer Institute, Detroit, MI, USA). This biological system has been extensively 
reviewed 
23, 24
 and culture conditions described 
25-27
. The BT474, SKBR3, CHO-K1, 
and NIH-3T3 cell lines were obtained from ATCC and cultured according to 
manufacturer’s directions. MCF10A cells overexpressing GFP or HER2 were a 
generous gift of Dr. Zachary Hartman, MD Anderson Cancer Center, and have been 
previously described elsewhere 
28, 29
. All cells were maintained in a humidified 
atmosphere of 5% CO2 at 37
o
 C. For the experimental treatment of cell lines with 
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inhibitors, cells were seeded in 6-well plates (2 x 10
4
) and treated with select 
inhibitors: LY294002 (#9901, Cell Signaling), PD98059 (#9900, Cell Signaling), 
AG1478 (#658548, Calbiochem), Triciribine (#124012, Calbiochem), Rapamycin 
(R0395, Sigma), Lapatinib (SC-202205, Santa Cruz), and BB-Cl-amidine, which was 
a generous gift of Dr. Paul Thompson (The Scripps Research Institute, Florida). 
 
Generation of stable cell lines 
The MCF10DCIS and BT474 cell lines where stably transduced with lentivirus 
expressing shRNA for PADI2 or non-targeting shRNA control. Mission shRNA 
lentivirus plasmids for PADI2 (TRCN0000051447 – NM_007365.1-995s1c1) and 
non-targeting control (SHC002) were purchased from Sigma. Lentivirus was prepared 
and transduced according to manufacturer’s instructions. Stable clones were generated 
after selection with 2 µg/ml of puromycin for 2-3-weeks. The MCF10AT cell line was 
previously generated from MCF10A cells that were stably transfected with T24 H-Ras 
under G418 selection 
30
. Because of this, we generated a pcDNA3.1-hyg (+) vector 
expressing FLAG-PADI2 by subcloning FLAG-PADI2 from the previously validated 
pcDNA3.1-neo (+) overexpression vector (pcDNA3.1-FLAG-PADI2 
16
) using NheI 
and XhoI restriction sites. MCF10AT cells were transfected with the pcDNA3.1-hyg-
FLAG-PADI2 plasmid using X-tremeGene 9 (Roche), and stable clones selected in 
100 µg/ml hygromycin. 
 
Transient siRNA 
Pooled small interfering RNA (siRNA) oligonucleotides (ON-TARGET plus human 
SMARTpool) against PADI2 and ERBB2 were purchased from Dharmacon RNA 
Technologies (Thermo Scientific). For siRNA transfection of MCF10DCIS and 
BT474 cell lines, cells were seeded at 100,000/well in 6-well plates, and transfected 
120 
 
with 50–100 nM of the pooled oligonucleotide mixture by using X-tremeGENE 
siRNA transfection reagent (Roche) following manufacturer's protocols. Cells were 
grown for 72h before subsequent analysis by western blot or qPCR. 
 
Chromatin-immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) experiments were performed as previously 
described
16, 31
.  Briefly, MCF10DCIS and BT474 cells were grown to ~80 to 90% 
confluence, cross-linked with 1% PFA for 10 min at 37
o
C, and quenched with glycine 
(125 mM) for 5 min at 4
o
C. The cells were lysed (1% SDS, 10 mM EDTA, 50 mM 
Tris·HCl, pH 7.9, 1x protease inhibitor cocktail) and sonicated under conditions 
yielding fragments ranging from 300bp to 700bp. The material was clarified by 
centrifugation, diluted 10-fold in dilution buffer (0.5% Triton X-100, 2 mM EDTA, 
150 mM NaCl, 20 mM Tris·HCl, pH 7.9, 1x protease inhibitor cocktail), and pre-
cleared with protein A-agarose beads. The pre-cleared, chromatin-containing 
supernatant was used in immunoprecipitation reactions with antibodies against PADI2 
(12110-1-AP, ProteinTech) and H3Cit26 (ab19847, Abcam). Ten percent of the 
supernatant was saved as reference control. The immunoprecipitated genomic DNA 
was cleared of protein and residual RNA by digestion with proteinase K and RNase 
(Roche), respectively. The DNA was then extracted with phenol:chloroform:isoamyl 
alcohol and precipitated with ethanol. ChIP analysis of the HER2/ERBB2 promoter 
and downstream ERE (intron 4) was performed using quantitative real-time PCR 
(qPCR) to determine the enrichment of immunoprecipitated DNA relative to the input 
DNA, using primers as previously described 
32
. Each ChIP experiment was conducted 
a minimum of three times with independent chromatin isolates to ensure 
reproducibility. 
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Immunofluorescence (IF)  
Immunofluorescence experiments were performed using a standard protocol as 
previously described 
13
.  Briefly, BT474 cells treated with BB-Cl-amidine were probed 
with primary antibody for anti-ERBB2 (A0485, Dako). The IF slides were incubated 
in streptavidin conjugated-488 (Invitrogen), washed, and then mounted using 
Vectashield containing DAPI (Vector Laboratories).  Negative control for IF was 
rabbit IgG antibody at the appropriate concentration. 
 
Western blotting  
Western blotting was carried out as previously described 
13
. Primary antibodies against 
the following proteins were incubated overnight at 4
o
C: PADI2 (12110-1-AP, 
ProteinTech), ERBB2 (A0485, Dako), pERBB2-Y1248 (2247S, Cell Signaling), 
EGFR (ab2430, Abcam), pEGFR-Y1173 (4407, Cell Signaling), AKT (4691P, Cell 
Signaling), pAKT-S473 (4060P, Cell Signaling), MAPK (4695, Cell Signaling), 
pMAPK-T202/Y204 (4370P, Cell Signaling), AIB1 (2126S, Cell Signaling), ER-alpha 
(SC-542, Santa Cruz), FLAG-M2 (F1804, Sigma), and Ki67 (ab15580-100, Abcam). 
To confirm equal protein loading, membranes were stripped and re-probed with anti-
β-actin (ab8227, Abcam). 
 
Quantitative real-time PCR (qPCR) 
RNA was purified using the Qiagen RNAeasy kit, including on-column DNase 
treatment to remove genomic DNA.  The resulting RNA was reverse transcribed using 
the ABI High Capacity RNA-to-cDNA kit according to the manufacturer’s protocol 
(Applied Biosystems).  TaqMan Gene Expression Assays (ABI) for human PADI2 
(Hs00247108_m1), ERBB2 (Hs01001580_m1), EGFR (Hs01076078_m1), AIB1 
(Hs00180722_m1), ESR1 (Hs00174860_m1), and GAPDH (4352934E), were used for 
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qPCR. In addition, primer sequences for gene expression analysis via SYBR-qPCR 
can be found in Table 3.1.  Expression levels were analyzed using the 2 
-ΔΔ C(t)
 method 
33
. Data are shown as means ± SD from three independent experiments, and were 
separated using Student’s t-test. 
 
Flow-cytometry 
Monolayers of MCF10DCIS, BT474, CHO-K1, and NIH3T3 cells were seeded into 
25 cm
2
 flasks (2 x 10
6
 cells) and treated with increasing concentrations of BB-Cl-
amidine or vehicle (DMSO, 0.6125µM, 1.25 µM, 2.5 µM, and 5.0 µM). Cells were 
harvested after 48h using Accutase (Innovative Cell Technologies), fixed, 
permeabilized, and blocked in FACS Buffer (0.1M Dulbecco’s phosphate buffered 
saline, 0.02% sodium azide, 1.0% bovine serum albumin, and 0.1% Triton X-100) 
containing 10% normal goat serum and stained (except the isotype controls) with 
rabbit anti-cleaved Caspase-3 antibody (Cell Signaling). Isotype controls were treated 
with normal rabbit IgG (Vector Laboratories). All samples were stained with 
secondary goat anti-rabbit IgG conjugated to Alexa-488 (Invitrogen) and DAPI 
(Invitrogen) according to the manufacturer’s instructions. Cells were analyzed on a 
FACS-Calibur (BD Biosciences) or a Gallios (Beckman Coulter) flow-cytometer and 
data analyzed for percent apoptotic cells (cleaved caspase-3-positive) and cell cycle 
analysis with FlowJo software (TreeStar Inc.). Data are shown as means ± SD from 
three independent experiments, and were separated using Student’s t-test. 
 
Assays for cellular malignancy 
Anchorage-independent growth assays were performed on MCF10DCIS-P2KD and 
MCF10AT-PADI2 cells, along with their respective control cell lines (MCF10DCIS-
SC and MCF10AT-emtpy). Briefly, the cells were plated at a density of 5,000 cells/ml 
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in medium containing 0.3% agarose onto media containing 0.6% agarose in 6-well 
dishes. Cultures were fed once a week and colonies counted after 3-weeks of growth. 
Each assay was repeated and means represent ± SD from three independent 
experiments (* p < 0.05). Focus formation assays were carried out on cells grown in 6-
well plates. Cells were fixed with 4% PFA and stained with crystal violet for 
subsequent analysis of focus formation.  
 
Statistical analysis 
All experiments were independently repeated at least three times unless otherwise 
indicated.  Values were expressed as the mean + the SD. Means were separated using 
Student’s t-test  
 
3.4 Results 
PADI2 is overexpressed in HER2-positive and basal-like tumors and is correlated 
with poor prognosis 
While we have previously shown that PADI2 is highly correlated with HER2 
expression levels across 57 breast cancer cell lines, we wanted to see whether this 
relationship holds up in primary mammary tumors. Recently, data from The Cancer 
Genome Atlas (TCGA) was published 
20
, with various sources currently available to 
access this data. The UCSC cancer browser offers the opportunity to view data in user 
generated gene-based heat maps 
21
. We examined a small group of genes known to be 
involved in PADI2 signaling in breast cancer. Consistent with our previous findings, 
we see the same relationship between PADI2 and HER2, as PADI2 expression clusters 
with HER2-positive tumors (Figure 3.1). Interestingly, we also see that PADI2 is 
upregulated in basal-like breast cancers, along with EGFR, which is known to be a 
marker for basal tumors; however, our previous data potentially supports this  
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Figure 3.1: PADI2 expression clusters with HER2-positive and basal-like tumors. 
TCGA heat map displaying gene expression for genes known to play a role in PADI2 
signaling: estrogen receptor-alpha (ESR1), epidermal growth factor receptor (EGFR), 
erythroblastic leukemia viral oncogene homolog-2 (ERBB2), and peptidylarginine 
deiminase-2 (PADI2). Gene mRNA levels were determined by Illumina HiSeq 2000 
RNA Sequencing platform by the University of North Carolina TCGA genome 
characterization center. Breast cancer subtypes are based on RNA-seq and array data. 
Mammary tumors (N = 1032) are from the TCGA breast cancer panel (as presented in 
TCGA, Nature, 2012 
20
). Data were collected from UCSC browser (TCGA portal), 
and heat map generated as detailed in Goldman et al., Nuc. Acids Res., 2013 
21
.  
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relationship, as we have shown PADI2 is upregulated in the transformed cell lines of 
the basal MCF10AT model of breast cancer progression 
15
. Surprisingly, we do not see 
any correlation between PADI2 and ESR1 (ER) expression levels, though our previous 
data suggest that PADI2 expression is upregulated upon estrogen stimulation in ER-
positive breast cancer 
16
. However, more work is needed to investigate this disparity.  
The TCGA data are also associated with clinical progression and outcome for each of 
the patients and associated primary tumors. We queried the cBio Cancer Genomics 
Portal, which is offered through Memorial Sloan Kettering Cancer Center (MSKCC) 
22
, and show that PADI2 upregulation in mammary tumors leads to decreased 
survivability and worse prognosis (p-value = 0.0435) (Figure 3.2). Interestingly, we 
see these data hold up for basal-like tumors, with elevated PADI2 significantly 
decreasing survivability in these patients (p-value = 0.0036). 
 
Knockdown of PADI2 reduces HER2/ERBB2 expression levels 
The coordinated increase in PADI2 and HER2 expression levels suggested a direct 
relationship, and given our previously established role for PADI2 as an ER co-
activator, we wanted to assess the potential effect of PADI2 on HER2 signaling. Using 
lentiviral delivery of shRNA targeting PADI2 (or scrambled control), we generated 
two different breast cancer cell lines that stably knocked-downed PADI2 expression. 
We first targeted the MCF10DCIS cell line, which we previously described as having 
high PADI2 expression levels in vitro and in vivo. This cell line is part of the 
MCF10AT model of breast cancer progression, and faithfully recapitulates highly 
invasive human comedo-like ductal carcinoma in situ tumors 
34
. We found that when 
we knocked-down PADI2 in MCF10DCIS cells, HER2 expression levels were 
reduced at both the protein and mRNA levels (Figure 3.3a and b). Interestingly, we 
also saw a slight reduction in the activated form of HER2/ERBB2, indicated by 
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Figure 3.2: PADI2 upregulation in mammary tumors leads to decreased 
survivability and worse prognosis. TCGA data showing that PADI2 upregulation 
significantly decreases survivability across all mammary tumors (a) and the basal 
subtype (b). Kaplan-Meier estimates of disease specific survival (event of death from 
breast cancer) across 447 samples for all mammary tumors (16/447, p-value 0.0435) 
and 81 cases for basal-like tumors (10/81, p-value 0.0036). 
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n=447 (16/447 = 3%) 
n=81 (10/81 = 12.3%) 
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 phosphorylation at tyrosine-1248 (pERBB2). We have previously shown, along with 
others, that MCF10DCIS cells have upregulated HER2/ERBB2 expression levels 
(when compared to their isogenic parental cell line, MCF10A) 
15, 35, 36
, but we wanted 
to compare whether we see this same effect in the HER2-amplified BT474 cell line. 
This cell line was chosen due to its high levels of HER2/ERBB2 and PADI2 
expression. Again, we see the same effect on HER2 /ERBB2 expression when we 
knockdown PADI2, with the effect on pERBB2 levels more pronounced in BT474 
than MCF10DCIS (Figure 3.3a and b). The reduction in activated HER2/ERBB2 in 
both cell lines could potentially be a byproduct of the decreased HER2/ERBB2 protein 
levels; however, we cannot rule out additional mechanisms. To validate these findings, 
we examined whether ER or the ER co-activator AIB1 had any changes in expression 
levels upon PADI2 knockdown (Figure 3.4a and b). As expected, we see that ER 
levels are reduced, which we have previously described in MCF7 cells 
16
. However, 
the reduction of AIB1 protein, a known ER cofactor that has been implicated in 
tamoxifen resistance, was surprising 
5, 32
. While we have previously established a role 
for PADI2 in ER-target gene signaling, these data suggest that PADI2 might also play 
a role in the development of tamoxifen resistance through ER/HER2 cross talk.  
 
PADI2 binds the HER2/ERBB2 promoter and downstream ERE and potentially acts 
as a co-activator of HER2 signaling 
Given our previously findings linking PADI2 and histone H3 arginine (H3R26) 
citrullination (H3Cit26) with ER-target gene expression, and our results here showing 
PADI2 knockdown leads to decreased HER2 expression levels, we predicted that 
PADI2 might directly regulate HER2 via the same mechanism. To test this hypothesis, 
we used chromatin immunoprecipitation (ChIP) to assay PADI2 binding to the 
HER2/ERBB2 promoter and downstream estrogen response element (ERE) in both 
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Figure 3.3: Stable knockdown of PADI2 leads to decreased HER2/ERBB2 
expression at both protein and mRNA levels. (a) Western blot analyses of PADI2, 
ERBB2, and phosphorylated ERBB2 protein levels (pERBB2-Y1248) in MCF10DCIS 
(DCIS) or BT474 cells stably expressing a scrambled control shRNA (SC) or shRNA 
directed against PADI2 (P2KD). Equal loading was determined by probing the 
membrane with β-actin antibody. (b) Relative PADI2 and ERBB2 mRNA levels in 
MCF10DCIS and BT474 P2KD cell lines compared to scrambled control. PADI2 and 
ERBB2 mRNA levels were determined by qPCR (TaqMan) using scrambled control 
(SC) cells as the reference and with GAPDH normalization. Expression levels were 
analyzed using the 2 
-ΔΔ C(t)
 method, and data are expressed as the mean ± SD from 
three independent experiments (* p < 0.05). 
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Figure 3.4: PADI2 stable knockdown leads to a decrease in the expression of 
estrogen receptor-alpha and ER-cofactor AIB1. (a) Western blot analyses of 
PADI2, ER-alpha (ERα), and the ERα co-activator AIB1 protein levels in 
MCF10DCIS (DCIS) or BT474 cells stably expressing a scrambled control shRNA 
(SC) or shRNA directed against PADI2 (P2KD). Two different stable clones were 
tested, (1) and (2), with (2) being the clone selected for further analysis in both 
MCF10DCIS and BT474 cell lines. Equal loading was determined by probing the 
membrane with β-actin antibody.   
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 MCF10DCIS and BT474 cells. Results show that the strong association of PADI2 
with ETS elements at the HER2/ERBB2 promoter, in addition to the recently identified 
downstream intronic ERE, is lost upon PADI2 knockdown in both the MCF10DCIS 
(Figure 3.5a) and BT474 (Figure 3.5b) cell lines. Furthermore, we also found a sharp 
reduction in the H3Cit26 modification at both of these sites in PADI2-depleted 
(PADI2-KD) cell lines (Figure 3.5a and b), suggesting that PADI2-catalyzed 
H3Cit26 modification may regulate HER2/ERBB2 expression. To examine whether 
PADI2-KD has any effects on genes known to be downstream of HER2 signaling, we 
analyzed the expression of a subset of genes using qPCR. We first looked at the 
MCF10DCIS cell line, and as expected, we see a reduction of HER2/ERBB2 gene 
levels, along with genes known to be downstream of HER2, including JAB1 
37, 38
, 
PEA3 
39, 40
, FOXAI 
41
, FOXMI 
42, 43
, and GRB7 
44
 (Figure 3.6). The same group of 
genes is also reduced in the BT474 cell line (Figure 3.7), indicating similar results in 
both cell lines upon PADI2-KD. HER2/ERBB2 signaling is known to drive the 
proliferation of breast cancer cells, leading to the upregulation of genes known to be 
involved with cell cycle progression, such as the cyclins and cyclin dependent kinases 
(CDKs). Interestingly, we show that PADI2-KD in both MCF10DCIS and BT474 
cells leads to a reduction across these genes, as well as in the proliferation markers, 
Ki67 and PCNA (Figures 3.6 and 3.7). Surprisingly, we also see an increase in 
markers of inflammation, IL6 and IL8, upon PADI2-KD in both cell lines. While 
PADI2 has been implicated in multiple inflammatory diseases, these results are 
surprising given the role of both of these genes in tumor progression. However, recent 
evidence suggests that both IL6 and IL8 are involved in inflammatory positive-
feedback loops during the progression of HER2-positive breast cancer 
29, 45, 46
. Not 
surprisingly, we also see a reduction in ER (ESR1), as well as the nuclear receptor co-
activators SRC1 and AIB1. The expression of co-activator proteins, such as SRC1,  
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Figure 3.5: PADI2 and H3Cit26 bind the HER2/ERBB2 promoter and intronic 
ERE in MCF10DCIS and BT474 cells. Chromatin-immunoprecipitation (ChIP) 
qPCR was used to analyze the binding of PADI2 and citrullinated H3R26 (H3Cit26) 
to the HER2/ERBB2 promoter and/or downstream ERE in MCF10DCIS (a) and 
BT474 (b) cells. ChIP-qPCR data are presented as % input for MCF10DCIS and 
signal/background for BT474. Error bars indicate ± SEM of three independent 
experiments. 
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Figure 3.6: Stable knockdown of PADI2 reduces expression of genes downstream 
of HER2/ERBB2 and ER signaling in MCF10DCIS cells. Genes known to be 
expressed downstream of HER2 and ER (full gene list and primers can be found in 
Table 3.1) were tested by SYBR qPCR on MCF10DCIS (DCIS) cells stably 
expressing a scrambled control shRNA or shRNA directed against PADI2 (P2KD). 
Relative mRNA levels in MCF10DCIS P2KD cell lines compared to scrambled 
control. Total RNA was isolated from cells and respective mRNA levels were 
determined by SYBR qPCR using scrambled control cells as the reference 
(represented by dashed line = ~1) and with GAPDH normalization. Expression levels 
were analyzed using the 2 
-ΔΔ C(t)
 method, and data are expressed as the mean ± SD 
from three independent experiments. 
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Figure 3.7: Stable knockdown of PADI2 reduces expression of genes downstream 
of HER2/ERBB2 and ER signaling in BT474 cells. Genes known to be expressed 
downstream of HER2 and ER (full gene list and primers can be found in Table 3.1) 
were tested by SYBR qPCR on BT474 cells stably expressing a control scrambled 
shRNA or shRNA directed against PADI2 (P2KD). Relative mRNA levels in BT474-
P2KD cell lines compared to scrambled control. Total RNA was isolated from cells 
and respective mRNA levels were determined by SYBR qPCR using scrambled 
control cells as the reference (represented by dashed line = ~1) and with GAPDH 
normalization. Expression levels were analyzed using the 2 
-ΔΔ C(t)
 method, and data 
are expressed as the mean ± SD from three independent experiments. 
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AIB1, and Polyomavirus Enhancer Activator-3 (PEA3), has been shown to correlate 
with endocrine resistance in breast cancer 
47
. 
 
PADI2 expression levels correlate with cellular malignancy 
Given the reduction in expression of genes downstream of HER2 signaling, including 
those involved in proliferation and ER/HER2 cross talk in breast cancer, we wanted to 
see what effects the knockdown of PADI2 has on cellular malignancy. We tested the 
ability of our PADI2 knocked-down MCF10DCIS cells to form colonies in soft-agar. 
The ability of cells to grow under anchorage-independent conditions is a hallmark of 
malignant transformation. We show that both the size (Figure 3.8a) and number 
(Figure 3.8b) of colonies are severely reduced in the PADI2-KD (DCIS-P2KD) cells, 
when compared to scrambled control shRNA cells (DCIS-SC). However, we did not 
see any effect on anchorage-independent growth of BT474-P2KD cells (data not 
shown). In addition, we assayed the focus-forming activity for both MCF10DCIS 
(Figure 3.8c) and BT474 (Figure 3.8d) cells, with both showing a marked reduction 
in PADI2-KD cell lines compared to the scrambled control. Conversely, we tested the 
ability of PADI2 overexpression to enhance malignancy in MCF10AT cells lines. 
While we do not see any significant difference in the number of colonies grown on 
soft-agar, the MCF10AT-PADI2 cells have larger colonies (Figure 3.9a and b). We 
also found a slight increase in HER2/ERBB2 expression in the stably overexpressing 
MCF10AT-PADI2 cells, when compared to the control empty vector cells 
(MCF10AT-empty) (Figure 3.9c). 
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Figure 3.8: PADI2 knockdown (KD) decreases cellular malignancy in breast 
cancer cells. (a) MCF10DCIS cells stably overexpressing shRNA for PADI2 or 
scrambled control were plated at a density of 5,000 cells/ml in medium containing 
0.3% agarose onto media containing 0.6% agarose in 6-well dishes. Cultures were fed 
once a week and colonies counted (b) after 3-weeks of growth. The data shown in (b) 
are expressed as the mean ± SD from three independent experiments (* p < 0.05). 
MCF10DCIS (c)  and BT474 (d) cells stably expressing scrambled or PADI2 shRNA 
were grown for 1-week, fixed with 4% PFA, and stained with crystal violet for 
subsequent analysis of focus formation.  
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Figure 3.9: Stable overexpression of PADI2 in premalignant MCF10AT cells 
leads to increased colony size in anchorage-independent growth. (a) MCF10AT 
cells stably overexpressing FLAG-tagged PADI2 (pcDNA3.1-FLAG-PADI2) or an 
empty vector control were plated at a density of 5,000 cells/ml in medium containing 
0.3% agarose onto media containing 0.6% agarose in 6-well dishes. Cultures were fed 
once a week and colonies counted (b) after 3-weeks of growth. The data shown in (b) 
are expressed as the mean ± SD from three independent experiments (* p < 0.05). (c)  
Western blot of PADI2 and ERBB2 protein levels in MCF10AT cells overexpressing 
PADI2 or empty vector. (β-actin = loading control)  
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Inhibition of PADI2 activity reduces HER2/ERBB2 associated oncogenic signaling 
and cellular malignancy 
To investigate whether PADI2 expression is important for HER2 gene expression and 
downstream signaling, we next tested the pharmacological inhibition of PADI2 on 
breast cancer cells in vitro. We have recently developed a next-generation PADI 
inhibitor, biphenyl-benzimidazole-Cl-amidine (BB-Cl-amidine), which has increased 
cellular permeability, stability, and potency compared to first-generation Cl-amidine. 
BB-Cl-amidine is a derivative of Cl-amidine (Figure 3.10a), and has much of the 
same properties, including the ability to bind irreversibly to the active site of PADIs, 
thereby blocking activity in vitro and in vivo 
48
. BB-Cl-amidine functions as a “pan-
PADI” inhibitor as it blocks the activity of all PADIs, though PADI2 has been shown 
to be the predominant isozyme expressed in both MCF10DCIS and BT474 cells 
(McElwee et al.
15
 and data not shown). We found that BB-Cl-amidine leads to a dose-
dependent reduction in HER2/ERBB2 protein expression in MCF10DCIS cells and 
the HER2-positive SKBR3 cell line (Figure 3.10b). Furthermore, we see the same 
dose-dependent reduction at the mRNA level in both cell lines (Figure 3.10c), 
indicating that PADI2 activity has a potential effect on HER2/ERBB2 gene 
transcription. When we knocked-down PADI2 in BT474 cells, we noticed that there 
was a reduction in both ER and AIB1 
47
 (Figure 3.4), both of which are involved, 
along with HER2/ERBB2 and EGFR 
4-6
, in the development of acquired resistance to 
hormone-therapy. Similarly, we found that BB-Cl-amidine reduces HER2/ERBB2 and 
EGFR, along with both of their tyrosine phosphorylated activated forms (pERBB2-
Y1248 and pEGFR-Y1173) (Figure3.11a). As expected, we also see a dose-dependent 
reduction in both ER and AIB1 levels (Figure 3.11a). This reduction in protein 
expression is concomitant with a reduction in gene expression (Figure 3.11b). 
Furthermore, this reduced growth-factor/ER cross talk leads to a reduction in cellular 
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Figure 3.10: The PADI inhibitor, BB-Cl-amidine, leads to a dose-dependent 
reduction of HER2/ERBB2 protein and mRNA. (a) The chemical structure of next-
generation PADI inhibitor, biphenyl-benzimidazole-Cl-amidine (BB-CLA); BB-CLA 
has increased cellular permeability, stability, and potency compared to first-generation 
Cl-amidine. (b) MCF10DCIS and BT474 cells were treated for 24h with increasing 
concentrations of BB-Cl-amidine or vehicle (DMSO, 500 nM, 1.25 µM, 2.5 µM, and 
5.0 µM). Whole-cell lysates were analyzed by western blot for PADI2 and ERBB2 
proteins, with β-actin serving as a loading control. (c) Relative PADI2 and ERBB2 
mRNA levels in MCF10DCIS and BT474 cells treated with BB-Cl-amidine compared 
to vehicle control (DMSO). PADI2 and ERBB2 mRNA levels were determined by 
qPCR (TaqMan) using DMSO treated cells as the reference and with GAPDH 
normalization. Expression levels were analyzed using the 2 
-ΔΔ C(t)
 method, and data 
are expressed as the mean ± SD from three independent experiments (* p < 0.05). 
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Figure 3.11: BB-Cl-amidine leads to decreased malignancy of breast cancer cells 
and dose-dependent reduction in the expression of genes involved in ER-signaling 
and tamoxifen resistance pathways. (a) Western blot analysis of proteins involved in 
ER-signaling and tamoxifen resistance in BT474 cells after treatment of cells for 24h 
with vehicle (DMSO) or increasing doses of BB-Cl-amidine (500 nM, 1.25 µM, 2.5 
µM, and 5.0 µM). Whole-cell lysates were analyzed by western blot for the indicated 
proteins, including active forms of ERBB2 (phosphorylated -ERBB2, Y1248) and 
EGFR (phosphorylated-EGFR, Y1173), with β-actin serving as a loading control. 
Total RNA was isolated after 24h of treatment and analyzed for ERBB2, EGFR, AIB1, 
PADI2, and ESR1 mRNA expression using qPCR (TaqMan). Values represent the 
averages of three independent experiments (* p < 0.05) using DMSO treated cells as 
the reference and with GAPDH normalization. (c) MCF10DCIS and BT474 cells were 
treated with increasing doses of BB-Cl-amidine over the course of 1-week, with 
replacement of media and drug every 3 days. Cells were fixed with 4% PFA and 
stained with crystal violet for subsequent analysis. 
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growth and malignancy in treated breast cancer cells. Both MCF10DCIS and BT474 
cells show a dose-dependent decrease in focus formation when treated with BB-Cl-
amidine (Figure 3.11c). Since we observed a reduction in expression of genes known 
to be downstream of HER2 signaling upon PADI2 knockdown, we wanted to see 
whether the inhibition of PADI2 activity has the same effect. As predicted, we show 
the same reduction in the genes downstream of HER2 signaling (Figures 3.12 and 
3.13); however, the decrease is not as pronounced as that seen in the PADI2-KD cells. 
Interestingly, we saw an increased reduction in expression of those genes involved in 
cellular proliferation (cyclins and CDKs) when compared to the PADI2-KD. This 
might indicate additional targeting of BB-Cl-amidine beyond PADI2. Surprisingly, we 
do not see increased IL6 and IL8 gene expression as we did with PADI2-KD, again 
suggesting that some of the effects of BB-Cl-amidine differ from the genetic 
knockdown of PADI2. As previously shown with our first-generation PADI inhibitor, 
we see increased expression of genes involved with DNA-damage and apoptosis, 
including p21, PUMA, and GADD45α, potentially indicating that BB-Cl-amidine leads 
to the same S-phase induced apoptosis seen with Cl-amidine 
15
. To investigate whether 
there was an increase in apoptosis in the treated MCF10DCIS and BT474 cells, we 
examined the cells by flow-cytometry for activated caspase-3 levels. Results show a 
dose-dependent reduction in cellular proliferation (Figure3.14a), as well as the 
induction of activated caspase-3 (Figure 3.14b), upon treatment with BB-Cl-amidine 
in both breast cancer cell lines. Conversely, we do not see any adverse effects on 
growth or apoptosis in two normal cell lines, CHO-KI and NIH-3T3. Taken together, 
these results suggest that BB-Cl-amidine blocks the growth of MCF10DCIS and 
BT474 cells by inducing cell cycle arrest and apoptosis. This prediction is supported 
by our previous finding that Cl-amidine drives apoptosis in lymphocytic cell lines 
17
, 
and can reduce tumor growth in vitro and in vivo, ultimately leading to S-phase  
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Figure 3.12: BB-Cl-amidine treatment reduces the expression of genes 
downstream of HER2/ERBB2 and ER signaling in MCF10DCIS cells. Genes 
known to be expressed downstream of HER2 and ER (full gene list and primers can be 
found in Table 3.1) were tested by SYBR qPCR on MCF10DCIS (DCIS) cells treated 
with 2.5 µM of BB-Cl-amidine for 24h. Total RNA was isolated and respective 
mRNA levels were determined by SYBR qPCR using DMSO treated control cells as 
the reference (represented by dashed line = ~1) and with GAPDH normalization. 
Expression levels were analyzed using the 2 
-ΔΔ C(t)
 method, and data are expressed as 
the mean ± SD from three independent experiments.  
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Figure 3.13: BB-Cl-amidine treatment reduces the expression of genes 
downstream of HER2/ERBB2 and ER signaling in BT474 cells. Genes known to 
be expressed downstream of HER2 and ER (full gene list and primers can be found in 
Table 3.1) were tested by SYBR qPCR on BT474 cells treated with 2.5 µM of BB-Cl-
amidine for 24h. Total RNA was isolated and respective mRNA levels were 
determined by SYBR qPCR using DMSO treated control cells as the reference 
(represented by dashed line = ~1) and with GAPDH normalization. Expression levels 
were analyzed using the 2 
-ΔΔ C(t)
 method, and data are expressed as the mean ± SD 
from three independent experiments.   
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Figure 3.14: BB-Cl-amidine treatment leads to a decrease in cellular proliferation 
and increased apoptosis in BT474 and MCF10DCIS breast cancer cell lines, with 
no significant negative effects on growth seen in normal CHO-K1 or NIH-3T3 
cells. (a) BT474 and MCF10DCIS cells were treated with increasing concentrations of 
BB-Cl-amidine or vehicle (DMSO, 0.6125µM, 1.25 µM, 2.5 µM, and 5.0 µM) and 
analyzed by flow-cytometry for proliferation (a) and apoptosis (b). (a) Cell counts 
(DAPI) show a dose-dependent decrease in growth of BT474 and MCF10DCIS cells 
after 48h of BB-Cl-amidine compared to DMSO treatment. Normal cell lines, CHO-
KI and NIH-3T3, were largely unaffected by treatment. (b) BT474 and MCF10DCIS 
cells show increased apoptosis upon treatment with BB-Cl-amidine, compared to 
normal cells (CHO-KI and NIH-3T3). Data represent cell number and percent 
apoptotic cells (cleaved Caspase-3 positive) after 48h of treatment and are expressed 
as the mean ± SD from three independent experiments (* p < 0.05). 
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induced apoptosis 
15
. Importantly, the lack of an apoptotic effect on CHO-K1 and 
NIH-3T3 cells suggests that BB-Cl-amidine may primarily target tumor cells for 
killing. Consistent with this possibility is the fact that our first-generation PADI 
inhibitor, Cl-amidine, did not affect the growth of “normal” MCF10A cells 15, in 
addition to non-tumorigenic NIH3T3 cells and HL60 granulocytes 
49
. We also found 
that BB-Cl-amidine slightly decreased the cell surface expression of HER2/ERBB2 
and potentially facilitated the internalization of the receptor in BT474 cells (Figure 
3.15). This has been previously noted to occur with the PI3K inhibitor, LY294002, but 
the mechanism behind this phenomenon is still under investigation 
50
. 
 
HER2/ERBB2 upregulates PADI2 expression through PI3K pathway signaling 
HER2/ERBB2 signaling often occurs within positive feedback loops, including genes 
such as ADAM12 
51
, ERα36 52, BEX2 53, MED1 54, and the inflammatory gene, IL6 29. 
These signaling loops enhance the oncogenic signaling of HER2 and drive 
tumorigenesis, and in the case of MED1, tamoxifen resistance. Interestingly, we find 
that PADI2 appears to be both upstream and downstream of HER2/ERBB2 signaling. 
When we treat BT474 cells with the dual-tyrosine kinase inhibitor (EGFR/HER2), 
lapatinib, we see reduced protein levels of PADI2 (Figure 3.16b). Based on this, we 
wanted to test whether the overexpression of HER2/ERBB2 in MCF10A cells, which 
have very low basal levels of PADI2, can upregulate the expression of PADI2. 
Surprisingly, MCF10A-HER2 cells show an increase in both PADI2 protein and 
mRNA (Figure 3.16b). Using siRNA to transiently knockdown HER2/ERBB2, we 
show that in BT474 cells, reduced HER2/ERBB2 leads to a decrease in PADI2 
expression (Figure 3.17a). We see the same effect in MCF10DCIS cells, albeit to a 
lesser extent (Figure 3.17b). Signaling downstream of HER2/ERBB2 is known to 
occur through either the MAPK or PI3K pathway. To determine which signaling  
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Figure 3.15: Immunofluorescence examination of HER2/ERBB2 localization in 
BT474 cells after treatment with BB-Cl-amidine shows increased internalization 
of the receptor. BT474 cells were treated with either 1.25 µM or 2.5 µM of BB-Cl-
amidine for 48h. Cells were probed with anti-HER2/ERBB2 (green) and nuclei were 
stained with DAPI (blue). 
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Figure 3.16: PADI2 expression is downstream of HER2/ERBB2 signaling. (a) 
Western blot analysis of ERBB2/pERBB2 (Y1248) and PADI2 protein expression in 
BT474 cells treated with BB-Cl-amidine (BB-CLA, 2.5 µM) and lapatinib (LAP, 1 
µM) for 24h. (b) MCF10A cells stably overexpressing HER2 (10A-HER2) or GFP 
(10A-GFP) were analyzed by western blot for ERBB2 and PADI2 expression.  β-actin 
was used as a loading control for both blots. Total RNA from GFP or HER2 
expressing MCF10A cells was isolated and PADI2 and ERBB2 mRNA levels were 
determined by qPCR (TaqMan) using MCF10A-GFP control cells as the reference 
with GAPDH normalization. Expression levels were analyzed using the 2 
-ΔΔ C(t)
 
method, and data are expressed as the mean ± SD from three independent experiments.  
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Figure 3.17: Transient siRNA knockdown of ERBB2/HER2 in BT474 and 
MCF10DCIS cells reduces PADI2 expression. BT474 (a) and MCF10DCIS (b) cells 
were transfected with siRNA targeting PADI2 and ERBB2, or control non-targeting 
siRNA, for 72h. Western blot analyses of siRNA treated BT474 (a) and MCF10DCIS 
(b) cells for ERBB2 and PADI2 protein expression with β-actin serving as a loading 
control.  Total RNA from PADI2 and ERBB2 siRNA transfected BT474 (a) and 
MCF10DCIS (b) cells was isolated and PADI2 and ERBB2 mRNA levels were 
determined by qPCR (TaqMan) using control siRNA as the reference with GAPDH 
normalization. Expression levels were analyzed using the 2 
-ΔΔ C(t)
 method, and data 
are expressed as the mean ± SD from three independent experiments.      
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pathway may affect PADI2 expression, we treated BT474 cells with inhibitors for both 
the PI3K and MAPK pathways. We found that PADI2 signaling is reduced when PI3K 
pathway inhibitors (LY294002-PI3K, triciribine-Akt, and rapamycin-mTOR) were 
used (Figure 3.18a), while the MAPK pathway inhibitor (PD98059-MEK1) had no 
effect, indicating that PADI2 expression is downstream of the PI3K-AKT-mTOR axis.  
 
PADI inhibitor BB-Cl-amidine enhances HER2/ERBB2 and PI3K pathway inhibitors 
As we previously noted here, BB-Cl-amidine treatment leads to a marked reduction in 
activated HER2/ERBB2 and EGFR. This potentially suggests that PADI2 may act 
directly on proteins, and that reducing PADI2-mediated citrullination might have an 
effect on these proteins phosphorylation levels. To test this, we treated BT474 cells 
with BB-Cl-amidine and the same PI3K pathway inhibitors, along with lapatinib, as 
well as combinations of the two. Interestingly, we found that BB-Cl-amidine reduces 
both phospho-AKT (serine-473) and phospho-MAPK (threonine-202/ tyrosine-204) 
levels (Figure 3.18b). Furthermore, the combination of BB-Cl-amidine with the PI3K 
inhibitors, and lapatinib, had synergistic effects and greatly reduced cellular 
proliferation in BT474 cells (Figure 3.19). We confirmed these results by testing 
decreasing levels of lapatinib along with a low-dose of BB-Cl-amidine (500 nM), and 
confirmed that the combination of the two had a much greater effect on the growth of 
BT474 cells (Figure 3.20a). However, we did not see the same effect on the 
MCF10DCIS cells (Figure 3.20b). This was not surprising, as MCF10DCIS cells 
have been reported to be resistant to lapatinib treatment due to an activating mutation 
in the PIK3CA gene (H1047R) 
55, 56
. The following results establish a novel role for 
any PADI inhibitor, and potentially indicate an enhanced role for this small molecule 
in the treatment of breast cancers. Future studies might examine whether PADI2 
knockdown might have any effect on the lapatinib resistance of MCF10DCIS cells. 
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Figure 3.18: PADI2 expression is downstream of HER2/ERBB2 signaling via the 
PI3K-ATK-mTOR pathway, and BB-Cl-amidine can reduce activation of both 
PI3K and MAPK signaling.  (a) Western blot analysis of protein expression in 
BT474 cells treated with the following small molecule inhibitors: AG1478 (EGFR, 10 
µM), lapatinib ([LAP] EGFR/HER2, 1 µM), LY294002 (PI3K, 20 µM), triciribine 
(Akt, 1 µM), rapamycin (mTOR, 100 nM), and PD98059 (MAPK/MEK, 20 µM). 
Antibodies against ERBB2/pERBB2 (Y1248), PADI2, phospho-AKT (S473), and 
phospho-MAPK (T202/Y204) were used, with β-actin serving as a loading control. (b) 
BT474 cells were treated for 48h with BB-Cl-amidine, BB-Cl-amidine and lapatinib 
together, or with a combination of BB-Cl-amidine plus PI3K pathway inhibitors 
(LY294002, triciribine, and rapamycin). Whole-cell lysates were probed for 
ERBB2/pERBB2 (Y1248), AKT/pAKT (S473), and MAPK/pMAPK (T202/Y204), 
with β-actin serving as a loading control. 
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Figure 3.19: BB-Cl-amidine enhances the effect of small molecular inhibitors that 
target the HER2/ERBB2 and the PI3K pathways. Epithelial morphology of BT474 
cells treated with BB-Cl-amidine alone, or in combination with LY294002 (PI3K, 20 
µM), triciribine (Akt, 1 µM), rapamycin (mTOR, 100 nM), and lapatinib ([LAP] 
EGFR/HER2, 1 µM).  
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Figure 3.20: BB-Cl-amidine has a synergistic effect with lapatinib in the 
treatment of BT474, but not MCF10DCIS breast cancer cells. BT474 (a) or 
MCF10DCIS (b) cells were treated with increasing concentrations of BB-Cl-amidine 
or lapatinib alone, or with a combination of BB-Cl-amidine (0.5 µM) and increasing 
concentrations of lapatinib. BT474 cells were treated over the course of 3-weeks, and 
MCF10DCIS cells 1-week, with new media and drug added every 3d. Cells were fixed 
with 4% PFA and stained with crystal violet for subsequent analysis of focus 
formation.   
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3.5 Discussion 
Our previous work has established a role for PADI2 as an epigenetic regulator of ER-
target gene expression in mammary tumorigenesis 
16
, in addition to establishing a 
correlation between PADI2 and HER2/ERBB2 expression across 57 breast cancer cell 
lines 
15
. The work presented here looks to expand on both of these studies, and to 
establish a role for PADI2 in the expression of the HER2 oncogene. We set out to 
explore the functional relationship between PADI2 and HER2, i.e. whether PADI2 
enhances HER2 expression or vice-versa. Interestingly, PADI2 appears to function 
both upstream and downstream of HER2, potentially indicating a role in an oncogenic 
positive-feedback loop with HER2. Previous evidence from our lab has shown that 
PADI2 can act as an ER co-activator via the citrullination of H3R26 
16
 , so we were 
curious to see if PADI2 regulates HER2 expression using the same mechanism. 
Interestingly, a recent report by Hurtado et al. has found that ER can regulate 
HER2/ERBB2 expression by binding to an estrogen response element (ERE) within 
intron 4 of the HER2/ERBB2 gene 
32
. Therefore, it is possible that, similar to other ER 
target genes, PADI2 regulates HER2/ERBB2 expression by functioning as an ER co-
factor. We show here that PADI2 strongly binds the HER2 proximal promoter (ETS 
region), in addition to the recently characterized ERE. In the presence of the PADI 
inhibitor, BB-Cl-amidine, we see a dose-dependent reduction in HER2 protein and 
mRNA. We also see the reduction of HER2 protein and mRNA in cells that were 
stably transfected with shRNA for PADI2. Furthermore, there was also a concomitant 
reduction in the growth and malignant progression of these cells upon inhibition or 
shRNA knockdown of PADI2. It is interesting to speculate how PADI2 can function 
both as an ER and HER2 cofactor, especially with regard to mammary tumorigenesis. 
Previous evidence suggests that histone acetylation and phosphorylation play key roles 
in inducing HER2 expression 
57
, and we have previously shown that histone 
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citrullination enhances histone acetylation and vice-versa 
58
. Therefore, provided with 
what we know about PADI2 as a co-activator of ER target genes, we can hypothesize 
that HER2 gene expression might work in the same fashion. Recent evidence from our 
lab using in vitro biochemical assays with bulk histones revealed that the H3Cit26 
modification was found only on peptides that contained acetylated H3K27 (H3K27ac); 
thus, suggesting that H3K237ac enhances PADI2-mediated H3R26 citrullination 
16
.  
ER is known to associate with a number of multi-protein complexes, including heat 
shock proteins (HSPs) 
59
, steroid receptor co-activators (SRCs) 
60
, p300-containing co-
activator complexes 
61
, and HDAC containing co-repressor complexes 
62
. The p300 
co-activator is known to have intrinsic histone acetyltransferase (HAT) activity, which 
helps to relax the chromatin structure at gene promoters, leading to gene activation. 
Studies have shown that p300 can function as an ER co-activator, and is required for 
acetylation at H3K27 
61
. This supports our hypothesis that ER uses p300-mediated 
H3K27 acetylation and PADI2-mediated H3R26 citrullination to promote chromatin 
decondensation, allowing for the binding of ER and associated co-factors (i.e. SRC1 
or AIB1) to EREs and enhancing ER-target and potentially HER2 gene transcription. 
 Alternatively, PADI2 may activate HER2 expression by functioning as an ETS 
co-factor (e.g. PEA3), thereby enhancing HER2 transcription. PEA3 is a well-known 
ETS co-factor and transcriptional activator of HER2 
63, 64
, and the primers used for 
detecting PADI2 at the HER2 promoter are within the known PEA3 binding site 
32
. 
Interestingly, one of the most commonly documented mechanisms of tamoxifen 
resistance is the overexpression of growth factor receptors, particularly EGFR and 
HER2 
4-6
. In addition, the expression of previously mentioned co-activator proteins, 
SRC1, AIB1, and Polyomavirus Enhancer Activator-3 (PEA3), have been shown to 
correlate with endocrine resistance in breast cancer 
47
. Particularly, the AIB1 gene has 
been shown to be critical in the development of tamoxifen resistance via ER/HER2 
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cross-talk 
5, 32
, as MCF7 breast cancer cells overexpressing HER2 (MCF-7/HER2-18) 
showed cross-phosphorylation and activation of ER and EGFR/HER2 receptors when 
treated with tamoxifen 
65
. This was coincident with the phosphorylation and activation 
of the signaling molecules AKT and MAPK, as well as AIB1. We show here that the 
targeting of PADI2 by both shRNA and BB-Cl-amidine leads to a reduction in both 
SRC and AIB1 at the mRNA levels, and ER and AIB1 at the protein levels, as well as 
both activated EGFR and HER2/ERBB2. This has potential implications for the 
treatment of patients with acquired resistance to endocrine therapies.  
Finally, we also provide evidence that PADI2 functions in a positive-feedback 
loop with HER2/ERBB2. We found using inhibitors for MAPK and PI3K pathways, 
that HER2/ERBB2 induces PADI2 expression downstream of PI3K-AKT-mTOR 
signaling. Interestingly, we also note that using the PADI2 inhibitor BB-Cl-amidine, 
along with lapatinib, had synergistic inhibitory effects on the growth and malignant 
nature of tumor cells in vitro. Currently, PI3K-AKT and mTOR inhibitors are 
effective therapies for the treatment of breast cancer, but they are often plagued by 
acquired resistance through the upregulation of receptor tyrosine kinase (RTK) 
activation via MAPK-ERK signaling 
66
. Surprisingly, we showed that BB-Cl-amidine 
treatment can reduce both pMAPK and pAKT, in addition to pERBB2; thus, relieving 
the RTK-activation seen when cells are treated with the mTOR inhibitor rapamycin.  
 
Conclusions 
Taken together, these results suggest an enhanced role for PADI2 in HER2 expressing 
breast cancers, and that the PADI inhibitor, BB-Cl-amidine, represents a potential 
novel therapy for the treatment of patients with HER2-positive mammary tumors, and 
potentially for those with acquired resistance to endocrine therapies 
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Table 3.1: Primer sequences for genes tested by SYBR-qPCR 
Gene Name Primer Name Sequence 
AIB1 (SRC3, NCOA3) AIB1-F AGCTGAGCTGCGAGGAAA 
 
AIB1-R GAGTCCACCATCCAGCAAGT 
AKT1 AKT1-F GGCTATTGTGAAGGAGGGTTG 
 
AKT1-R TCCTTGTAGCCAATGAAGGTG 
AKT2 AKT2-F CTCACACAGTCACCGAGAGC 
 
AKT2-R TGGGTCTGGAAGGCATACTT 
AKT3 AKT3-F TTGCTTTCAGGGCTCTTGAT 
 
AKT3-R CATAATTTCTTTTGCATCATCTGG 
β-actin (ACTB) B-ACTIN-F CCAACCGCGAGAAGATGA 
 
B-ACTIN-R CCAGAGGCGTACAGGGATAG 
BAX BAX-F AGCAAACTGGTGCTCAAGG 
 
BAX-R TCTTGGATCCAGCCCAAC 
β-Catenin (CTNNB1) BCAT-F GCTTTCAGTTGAGCTGACCA 
 
BCAT-R CAAGTCCAAGATCAGCAGTCTC 
BCL2 BCL2-F AGTACCTGAACCGGCACCT 
 
BCL2-R GCCGTACAGTTCCACAAAGG 
BIRC5 (Survivin) BIRC5-F AGAACTGGCCCTTCTTGGA 
 
BIRC5-R CAAGTCTGGCTCGTTCTCAGT 
Cyclin B1 (CCNB1) CCNB1-F CATGGTGCACTTTCCTCCTT 
 
CCNB1-R AGGTAATGTTGTAGAGTTGGTGTCC 
Cyclin D1 (CCND1) CCND1-F GAAGATCGTCGCCACCTG 
 
CCND1-R GACCTCCTCCTCGCACTTCT 
Cyclin D2 (CCND2) CCND2-F GGACATCCAACCCTACATGC 
 
CCND2-R CGCACTTCTGTTCCTCACAG 
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Cyclin E1 (CCNE1) CCNE1-F GGCCAAAATCGACAGGAC 
 
CCNE1-R GGGTCTGCACAGACTGCAT 
CDK1 (CDC2) CDK1-F AACTGGCTGATTTTGGCCTTG 
 
CDK1-R TGAGTAACGAGCTGACCCCA 
CDK2 CDK2-F AAAGCCAGAAACAAGTTGACG 
 
CDK2-R GTACTGGGCACACCCTCAGT 
CDK4 CDK4-F GTGCAGTCGGTGGTACCTG 
 
CDK4-R TTCGCTTGTGTGGGTTAAAA 
CDK6 CDK6-F TGATCAACTAGGAAAAATCTTGGA 
 
CDK6-R GGCAACATCTCTAGGCCAGT 
COX-2 (PTGS2) COX2-F GCTTTATGCTGAAGCCCTATGA 
 
COX2-R TCCAACTCTGCAGACATTTCC 
E-cadherin (CDH1) ECAD-F TGGAGGAATTCTTGCTTTGC 
 
ECAD-R CGCTCTCCTCCGAAGAAAC 
EGFR (HER1, ERBB1) EGFR-F GATCCAAGCTGTCCCAATG 
 
EGFR-R GGCACAGATGATTTTGGTCAG 
ERK1 (MAPK3-p44) ERK1-F CCCTAGCCCAGACAGACATC 
 
ERK1-R GCACAGTGTCCATTTTCTAACAGT 
ERK2 (MAPK1-p42) ERK2-F TCTGCACCGTGACCTCAA 
 
ERK2-R GCCAGGCCAAAGTCACAG 
ESR1 ESR1-F TTACTGACCAACCTGGCAGA 
 
ESR1-R ATCATGGAGGGTCAAATCCA 
FN1 FN1-F CTGGCCGAAAATACATTGTAAA 
 
FN1-R CCACAGTCGGGTCAGGAG 
FOXA1 FOXA1-F AGGGCTGGATGGTTGTATTG 
 
FOXA1-R ACCGGGACGGAGGAGTAG 
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FOXM1 FOXMI-F ACTTTAAGCACATTGCCAAGC 
 
FOXMI-R CGTGCAGGGAAAGGTTGT 
GADD45α (GADD45A) GADD45a-F TTTGCAATATGACTTTGGAGGA 
 
GADD45a-R CATCCCCCACCTTATCCAT 
GRB7 GRB7-F GGAACGGGTGTCCTGCTAC 
 
GRB7-R AACCAGTTGTGTGCCCTTGT 
GSK3β (GSK3B) GSK3β-F GACATTTCACCTCAGGAGTGC 
 
GSK3β-R GTTAGTCGGGCAGTTGGTGT 
HER2 (ERBB2) HER2-F TGCTGTCCTGTTCACCACTC 
 
HER2-R TCATCCTCATCATCTTCACATTG 
HER3 (ERBB3) HER3-F CTGATCACCGGCCTCAAT 
 
HER3-R GGAAGACATTGAGCTTCTCTGG 
HRAS HRAS-F GGACGAATACGACCCCACTAT 
 
HRAS-R TGTCCAACAGGCACGTCTC 
IGFR1 IGFR1-F TCAGCGCTGCTGATGTGTA 
 
IGFR1-R GGCTCATGGTGATCTTCTCC 
IL6 IL6-F GCCCTGAGAAAGGAGACATGTAA 
 
IL6-R TTGTTTTCTGCCAGTGCCTC 
IL8 IL8-F ACTGAGAGTGATTGAGAGTGGAC 
 
IL8-R AACCCTCTGCACCCAGTTTTC 
JAB1 (COPS5) JAB1-F CGAAGCCCTGGACTAAGGAT 
 
JAB1-R CTGGCATGCATCACCATCT 
KI67 (MKI67) KI67-F TTACAAGACTCGGTCCCTGAA 
 
KI67-R TTGCTGTTCTGCCTCAGTCTT 
KRAS KRAS-F TGGACGAATATGATCCAACAAT 
 
KRAS-R TCCCTCATTGCACTGTACTCC 
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MEK1 (MAP2K1) MEK1-F TCTGCAGTTAACGGGACCA 
 
MEK1-R GCTGCTGCTCATCAAGCTC 
MMP2 MMP2-F CCCCAAAACGGACAAAGAG 
 
MMP2-R CTTCAGCACAAACAGGTTGC 
MTOR (FRAP1) mTOR-F AGCTGCATGGGGTTTAGGT 
 
mTOR-R CCCGAGGGATCATACAGGT 
MYC MYC-F CACCAGCAGCGACTCTGA 
 
MYC-R GATCCAGACTCTGACCTTTTGC 
N-cadherin (CDH2) NCAD-F CTCCATGTGCCGGATAGC 
 
NCAD-R CGATTTCACCAGAAGCCTCTAC 
NFKB1(p105/p50) NFKB1-F CTGGCAGCTCTTCTCAAAGC 
 
NFKB1-R TCCAGGTCATAGAGAGGCTCA 
NRAS NRAS-F GCAAGTCATTTGCGGATATTAAC 
 
NRAS-R CATCCGAGTCTTTTACTCGCTTA 
NRG1 NRG1-F GATCAGCAAATTAGGAAATGACAG 
 
NRG1-R GGCATACCAGTGATGATCTCG 
p21 (CDKN1A) p21-F CCTGTCACTGTCTTGTACCCT 
 
p21-F GCGTTTGGAGTGGTAGAAATCT 
p27 (CDKN1B) p27-F TTTGACTTGCATGAAGAGAAGC 
 
p27-R AGCTGTCTCTGAAAGGGACATT 
p53 (TP53) p53-F CCCCAGCCAAAGAAGAAAC 
 
p53-R AACATCTCGAAGCGCTCAC 
PADI2 PADI2-F TCTCAGGCCTGGTCTCCAT 
 
PADI2-R AAGATGGGAGTCAGGGGAAT 
PARP1 PARP1-F TGGAGGACGACAAGGAAAAC 
 
PARP1-R TGTTGCTACCGATCACCGTA 
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PCNA PCNA-F TGGAGAACTTGGAAATGGAAA 
 
PCNA-R GAACTGGTTCATTCATCTCTATGG 
PEA3 (ETV4) PEA3-F ACTTCGCCTACGACTCAGATG 
 
PEA3-R GAGGTTTCTCATAGCCATAGCC 
PI3K (PIK3CA-p110α) PI3K-F CACGAGATCCTCTCTCTGAAATC 
 
PI3K-R GGTAGAATTTCGGGGATAGTTACA 
PUMA (BBC3) PUMA-F GACCTCAACGCACAGTACGA 
 
PUMA-R GAGATTGTACAGGACCCTCCA 
RB1 RB1-F TCCTGAGGAGGACCCAGAG 
 
RB1-R AGGTTCTTCTGTTTCTTCAAACTCA 
RELA (p65) RELA-F ACCGCTGCATCCACAGTT 
 
RELA-R GATGCGCTGACTGATAGCC 
SMAD2 SMAD2-F CAGGACGATTAGATGAGCTTGA 
 
SMAD2-R CCCCAAATTTCAGAGCAAGT 
SMAD3 SMAD3-F CCATCCCCGAAAACACTAAC 
 
SMAD3-R TCCATCTTCACTCAGGTAGCC 
SMAD4 SMAD4-F CCTGTTCACAATGAGCTTGC 
 
SMAD4-R GCAATGGAACACCAATACTCAG 
SNAIL (SNAI1) SNAIL-F GCTGCAGGACTCTAATCCAGA 
 
SNAIL-R ATCTCCGGAGGTGGGATG 
SLUG (SNAI2) SLUG-F TGGTTGCTTCAAGGACACAT 
 
SLUG-R GCAAATGCTCTGTTGCAGTG 
SRC1 (NCOA1) SRC1-F ATGAGATCAGGCATGCAACA 
 
SRC1-R TGTGCCAACATTTGAGCATT 
TGFβ (TGFB1) TGFB-F ACTACTACGCCAAGGAGGTCAC 
 
TGFB-R TGCTTGAACTTGTCATAGATTTCG 
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TWIST1 TWIST1-F AGCTACGCCTTCTCGGTCT 
 
TWIST1-R CCTTCTCTGGAAACAATGACATC 
VEGFA VEGFA-F GCAGCTTGAGTTAAACGAACG 
 
VEGFA-R GGTTCCCGAAACCCTGAG 
VIM VIM-F GGCTCGTCACCTTCGTGAAT 
 
VIM-R GAGAAATCCTGCTCTCCTCGC 
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CHAPTER FOUR 
PADI2 OVEREXPRESSION IN TRANSGENIC MICE LEADS TO 
PREMALIGNANT SKIN LESIONS AND PROGRESSION TO SQUAMOUS 
CELL CARCINOMA 
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Sams; Dalton McLean; Iva Cvitaš; and Scott A. Coonrod. PADI2 overexpression in 
transgenic mice leads to premalignant skin lesions and progression to squamous cell 
carcinoma. In preparation.  
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4.1 Summary 
Introduction:  
Peptidylarginine deiminases (PADIs) are a family of posttranslational modification 
enzymes that convert positively charged arginine residues on substrate proteins to 
neutrally charged citrulline. This activity, called citrullination or deimination, has been 
shown to have wide-ranging effects on target protein structure, function, and protein-
protein interactions. PADI2 has been implicated in various diseases, including 
multiple sclerosis, inflammatory diseases such as RA and COPD, and more recently, 
cancer. We have recently reported that PADI2 and HER2 expression is correlated in 
breast cancer cell lines, and that PADI2 plays a role in the proliferation of mammary 
tumors in vitro and in vivo. The goal of this study was to analyze whether the 
transgenic expression of PADI2 driven by the MMTV-LTR promoter can induce 
oncogenesis in hormone-responsive epithelium. 
 
Methods: 
To examine whether the overexpression of PADI2 is sufficient to drive tumorigenesis 
in epithelial tissue, we cloned human FLAG-tagged PADI2 cDNA downstream of the 
hormone-responsive MMTV-LTR promoter. We generated four founder lines in FVB 
mice expressing the MMTV-FLAG-PADI2 transgene, and performed phenotypic and 
genetic analysis of these mice. Lastly, we have created stable cell lines overexpressing 
FLAG-PADI2 in the human skin cancer cell line A431 to validate our findings in the 
transgenic mice. 
 
Results: 
The ectopic expression of human PADI2 in mouse epithelium is sufficient to promote 
neoplasia, as we report that ~20% of transgenic mice develop skin lesions. 
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Interestingly we found that in a subset of these mice, these lesions further progress to 
more invasive squamous cell carcinomas, as noted by histopathological features.  In 
addition, we note that these skin lesions express high levels of transgene, as well as 
display markers of invasion/EMT (decreased E-cadherin) and inflammation (Il6/Il8). 
We confirmed these results in the human squamous cell carcinoma cell line A431, 
where we report that stable expression of FLAG-PADI2 increases markers of 
inflammation (IL6/IL8) and EMT, ultimately increasing the cellular malignancy and 
invasiveness of these cells. 
 
Conclusion: 
Collectively, these studies provide functional and mechanistic evidence establishing 
PADI2 as a potential novel oncogene in the development of skin neoplasia, and might 
offer a new target for cancer therapy. 
 
Key words: Peptidylarginine deiminase, PAD2/PADI2, MMTV-LTR, MMTV-
FLAG-PADI2, Skin Neoplasia/Lesions, Squamous Cell Carcinoma, A431 
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4.2 Introduction 
The peptidylarginine deiminase family of posttranslational modification enzymes 
converts positively charged arginine residues on substrate proteins to neutrally 
charged citrulline. This activity, alternatively called citrullination or deimination, has 
been shown to have wide-ranging effects on target protein structure, function, and 
protein-protein interactions.  The PADI enzyme family is thought to have arisen by 
gene duplication and localizes within the genome to a highly organized cluster at 
1p36.13 in humans. At the protein level, each of the five well-conserved PADI 
members shows a relatively distinct pattern of substrate specificity and tissue 
distribution 
1, 2
. Increasingly, the dysregulation of PADI activity is associated with a 
range of diseases, including rheumatoid arthritis (RA), multiple sclerosis, ulcerative 
colitis, neural degeneration, COPD, and cancer 
3-5
. While the presumptive function of 
PADI activity in most diseases is linked to inflammation, the role that PADIs play in 
cancer progression is still under investigation. Others have shown that citrullination of 
the p53 tumor suppressor protein by PADI4 affects the expression of p53-target genes 
p21, OKL38, CIP1 and WAF1 
6-8
. While PADI2 has historically been defined as a 
cytoplasmic protein, recent evidence from our lab shows that PADI2 can localize to 
the nucleus and directly bind chromatin to influence target gene expression 
9-12
.  
Our recent studies suggest a role for PADI2 in the oncogenic progression of 
breast cancer, more specifically, HER2-positive tumors, as RNA-seq data reveal that 
PADI2 is highly correlated with HER2/ERBB2 overexpression across 57 breast cancer 
cell lines. We concluded this study with the first preclinical evidence showing that the 
PADI inhibitor, Cl-amidine, could be utilized as a therapeutic agent for the treatment 
of tumors in vivo.  
To further investigate the involvement of PADI2 in the oncogenesis of 
epithelial tumors, we generated FVB mice expressing FLAG-PADI2 under the control 
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of the hormone-responsive mammary tumor virus (MMTV) promoter. However, while 
transgenic expression of human PADI2 in mammary glands was detected, the MMTV-
FLAG-PADI2 mice failed to develop any mammary tumors. While expression from 
the MMTV-LTR promoter is normally found to be localized to the mammary and 
salivary gland, other tissues have been implicated, including the skin and ovaries 
13, 14
.  
Our results confirm this, as we see increased transgenic human PADI2 transcript levels 
in the all four of those tissues. Surprisingly, we discovered that 20% of the mice 
developed skin lesions after five months. These tumors expressed high levels of 
transgenic human PADI2 and display markers of increased invasiveness and epithelial 
to mesenchymal transition (EMT). Furthermore, some of these tumors display the 
hallmarks of malignant progression to highly invasive squamous cell carcinomas.  
Previous studies have reported that three PADI isozymes, PADI1, PADI2, and 
PADI3, show expression in the epidermis, with all three displaying the ability to target 
filaggrin for citrullination, a key protein involved in tissue hydration and barrier 
functions 
15
. PADI1 and PADI3 have been the primary isozymes characterized in the 
epidermis to date; with PADI3 being found to deiminate trichohyalin in hair follicles 
16, 17
 and PADI1 deiminating keratin (K1 and K10) and filaggrin during epidermal 
differentiation 
18, 19
. Moreover, the overexpression of PADI1 (along with PADI2 and 
PADI3), has been shown to generate abnormal levels of citrullinated keratin K1 in the 
epidermis of psoriatic patients 
20
. This suggests that aberrant expression of PADIs, 
including PADI2, might play a role in diseases of the skin, including cancer.  
Interestingly, the original cloning of human PADI2 cDNA was from the human 
skin cancer cell line, HSC-1, which is derived from a cutaneous squamous carcinoma 
21
. We report here a novel model of skin neoplasia in FVB transgenic mice, driven by 
human PADI2 under the MMTV-LTR promoter; thus, establishing a novel role for 
PADI2 in the progression of cancer. 
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4.3 Materials and Methods 
Generation of MMTV-FLAG-PADI2 mice 
To generate the MMTV-FLAG-PADI2 construct, a human PADI2 cDNA fragment 
was removed from pcDNA3.1-FLAG-PADI2 
11
, and cloned into the EcoRI sites of the 
MMTV-SV40-Bssk plasmid (Addgene plasmid #1824) that was originally generated 
in the laboratory of Dr. Philip Leder at Harvard Medical School 
22
. The linear MMTV-
FLAG-PADI2 construct was purified and microinjected into the pronuclei of fertilized 
embryos from super-ovulated FVB mice, and 2-cell stage embryos were transferred to 
pseudopregnant mothers. The microinjection and embryo transfer was performed by 
the Stem Cell and Transgenics Core at the Cornell University College of Veterinary 
Medicine. Mice were genotyped for the presence of human PADI2 transgene by PCR 
with the primers hPADI2-cds-F/R (see Table 4.1). 
 
Lentivirus and plasmids for stable FLAG-PADI2 expression in A431 cells 
The human squamous cell carcinoma A431 cell line was obtained from ATCC and 
cultured according to manufacturer’s directions. To generate A431 cells 
overexpressing FLAG-tagged PADI2, two separate plasmids were generated. First, for 
stably and transiently transfected A431, FLAG-PADI2 was subcloned (NheI/XhoI) 
from pcDNA3.1-FLAG-PADI2 
11
 into the pIRES2-EGFP vector (Clontech). This 
vector has bicistronic expression of both FLAG-PADI2 and EGFP by means of an 
internal ribosome entry site (IRES). A431 cells were transfected with pIRES2-FLAG-
PADI2 using X-tremeGENE 9 (Roche) and stable cells were selected in 800 µg/ml 
G418 for 2-weeks. To generate lentiviral-transduced cells, the FLAG-PADI2-IRES-
EGFP fragment was excised from the pIRES2-FLAG-PADI2 plasmid by digestion 
with MluI and SspI. The linearized fragment was blunted with T4 DNA polymerase 
(NEB), and subcloned into the BamHI-SalI digested/T4 blunted pLenti-PGK-GFP-
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Puro plasmid (Addgene #19070) that was originally generated by Campeau et al. at 
the University of Massachusetts Medical School 
23
. This plasmid was verified by 
restriction digest and sequencing, and transduction of A431 cells was performed as 
previously described in Campeau et al. using 3
rd
 generation lentiviral 
packaging/envelope vectors (pLP1-pMDLg/pRRE, Addgene #12251; pLP2-pRSV-
Rev, Addgene #12253; and pVSV-G-pMD2.G, Addgene #12259). Stably transduced 
cells were selected in 1 µg/ml puromycin for 2-weeks. 
 
Immunohistochemistry (IHC) and immunofluorescence (IF)  
IHC and IF experiments were carried out using a standard protocol as previously 
described 
9
.  Primary antibodies are as follows: anti-PADI2 (12110-1-AP, 
ProteinTech), anti-FLAG-M2 (F1804, Sigma), anti-Ki67 (ab15580, Abcam), and anti-
GFP (ab290, Abcam). Sections prepared for IHC were incubated in DAB chromagen 
solution (Vector Laboratories) according to the manufacturer’s protocol, washed, and 
then counterstained with hematoxylin.  The IF slides were incubated in streptavidin 
conjugated-488 (Invitrogen), washed, and then mounted using Vectashield containing 
DAPI (Vector Laboratories).  Negative controls for both IHC and IF experiments were 
either rabbit or mouse IgG antibody at the appropriate concentrations. Tumor sections 
were examined for general morphological differences after hematoxylin and eosin 
(H&E) staining.  
 
Western blotting  
Western blotting was carried out as previously described 
9
. Primary antibodies against 
PADI2 (12110-1-AP, ProteinTech) and FLAG-M2 (F1804, Sigma) were incubated 
overnight at 4
o
C. To confirm equal protein loading, membranes were stripped and re-
probed with anti-β-actin (ab8227, Abcam). 
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RNA isolation, semi-quantitative, and quantitative Real-Time PCR (qRT-PCR) 
RNA was purified using the Qiagen RNAeasy kit, including on-column DNase 
treatment to remove genomic DNA.  The resulting RNA was reverse transcribed using 
the ABI High Capacity RNA-to-cDNA kit according to the manufacturer’s protocol 
(Applied Biosystems).  Semi-quantitative PCR was performed using primers (see 
Table 4.2) for human PADI2 and mouse Padi1, Padi2, Padi3, and Padi4, using mouse 
Gapdh as the loading control. TaqMan Gene Expression Assays (ABI) were used to 
measure relative mRNA levels for the transgenic human PADI2 (Hs00247108_m1), 
along with endogenous mouse Padi1 (Mm00478062_m1), Padi2 (Mm00447020_m1), 
Padi3 (Mm00478075_m1), and Padi4 (Mm01341658_m1). Mouse Gapdh 
(4352932E) was used as the loading control. In addition, primer sequences for gene 
expression analysis via SYBR-qPCR can be found in Table 4.3 for mouse genes, and 
Table 4.4 for human genes.  Expression levels were analyzed using the 2 
-ΔΔ C(t)
 
method 
24
. Data are shown as means ± SD from three independent experiments, and 
were separated using Student’s t-test. 
 
Assays for cellular malignancy and invasion 
Collagen coated inserts for 24-well plate wells (Falcon BD Fluoroblok; Catalog 
number: 351152, 8 µm pore size) were used to conduct transwell migration 
assays. Briefly, cells were trypsinized into an individual cell suspension, washed with 
DPBS, and added on the coated filters in serum-free DMEM (10,000 cells per 
filter). The lower chamber of the companion plate (Falcon BD Labware) was filled 
with DMEM supplemented with 10% FBS. At different time points (4 and 24 hours) 
of incubation, the filters were removed for evaluation. Cells that had migrated to the 
other side of the membrane were fixed in 4% paraformaldehyde (PFA), and stained 
with DAPI for visualization of the nuclei. The nuclei were counted under fluorescent 
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wide-field microscope. Values for cell invasion are expressed as the mean number of 
cells/20X microscopic field over five fields per filter for triplicate experiments. Focus 
formation assays were carried out using stable A431 cells (pIRES2-EGFP-FLAG-
PADI2 or empty vector control) that were grown in 6-well plates. After 4d, cells were 
fixed with 4% PFA, and stained with crystal violet for subsequent analysis of focus 
formation. After imaging, the crystal violet was removed from the cells with 10% 
acetic acid and absorbance levels were measured (600 nM). 
 
Statistical analysis 
All experiments were independently repeated at least three times unless otherwise 
indicated.  Values were expressed as the mean + the SD. Means were separated using 
Student’s t-test. 
 
4.4 Results 
Generation of MMTV-FLAG-PADI2 transgenic mice 
To assess the potential role of PADI2 in the oncogenesis of epithelial tissue, we 
generated a mouse model in which the human PADI2 gene is overexpressed under 
control of the hormone-responsive MMTV-LTR promoter. The transgenic construct 
consists of a MMTV-LTR promoter placed upstream of the human FLAG-tagged 
PADI2 cDNA, followed by an SV40 splice/polyadenylation site (Figure 4.1). 
MMTV-FLAG-PADI2 mice were generated, and seven potential founders were tested 
for the presence of transgene by PCR.  We identified 4 founders (indicated in red, 
Figure 4.2a), 4807, 4853, 4680, and 4863, that carried germline transmission of the 
FLAG-PADI2 transgene. While founder 4854 initially appeared to be a low-copy 
founder line, we failed to see transmission of the transgene to subsequent generations 
at Mendelian ratios, perhaps indicating mosaicism. Using semi-quantitative RT-PCR, 
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Figure 4.1: MMTV-FLAG-PADI2 transgenic construct. Schematic of the 
linearized MMTV-FLAG-hPADI2 transgene, containing a FLAG-tagged human 
PADI2 cDNA fragment that was cloned between the EcoRI sites of the MMTV-SV40-
Bssk plasmid 
22
. The construct used for generation of FLAG-hPADI2-transgenic mice 
(also referred to as FLAG-PADI2) consists of FLAG-PADI2 under the control of the 
hormone-responsive MMTV-LTR promoter-enhancer with an SV40 splice-
polyadenylation signal (SV40pA). 
 
  
193 
 
 
 
 
 
 
Figure 4.2: Generation of MMTV-FLAG-PADI2 transgenic mice. (a) PCR 
screening of DNA extracted from mouse tails for the presence of integrated human 
PADI2 transgene (TG – hPADI2). Four founders were identified (red); primers for 
mouse Padi4 were used as a wild-type (WT – mPADI4) control for amplification. 
Primer sequences can be found in Table 4.1. (b) Semi-quantitative RT-PCR was 
performed on tissues known to have high expression in MMTV-LTR transgenic mice: 
skin, salivary gland (SG), mammary gland (MG), and ovary (note: 4807 founder line 
was not used due to breeding issues and this line was subsequently terminated). Total 
RNA was isolated from tissues and relative mRNA levels for the transgenic human 
PADI2, along with endogenous mouse Padi1, Padi2, Padi3, and Padi4 are shown. 
Mouse Gapdh was used as the loading control. (c) Quantitative RT-PCR (qPCR) for 
the human PADI2 transgene was performed across the same tissues, using WT skin as 
the reference, with mouse Gapdh normalization. Expression levels were analyzed 
using the 2 
-ΔΔ C(t)
 method, and data are expressed as the mean ± SD from three 
independent experiments (* p < 0.05). 
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we confirmed the presence of FLAG-PADI2 transcript in the skin, salivary gland, 
mammary gland, and ovary of the transgenic mice (Figure 4.2b). These four tissues 
were chosen for analysis as they have previously been shown to have high expression 
of MMTV-LTR driven transgenes 
14
. We note that the subsequent analysis is for only 
three founders (4853, 4860, 4863), as founder line 4807 had breeding issues and was 
subsequently terminated. Quantitative real-time PCR analysis (qPCR) of these 
founders for the four same tissues was performed; in comparison to other founders, 
founder 4853 showed the highest expression in skin, while founder 4863 had the 
highest expression in salivary and mammary glands (Figure 4.2c). 
We first analyzed the mammary glands of the transgenic mice, as we have 
previously established a link between PADI2 and breast cancer. Our initial goal was to 
generate MMTV-driven transgenic mice to investigate the effects of ectopic PADI2 
overexpression in mammary epithelium in vivo. However, while PADI2 transgenic 
expression in the mammary glands was detected at high levels in both virgin (Figure 
4.3a) and multiparous mice (Figure 4.3b), we failed to detect any gross abnormalities 
or any observable phenotype in the mammary gland of these mice.  
 
PADI2 transgenic mice develop skin lesions with the potential to advance to invasive 
squamous cell carcinomas 
While expression from the MMTV-LTR promoter is predominantly localized to the 
mammary and salivary gland, other tissues have been implicated, including the skin 
and ovaries 
13, 14
. Surprisingly, we discovered that 20% of the mice developed skin 
lesions after five months (Table 4.2). These lesions are characterized by gross 
abnormalities, such as alopecia, multifocal epidermal ulceration often covered in sero-
cellular crust, dysplasia, and thickening of the adjacent epidermis (Figure 4.4a). These 
lesions occur on both the dorsum and ventrum of transgenic mice. We note that we  
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Figure 4.3: MMTV-FLAG-PADI2 expression in the mammary gland.  
(a) Confocal immunofluorescence analysis of FLAG (red) expression in virgin mouse 
mammary gland of a transgenic mouse. The luminal epithelial cells of mammary acini 
strongly express FLAG-PADI2 protein. (b) Immunohistochemical staining for PADI2 
and FLAG in a multiparous mammary gland. The representative image shows a 
hyperplastic mammary gland with acinar epithelial cells strongly expressing both 
PADI2 and FLAG, confirming proper expression of the tagged transgene. 
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Table 4.2: Occurrence of skin lesions in MMTV-FLAG-PADI2 mice 
 
Total mice WT mice Tg mice 
Mice > 5 months old (#) 86 31 55 
Mice with lesions (#) 11 0 11 
% of mice with lesions 13 0 20 
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have yet to see any of these lesions in the wild-type FVB mice, indicating that the 
phenotype is most likely a result of the FLAG-PADI2 transgene. Histological 
evaluation of skin lesions by H&E reveals highly neoplastic tissue, with features 
consistent with invasive squamous cell carcinoma (SCC). There are nests of neoplastic 
cells arising from the epidermis invading the dermis and subcutis (Figure 4.4b, i). 
Epidermis overlying the neoplasm is extensively ulcerated and the adjacent epidermal 
layers are hyperplastic (Figure 4.4b, i). Concentric layers of keratin surrounding 
tumor cells form keratin pearls, which are a characteristic of SCC (Figure 4.4b, ii and 
iii). The nests and islands of neoplastic cells within the subcutis show high degree of 
anisokaryosis and anisocytosis, with the nuclei often containing one to two prominent 
nucleoli (Figure 4.4b, iv). Clusters of neoplastic cells are surrounded by loose 
collagenous stroma with a marked loss of adnexal structures, consistent with a 
desmoplastic response (Figure 4.4b, iii and iv). Moreover, these skin lesions often 
contain carcinoma cells that are found budding off from the primary neoplasm (Figure 
4.4b, iv), again indicating an invasive component to these tumors. 
These skin lesions express high levels of transgenic PADI2, as 
immunohistochemical analysis shows PADI2 protein expression in the hyperplastic 
epidermis, neoplastic islands, and in hair follicular epithelium (Figure 4.5a, i). In 
addition, we see high expression of PADI2 protein in the neoplastic epithelium 
surrounding the keratin pearl (Figure 4.5a, ii and iii). Furthermore, these tumors are 
characterized by budding nests of carcinoma cells, which invade the adjacent stroma 
from the primary neoplasm. We note that PADI2 protein expression is high in these 
invasive cells (Figure 4.5a, iv). Because the PADI2 antibody can also detect 
endogenous mouse Padi2, we also stained for FLAG, and found that we see identical 
expression within the proliferating basal layers of hyperplastic/neoplastic epidermis; 
thus, suggesting that the increased PADI2 expression is a result of the transgene. We  
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Figure 4.4: Transgenic FLAG-PADI2 expression in the epidermis of mice leads to 
the development of skin lesions. (a) Representative gross lesion showing the skin 
phenotype, which includes alopecia, multifocal epidermal ulceration often covered in 
a sero-cellular crust, and thickening of the adjacent epidermis. (b)  Histological 
evaluation of the skin sections by H&E reveals features consistent with invasive 
squamous cell carcinoma. (i) Nests of neoplastic cells arising from the epidermis are 
shown invading the deep dermis and subcutis, with the epidermis overlying the  
neoplasm extensively ulcerated. (i) and (ii) Adjacent epidermal layers are hyperplastic 
with the loss of adnexal structures and increase in desmoplastic response (iii). 
Carcinoma cells are often found budding off from the primary neoplasm (iv). 
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Figure 4.5: FLAG-PADI2 expression is high in the skin lesions of transgenic 
mice. (a) Immunohistochemical analysis of FLAG-PADI2 protein expression in skin 
neoplasms from transgenic mice. (i) Lower magnification image showing PADI2 
protein expression in the hyperplastic epidermis, neoplastic islands, and in the hair 
follicular epithelium. (ii) – (iii) PADI2 protein expression in neoplastic cells 
surrounding concentric layers of keratin (arrow = keratin pearl). (iv) Representative 
image showing high levels of PADI2 protein expression in budding nest of carcinoma 
cells (broken arrow). (b) FLAG expression in skin neoplasms from transgenic mice. 
Scattered clusters of neoplastic cells show strong FLAG-tag expression. This staining 
is especially evident in the proliferating basal layers of hyperplastic or neoplastic 
epidermis. 
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confirmed this using indirect-immunofluorescence to co-stain for FLAG and PADI2 
expression in the skin lesions of transgenic mice. PADI2 and FLAG both co-localize 
to the neoplastic epithelial cells of a squamous cell carcinoma (Figure 4.6, i-iv). 
While PADI2 shows strong staining in multiple layers of the epidermis, we find that 
FLAG (i.e. transgene) is slightly more restricted to the basal layer, which is known to 
be more stem-cell like and highly proliferative 
25
. Interestingly, we also see a slight 
increase in the proliferative marker, Ki67, within the FLAG staining section of the 
SCC lesion (Figure 4.6b, ii-iv). Therefore, this indicates that transgene expression in 
the skin might lead to an increase in proliferation, which is also supported by the 
identification of a subset of these lesions as highly proliferative and invasive SCC. We 
also note that we do not see any expression of the FLAG transgene in normal skin 
from wild-type mice (Figure 4.7, i-vi), as well as very little to any in adjacent normal 
skin from transgenic mice (data not shown). 
 
Transgenic skin lesions have decreased levels of endogenous mouse Padis and 
increased markers of inflammation and EMT 
Since we know that other PADIs can play a role in diseases of the skin, we were 
curious to see what the levels of other PADIs might be in the lesions from transgenic 
mice. Using semi-quantitative RT-PCR, we show human PADI2 transgene levels are 
present as expected in the lesions, as well as varying degrees of endogenous mouse 
Padis (Figure 4.8a). We show by qPCR that representative lesions (2) and (4) have 
the highest transgene expression (Figure 4.8b), and that these two lesions have the 
highest levels of protein expression (lesion 2 = SCC, Figure 4.8c). Surprisingly, we 
noticed what appeared to be a protein-dimer in the western blot that was probed with 
anti-FLAG. Previous evidence has indicated that PADI4 can associate as a dimer, and 
that PADI-activity (i.e. citrullination) is highest in dimerized PADI4 
26
. Interestingly,  
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Figure 4.6: Confocal immunofluorescence analysis of PADI2, FLAG, and Ki67 
expression in neoplastic skin lesions of the FLAG-PADI2 transgenic mouse.  
(a) Representative image showing co-staining (iv) of FLAG (red, ii) and PADI2 
(green, iii) in the neoplastic epithelial cells of a squamous cell carcinoma from a 
transgenic mouse. Nuclei are stained with DAPI (blue, i). Endogenous Padi2 shows 
strong positive staining in 2-3 layers of epidermal cells, while FLAG-PADI2 is 
predominantly localized to the basal cell layer. Scattered tumor cell islands underlying 
the epidermis show high levels of PADI2 expression. (b) Representative image 
showing co-staining (iv) of the proliferative marker, FLAG (red, ii), and Ki67 (green, 
iii) in neoplastic epithelial cells of squamous cell carcinoma. Tumor islands that are 
strongly positive for FLAG-PADI2 expression levels contain an increased number of 
Ki67 positive cells (iv). Nuclei are stained with DAPI (blue, i) 
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Figure 4.7: Normal skin from wild-type mice is absent for transgene expression, 
and has low levels of the proliferation marker, Ki67. (a) Representative image 
showing co-staining (vi) of FLAG (red, iii) and Ki67 (green, iv) in normal skin 
sections from a wild-type (WT) mouse. Bright-field image (ii and v). Both FLAG-tag 
and PADI2 protein expression are absent, concomitant with reduced Ki67 levels. 
Nuclei are stained with DAPI (blue, i) 
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Figure 4.8: Transgene expression in the skin lesions of MMTV-FLAG-PADI2 
mice. (a) Semi-quantitative RT-PCR on four representative skin lesions from 
transgenic mice (Lesions 1-4). Total RNA was isolated from lesions and normal wild-
type skin, and relative mRNA levels for the transgenic human PADI2, along with 
endogenous mouse Padi1, Padi2, Padi3, and Padi4 are shown. Mouse Gapdh was 
used as the loading control. (b) Quantitative RT-PCR (TaqMan) for the human PADI2 
transgene was performed across the same lesions, using normal WT skin as the 
reference, along with mouse Gapdh normalization. Expression levels were analyzed 
using the 2 
-ΔΔ C(t)
 method, and data are expressed as the mean ± SD from three 
independent experiments (* p < 0.05). (c) Representative western blot for skin from 
WT and transgenic (TG) mice, along with lesions (3) and (4), as well as (2), which is 
noted as a SCC skin tumor. Whole-cell lysates were probed for FLAG expression, 
with a predicted protein size of ~75 kDa (note the presence of a suspected homodimer 
at 150 kDa). β-actin was used as a loading control. 
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Liu et al. predict that PADI2 also functions as a dimer, as they report a high degree of 
conservation between the two family members, especially at the residues important for 
dimerization 
26
. We wanted to quantify the levels of endogenous mouse Padis by 
qPCR, and show that in lesions (2) and (4), which have the highest levels of human 
PADI2, also have the lowest levels of mouse Padi1, Padi3, and Padi4 (Figure 4.9). 
There is no observable difference reported for endogenous mouse Padi2 levels. To 
gain better perspective as to the potential pathways involved in the progression of 
MMTV-FLAG-PADI2 skin lesions, we examined genes known to be involved in 
inflammation and invasion in cancer. We chose these genes based on previous reports 
indicating a role for PADI2 in inflammatory diseases, coupled with our report here of 
the invasive nature of these carcinomas. Interestingly, when we examined the two 
representative lesions with the highest levels of transgenic PADI2 (lesions 2 and 4), 
we found that they have sharply elevated levels of Il6 and Il8 (Cxcl15) gene 
expression (Figure 4.10). Furthermore, these two lesions also display markers of 
EMT, as E-cadherin is decreased, along with a concomitant increase in vimentin (Vim) 
and the E-cadherin repressor, Snai1 (Figure 4.10). 
 
Overexpression of PADI2 in human squamous cell carcinoma A431 cells increases 
invasiveness and malignancy 
Transgenic MMTV-FLAG-PADI2 mice show that ectopic expression of PADI2 is 
sufficient to drive tumorigenesis in epithelial cells and that this expression correlates 
with an increase in markers of invasion and EMT. We wanted to see if could replicate 
these results in a human skin cancer cell line, A431. The A431 cell line is a human 
squamous carcinoma cell line that was isolated from a vulva epidermoid carcinoma. 
To test the oncogenic potential of PADI2 in this cell line, we first transiently 
expressed FLAG-PADI2 using standard plasmids for mammalian protein expression  
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Figure 4.9: Lesions from MMTV-FLAG-PADI2 transgenic mice that express the 
highest levels of human PADI2, have decreased mouse Padi1, Padi3, and Padi4. 
Total RNA from transgenic skin lesions (1-4) and normal wild-type skin was isolated 
and reverse transcribed to cDNA. The relative mRNA levels for human transgenic 
PADI2, along with mouse Padi1, Padi2, Padi3, and Padi4, were determined by qPCR 
(TaqMan) using normal WT skin as the reference, along with Gapdh normalization. 
Expression levels were analyzed using the 2 
-ΔΔ C(t)
 method, and data are expressed as 
the mean ± SD from three independent experiments (* p < 0.05). 
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Figure 4.10: Skin lesions from MMTV-FLAG-PADI2 transgenic mice express 
markers of inflammation and EMT. Total RNA from transgenic skin lesions (1-4), 
along with transgenic and wild-type (WT) skin, was isolated and reverse transcribed to 
cDNA. Relative mRNA levels for the representative genes (see Table 4.3 for gene list 
and primer sequences) were determined by qPCR (SYBR) using normal WT skin as 
the reference, along with β-actin (Actb) normalization. Expression levels were 
analyzed using the 2 
-ΔΔ C(t)
 method, and data are expressed as the mean ± SD from 
three independent experiments (* p < 0.05).  
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(pcDNA3.1-FLAG-PADI2) and (pIRES2-FLAG-PADI2) and associated empty 
vectors. We found that in both of the cell lines expressing high levels of FLAG-PADI2 
(Figure 4.11a and b), E-cadherin protein levels were reduced when compared to the 
empty vector control cells (Figure 4.11a). In addition, we see a concomitant increase 
in vimentin in these two cell lines. We examined the FLAG-PADI2 overexpressing 
A431 cells for expression of genes involved in inflammation and EMT, and found the 
results were similar to those seen in the transgenic mice. Both IL6 and IL8 gene levels 
are increased, while we see a reduction in E-cadherin, along with concomitant 
increases in SNAIL and SLUG (Figure 4.11b).  
 Given the data from our transiently transfected A431 cells, along with our data 
from the transgenic mice, we decided to test whether stable overexpression of FLAG-
PADI2 might have an effect on the cellular malignancy and/or invasiveness of A431 
cells. Using both lentiviral transduction of FLAG-PADI2, and traditional transfection, 
we created two stable cell lines overexpressing various levels of PADI2. The lentiviral 
generated stable cell line (pLenti-FLAG-PADI2) is under the control of the 
phosphoglycerate kinase (PGK) promoter, which is weaker than the cytomegalovirus 
promoter used in the pIRES2-FLAG-PADI2 stably transfected cells. After selecting 
for 2-3 weeks, we assayed for PADI2 levels, showing, as expected, that pLenti-FLAG-
PADI2 (pLenti-FP2) had slightly less expression of PADI2 than pIRES2-FLAG-
PADI2 (pIRES-FP2) (Figure 4.12a). Next, we tested the invasive properties of these 
cell lines by measuring their ability to migrate through a collagen matrix. For both cell 
lines, we see a significant increase in cellular migration after 24h, while the pIRES2-
FP2 cell line also has a significant increase after 4h (Figure 4.12b). These results 
suggest that PADI2 dosage might correlate with invasion. Recent evidence from our 
lab suggests that PADI2 can be expressed in the nucleus, as well as the cytoplasm 
10
; 
therefore, we decided to analyze the localization of PADI2 in vitro using indirect- 
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Figure 4.11: Transient overexpression of FLAG-PADI2 increases markers of 
inflammation and EMT in the human squamous cell carcinoma A431 cell line.  
(a) Human squamous cell carcinoma cells, A431, were transiently transfected with 
FLAG-PADI2 (pcDNA3.1-FP2 or pIRES2-FP2) or empty vector (pcDNA3.1-emtpy). 
Western blot analysis of protein expression for EMT markers, E-cadherin and 
vimentin, along with PADI2, was performed on transfected A431 cells. β-actin was 
used as a loading control. Total RNA was isolated and relative PADI2 levels for the 
FLAG-PADI2 transfected A431 cells, relative to empty vector control (ACTB 
normalized), were analyzed by qPCR (SYBR). Additional genes were also analyzed, 
see Table 4.4 for full gene list and primer sequences. Expression levels were analyzed 
using the 2 
-ΔΔ C(t)
 method, and data are expressed as the mean ± SD from three 
independent experiments (* p < 0.05).  
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Figure 4.12: A431 cells stably overexpressing PADI2 have increased invasion 
through a collagen matrix. (a) A431 cells were stably transfected with pIRES2-
FLAG-PADI2 (pIRES2-FP2) or infected with lentivirus expressing FLAG-PADI2-
EGFP (pLenti-FP2). Control vectors only express the EGFP gene (pIRES2-GFP and 
pLenti-GFP). Western blot analysis for PADI2 protein expression levels, β-actin was 
used as a loading control. Total RNA was isolated and relative PADI2 levels for the 
FLAG-PADI2 transfected A431 cells, relative to GFP vector control (ACTB 
normalized), were analyzed by qPCR (SYBR). Expression levels were analyzed using 
the 2 
-ΔΔ C(t)
 method, and data are expressed as the mean ± SD from three independent 
experiments (* p < 0.05). (b) Transwell migration assay through a collagen matrix – 
cells were seeded and allowed to migrate through a collagen matrix. After 4h or 24h, 
cells that migrated were counted under a microscope at 40X magnification.  Data are 
expressed as the mean ± SD from three independent experiments (* p < 0.05). 
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immunofluorescence and confocal microscopy. Interestingly, we show that FLAG-
PADI2 expression is predominantly nuclear in the stable A431-pIRES-FP2 cells 
(Figure 4.13b) compared to empty vector control cells (Figure 4.13a). Both the 
pLenti-FP2 and pIRES2-FP2 plasmids express GFP bicistronically via an internal 
ribosome entry site (IRES); therefore, we show that GFP in the pIRES2-FP2 stable 
cells is predominantly cytoplasmic (Figure 4.13a, iii; and b, iii), indicating different 
localization of the two overexpressed proteins (FLAG-PADI2 and GFP). Finally, we 
wanted to test the stable A431-pIRES2-FP2 cells for any increase in cellular 
malignancy. Assaying for focus formation, we show a significant increase in the 
FLAG-PADI2 overexpressing A431 cells compared to the empty vector control 
(Figure 4.14a). In addition, we show that the morphology of these cells also displays 
an elongated, fibroblast-like shape, indicative of cells that have undergone EMT 
(Figure 4.14b).  
 
4.5 Discussion 
In the present study, we have demonstrated that transgenic mice overexpressing 
PADI2 in the epidermis are sufficient to develop skin lesions that progress to invasive 
squamous cell carcinomas (SCC). Moreover, we have verified these results using the 
human squamous cell carcinoma cell line, A431, in which we stably overexpressed 
PADI2, resulting in the increased invasiveness and malignancy of these cells. 
While PADI2 transgenic expression in the mammary glands was detected, the 
MMTV-FLAG-PADI2 mice failed to develop any mammary tumors. Transgenic mice 
under control of the MMTV-LTR promoter can often have low expression in the 
mammary gland, or only noticeable expression in the mammary glands of lactating or 
multi-parous mice 
27-29
. In addition, the MMTV promoter often becomes 
hypermethylated, and thus silenced 
30
. While we have noted high expression in the  
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Figure 4.13: Co-localization of FLAG and GFP in A431 cells stably 
overexpressing FLAG-PADI2. (a) Confocal immunofluorescence analysis of the co-
localization (iv) of FLAG (red, ii) and GFP (iii) in the nucleus and cytoplasm of A431 
cells expressing the empty vector (pIRES2-GFP) or the FLAG-PADI2 expressing 
vector (b), which has bicistronic expression of both PADI2 and EGFP (pIRES2-GFP-
FLAG-PADI2). Note the nuclear expression of FLAG (PADI2). Nuclei are stained 
with DAPI (blue, i). 
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Figure 4.14: A431 skin cancer cells overexpressing FLAG-PADI2 show increased 
malignancy and EMT morphology. (a) Cells stably overexpressing FLAG-PADI2 
(A431-FP2), or EGFP control (A431-GFP), were grown for 4d in a 6-well plate, fixed 
with 4% PFA, and stained with crystal violet for subsequent analysis of focus 
formation. After imaging, the crystal violet was removed from the cells with 10% 
acetic acid and absorbance levels were measured (600 nM). Data are expressed as the 
mean ± SD from three independent experiments (* p < 0.05). (b) Representative 
morphology of A431 cells overexpressing FLAG-PADI2, showing elongated cells 
with fibroblast-like shape, indicative of cells that have undergone EMT. 
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mammary glands of our transgenic mice, perhaps further analysis of transgenic PADI2 
expression over the life span of the mice might indicate age-related variation in 
expression. Future studies will examine the effectiveness of challenging our MMTV-
FLAG-PADI2 mice, either genetically or chemically, to induce mammary carcinomas. 
Recent research has shown that inflammation plays an important role in the 
development of advanced SCC tumors in mice 
31
. As mentioned previously, numerous 
studies have documented a role for PADI-mediated citrullination in immune diseases 
characterized by inflammation. In addition, we recently identified a new role for 
PADI2 in inflammation, as we found that PADI2-mediated histone tail 
hypercitrullination is important during macrophage extracellular trap (MET) formation 
in inflamed tissues 
32, 33
.  Increasing evidence supports a pro-tumorigenic role for 
immune cells and inflammatory processes, with tumor-promoting inflammation 
recently defined as an emerging hallmark of cancer 
34, 35
. Many inflammatory 
mediators, including cytokines and chemokines, are important for the growth and 
proliferation of pre-malignant cells 
36
. These mediators often activate oncogenic 
transcription factors, such as NFκB and STAT3 37-39. PADI2 has been shown to 
regulate cytokine signaling in macrophages via citrullination of IKKγ, which controls 
NFκB expression activity 40. Furthermore, PADI2 has also been shown to citrullinate 
CXCL8 (IL8) 
41
, again suggesting a role for regulating the inflammatory 
microenvironment of the cancer microenvironment.  
We show here that Il6 and Il8 expression is increased in the skin lesions of 
MMTV-FLAG-PADI2 transgenic mice. These results were also confirmed using the 
A431 cell line overexpressing FLAG-PADI2. Both IL6 and IL8 have been shown to 
be important in the progression of cancer, having a critical role in tumor growth, 
angiogenesis, and EMT 
42-51
. Further work is needed to identify exactly how PADI2 
regulates the expression of these two inflammatory mediators. 
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Lastly, we show that, in addition to increased Il6 and Il8 expression, skin 
lesions in the MMTV-FLAG-PADI2 mice also display increased markers of 
invasiveness and EMT. Furthermore, the A431 cells overexpressing FLAG-PADI2 
show increased invasion through a collagen matrix when compared to control 
transfected cells. Cells undergoing EMT are often at the leading edge of invasive 
tumors that are epithelial in origin. EMT is an important process during normal 
development by which epithelial cells acquire mesenchymal, fibroblast-like properties, 
and show reduced intercellular adhesion and increased motility. Several oncogenic 
pathways have been implicated in EMT, including Src, Ras, Ets, Wnt/β-catenin, as 
well as signaling downstream from the PI3K-AKT-axis resulting from IGF1, TGFβ, 
EGFR, and HER2 activation 
52, 53
. Recently, studies have suggested a variety of 
epigenetic mechanisms may also play a role in EMT 
54
. Interestingly, we have recently 
reported on a role for PADI4 in the progression of breast cancer and EMT, via the 
citrullination of GSK3β, which is known to regulate TGFβ 55. Stadler et al. establish 
that PADI4 serves as a tumor suppressor, with dysregulation of PADI4-mediated 
citrullination of nuclear GSKβ activating TGFβ signaling, thereby inducing EMT in 
breast cancer cells and the production of more invasive tumors in vivo. Interestingly, 
the two representative skin lesions from MMTV-FLAG-PADI2 mice, which express 
the highest levels of transgenic PADI2, have markedly reduced levels of endogenous 
Padi4. Perhaps this indicates cross-talk between PADI2 and Padi4, working in 
opposite fashion to promote tumorigenesis and invasiveness in tumors. Nevertheless, 
the critical molecular feature of EMT is the downregulation of E-cadherin, a cell 
adhesion molecule present in the plasma membrane of most normal epithelial cells. 
This is the earliest event in EMT; however, as the cell progresses from epithelial-like 
to mesenchymal-like cells, they are often accompanied by the increased expression of 
Snail1 (Snai1) and the intermediate filament vimentin. We show here that Snail1 is 
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upregulated in the skin lesions of MMTV-FLAG-PADI2 mice, E-cadherin is reduced, 
and that vimentin levels increase, all indicative of EMT. This molecular evidence 
matches well with the invasive histology of the lesions, as we report that a subset of 
lesions advance to highly invasive squamous cell carcinomas. Snail expression is 
inversely correlated with E-cadherin expression, and has been shown to bind to E-
boxes in the promoter of E-cadherin, directly repressing gene expression via various 
mechanisms 
56, 57
. The most established method of repression is via the recruitment of 
HDAC containing complexes to the E-cadherin promoter, such as the 
Sin3A/HDAC1/HDAC2 complex 
58
. We have already shown that PADI2 can function 
as an epigenetic regulator of genes in breast cancer cells 
11
; however, further work is 
needed to characterize the mechanism behind PADI2 regulation of genes involved in 
both inflammation and EMT. 
 
Conclusions 
These tumors express high levels of transgenic human PADI2 and display markers of 
increased invasiveness (i.e. EMT). Furthermore, a subset of these tumors shows the 
hallmarks of malignant progression from skin lesions to highly invasive squamous cell 
carcinomas. We have also replicated these results in the human squamous cell 
carcinoma cell line, A431. Collectively, these studies provide functional and 
mechanistic evidence establishing PADI2 as a potential novel oncogene in the 
progression of epidermal carcinomas.  
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Table 4.1: Primers for Semi-quantitative RT-PCR 
 
   Primer Name Sequence Amplicon 
mPADI4-gDNA-F CCCACCCTGTGTGAGTTCTT 395bp 
mPADI4-gDNA-R GCCCAGAGCTTCATGTCTTC 
 hPADI2-cds-F ATTGAGATCTCCCTGGATGTG 194bp 
hPADI2-cds-R TCCTTGAGATCTTCCTTGCTG 
 mPADI1-cds-F CGTCTATAGTGATGTGCCCA 219bp 
mPADI1-cds-R CTCCTGTGACTCAAAGTATGAC 
 mPADI2-cds-F CAAGATCCTGTCCAATGAGAG 189bp 
mPADI2-cds-R ATCATGTTCACCATGTTAGGGA 
 mPADI3-cds-F GATTCTTAACAACCAGAGCCT 183bp 
mPADI3-cds-R CAGCATATTCACCAAGTCGG 
 mPADI4-cds-F CTACTCTGACCAAGAAAGCC 193bp 
mPADI4-cds-R ATTTGGACCCATAACTCGCT 
 mGAPDH-cds-F GGGCATCTTGGGCTACAC 209bp 
mGAPDH-cds-R GGTCCAGGGTTTCTTACTCC 
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Table 4.3: Primers for mouse quantitative RT-PCR (SYBR) 
  Primer Name Sequence 
mECAD-F ATCCTCGCCCTGCTGATT 
mECAD-R ACCACCGTTCTCCTCCGTA 
mVIM-F TGCGCCAGCAGTATGAAA 
mVIM-R GCCTCAGAGAGGTCAGCAAA 
mSNAIL-F CTTGTGTCTGCACGACCTGT 
mSNAIL-R CAGGAGAATGGCTTCTCACC 
mCOX2-F GATGCTCTTCCGAGCTGTG 
mCOX2-R GGATTGGAACAGCAAGGATTT 
mGSK3B-F TCCTTATCCCTCCACATGCT 
mGSK3B-R CCACGGTCTCCAGCATTAGT 
mIL6-F GCTACCAAACTGGATATAATCAGGA 
mIL6-R CCAGGTAGCTATGGTACTCCAGAA 
mIL8-F TGCTCAAGGCTGGTCCAT 
mIL8-R GACATCGTAGCTCTTGAGTGTCA 
mKI67-F CAAGAGGAAGTCTCTTGGCACT 
mKI67-R ACTCTTGTTTCCCTGGAGACTG 
mPADI1-F ATGACCCCCAACACTCAGC 
mPADI1-R CGGCCGTGGATATCTGTC 
mPADI2-F GATCCTCATCGGAAGCAGTT 
mPADI2-R AGTCGCGTACCACCTTGG 
mPADI3-F CCCCTAGCAATGACCTCAAC 
mPADI3-R ATAGGCCAGGGGCAAATG 
mPADI4-F TGACCCTACAGGTGAAAGCA 
mPADI4-R GGGTCCATAGTATGAAACTCGAA 
mACTB-F CTAAGGCCAACCGTGAAAAG 
mACTB-R ACCAGAGGCATACAGGGACA 
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Table 4.4: Primers for human quantitative RT-PCR (SYBR) 
  Primer Name Sequence 
hPADI2-F TCTCAGGCCTGGTCTCCAT 
hPADI2-R AAGATGGGAGTCAGGGGAAT 
hECAD-F TGGAGGAATTCTTGCTTTGC 
hECAD-R CGCTCTCCTCCGAAGAAAC 
hVIM-F GGCTCGTCACCTTCGTGAAT 
hVIM-R GAGAAATCCTGCTCTCCTCGC 
hGSK3β-F GACATTTCACCTCAGGAGTGC 
hGSK3β-R GTTAGTCGGGCAGTTGGTGT 
hSNAIL-F GCTGCAGGACTCTAATCCAGA 
hSNAIL-R ATCTCCGGAGGTGGGATG 
hSLUG-F TGGTTGCTTCAAGGACACAT 
hSLUG-R GCAAATGCTCTGTTGCAGTG 
hNFκB-F CTGGCAGCTCTTCTCAAAGC 
hNFκB-R TCCAGGTCATAGAGAGGCTCA 
hRELA-F ACCGCTGCATCCACAGTT 
hRELA-R GATGCGCTGACTGATAGCC 
hCOX2-F GCTTTATGCTGAAGCCCTATGA 
hCOX2-R TCCAACTCTGCAGACATTTCC 
hIL6-F GCCCTGAGAAAGGAGACATGTAA 
hIL6-R TTGTTTTCTGCCAGTGCCTC 
hIL8-F ACTGAGAGTGATTGAGAGTGGAC 
hIL8-R AACCCTCTGCACCCAGTTTTC 
hCCND1-F GAAGATCGTCGCCACCTG 
hCCND1-R GACCTCCTCCTCGCACTTCT 
hKI67-F TTACAAGACTCGGTCCCTGAA 
hKI67-R TTGCTGTTCTGCCTCAGTCTT 
hMYC-F CACCAGCAGCGACTCTGA 
hMYC-R GATCCAGACTCTGACCTTTTGC 
hHRAS-F GGACGAATACGACCCCACTAT 
hHRAS-R TGTCCAACAGGCACGTCTC 
hACTB-F CCAACCGCGAGAAGATGA 
hACTB-R CCAGAGGCGTACAGGGATAG 
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CHAPTER FIVE 
DISCUSSION – SUMMARY AND FUTURE ROLE FOR PADI2 IN 
ONCOGENESIS 
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5.1 Summary of findings 
At the onset of this project, little was known about the function of PADI2 during 
breast cancer progression and metastasis. While PADI2-mediated citrullination has 
been associated with various other diseases (Chapter 1), PADI4 was previously the 
only PADI family member with an established role in the development of cancer. The 
goal of this thesis research was to gain better insight into the potential role for PADI2 
in the progression of breast cancer, elucidate the PADI2-mediated mechanisms during 
tumorigenesis, and validate PADI2 as a novel therapeutic target in vitro and in vivo 
using inhibitors of PADI-mediated activity (citrullination). 
 To meet the first goal, we used an in vitro model of breast cancer progression 
(MCF10AT) to provide us with evidence that PADI2 might be upregulated upon the 
malignant transformation of cells (Chapter 2). Following this, we turned to genomics 
based tools (RNA-seq) to allow us to gain a better perspective of PADI2 expression 
across a large set of breast cancer cells. The value of using global gene expression 
profiling to drive scientific hypotheses cannot be understated. Armed with subtype and 
full transcriptome data for all 57 breast cancer cell lines, we were able to identify that 
PADI2 is highly correlated with luminal (ER-positive) and HER2-positive breast 
cancers. Furthermore, we showed for the first time that PADI2 is potentially a novel 
target for cancer therapy using the PADI-inhibitor Cl-amidine both in vitro and in 
vivo. 
These findings led to additional questions, mainly, what was the functional 
relationship between PADI2 and HER2 in breast cancer. Thus, in Chapter 3, we set 
out to explore whether PADI2 enhances HER2 expression or vice-versa. Interestingly, 
PADI2 appears to function both upstream and downstream of HER2, potentially 
indicating a role in an oncogenic positive-feedback loop with HER2. Previous 
evidence from our lab has shown that PADI2 can act as an ER co-activator via the 
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citrullination of H3R26, so we were curious to see if PADI2 regulates HER2 
expression using the same mechanism. Using both PADI2 shRNA and PADI 
inhibitors, we showed that the reduction of PADI2, as well as the inhibition of PADI2-
mediated citrullination of H3R26 (BB-Cl-amidine), leads to decreased expression of 
HER2. Conversely, HER2 regulation of PADI2 gene expression is most likely 
downstream of PI3K signaling. Using inhibitors for both the MAPK or PI3K 
pathways, which are both downstream of HER2, we showed that PADI2 expression is 
reduced downstream of PI3K-AKT-mTOR signaling. Interestingly, we also noticed 
that using the PADI2 inhibitor BB-Cl-amidine, along with lapatinib, had synergistic 
inhibitory effects on the growth and malignant nature of tumor cells in vitro. 
Currently, PI3K-AKT and mTOR inhibitors are effective therapies for the treatment of 
breast cancer, but they are often plagued by acquired resistance through the 
upregulation of RTK activation (e.g. phosphorylation of HER2) via MAPK-ERK 
signaling 
1
. Surprisingly, we showed that BB-Cl-amidine treatment can also lead to a 
reduction in phosphorylated MAPK (pMAPK), as well as pHER2; thus, relieving the 
RTK-activation seen when cells are treated with the mTOR inhibitor rapamycin. 
Taken together, these results suggest an enhanced role for PADI2 in HER2 expressing 
breast cancers, and that the PADI inhibitor, BB-Cl-amidine, represents a potential 
novel therapy for the treatment of patients with HER2-positive mammary tumors. 
Lastly, we wanted to examine whether PADI2 was sufficient for tumorigenesis 
in vivo, so we decided to generate a transgenic model of human PADI2 overexpression 
under control of the hormone-responsive MMTV-LTR promoter in FVB mice 
(Chapter 4). However, while PADI2 transgenic expression in the mammary glands 
was detected, the MMTV-FLAG-PADI2 mice failed to develop any mammary tumors. 
While expression from the MMTV-LTR promoter is found predominantly in the 
mammary and salivary gland, other tissues have been implicated, including the skin 
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and ovaries 
2, 3
.  Surprisingly, we discovered that 20% of the mice developed skin 
lesions after five months. These tumors expressed high levels of transgenic human 
PADI2 and displayed markers of increased invasiveness (i.e. EMT). Furthermore, a 
subset of these tumors showed the hallmarks of malignant progression to highly 
invasive squamous cell carcinomas. 
Collectively, these studies provide functional and mechanistic evidence 
establishing PADI2 as a potential novel oncogene and target for cancer therapy. 
However, there are still some unanswered questions regarding the molecular 
mechanisms behind this role. Specifically, how does PADI2-mediated citrullination of 
H3R26 lead to the increase of HER2 gene expression? Secondly, is there a role for 
PADI2 at the tumor-stroma interface, perhaps through the enhanced expression of 
markers of inflammation and invasion? Lastly, more work is needed to fully 
understand the role of PADI2 in tumorigenesis in vivo. While the MMTV-FLAG-
PADI2 mouse model is promising, due to the spontaneous development of skin lesions 
in transgenic mice, we would like to investigate whether PADI2 enhances the 
development of tumors in oncogenically challenged mice. The following sections will 
outline several hypotheses and approaches to further explore these questions, 
beginning with our current working model of how PADI2 regulates HER2 expression. 
 
5.2 Model for PADI2-mediated citrullination and regulation of HER2 
Breast cancer is the second most common cancer in women in the US, with ~40,000 
women dying from the disease each year. As covered in chapter 1, approximately 
75% of breast cancers are ER-positive, with anywhere between 15-20% of breast 
cancers positive for HER2 amplification or overexpression 
4
. Between ER and HER2, 
the majority of breast cancers express at least one or both of these markers. While 
there are drugs targeting both of these hormone receptors, about ~30% of patients with 
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ER-positive breast cancers fail to respond to treatments such as tamoxifen; in addition, 
the majority of those patients that do initially respond develop resistance over time 
5
. 
Interestingly, the most commonly documented mechanism of resistance to tamoxifen 
occurs via EGFR and HER2 overexpression 
6-8
. The same problem exists for patients 
with HER2-positive tumors, as greater than 60% of patients fail to respond to 
trastuzumab monotherapy, with initial responders developing resistance within 1 year 
9, 10
. In addition, a significant portion of those patients treated with trastuzumab must 
discontinue treatment because of cardiotoxic side effects, owing to the role of HER2 
receptor signaling in the heart 
11
. This has highlighted the critical need to discover and 
validate novel targets for both ER- and HER2-positive tumors, so that additional 
treatments may be used in combination with, or in the place of, current therapies to 
overcome issues with de novo and acquired resistance. 
 Our previous work has established a role for PADI2 as an epigenetic regulator 
of ER-target gene expression in breast cancer cells, but our recent evidence, presented 
here, establishes a role for PADI2 in the expression of the HER2 oncogene. We show 
that PADI2 strongly binds the HER2 proximal promoter (ETS region), in addition to 
the recently characterized ERE located downstream in intron 4 
12
. In the presence of 
the PADI inhibitor, BB-Cl-amidine, we see a dose-dependent reduction in HER2 
protein and mRNA. We also see the reduction of HER2 protein and mRNA in cells 
that were stably transfected with shRNA for PADI2. Furthermore, there was also a 
concomitant reduction in the growth and malignant progression of these cells upon 
inhibition/knockdown of PADI2. It is interesting to speculate how PADI2 can function 
both as an ER and HER2 cofactor, especially with regard to mammary tumorigenesis. 
Previous evidence suggests that histone acetylation and phosphorylation play key roles 
in inducing HER2 expression 
13
, and we have previously shown that histone 
citrullination enhances histone acetylation and vice-versa 
14
. Therefore, using what we 
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know about PADI2 as a co-activator of ER target genes, we can hypothesize that 
HER2 gene expression might work in the same fashion. Recent evidence from our lab 
using in vitro biochemical assays with bulk histones revealed that the H3Cit26 
modification was found only on peptides that contained acetylated H3K27 (H3K27ac); 
thus, suggesting that H3K237ac enhances PADI2-mediated H3R26 citrullination 
15
.  
ER is known to associate with a number of multi-protein complexes (see Chapter 1), 
including: heat shock proteins (HSPs) 
16
, steroid receptor co-activators (SRCs) 
17
, 
p300-containing co-activator complexes 
18
, and HDAC containing co-repressor 
complexes 
19
. The p300 co-activator is known to have intrinsic histone 
acetyltransferase (HAT) activity, which helps to relax the chromatin structure at gene 
promoters, leading to gene activation. Studies have shown that p300 can function as an 
ER co-activator, and is required for acetylation at H3K27 
18
. This supports our 
hypothesis that ER uses p300-mediated H3K27 acetylation and PADI2-mediated 
H3R26 citrullination to promote chromatin decondensation, allowing for the binding 
of ER and associated co-factors (i.e. SRC or AIB1) to EREs and enhancing gene 
transcription (Figure 5.1a). Previous studies have shown that ER binds poorly to 
nucleosomal DNA in vitro 
20
; based on this and additional studies 
21, 22
, we predict that 
this is due to H3 tail occluding ER binding to the ERE, due to electrostatic interactions 
with DNA (Figure 5.1b). Recent work has shown that p300 and H3K27ac are 
enriched at active enhancers and ER binding sites 
23
. We predict that ER recruits p300 
(HAT) to acetylate H3K27, which weakens the H3 tail-DNA binding, allowing for 
weak binding of ER to the ERE (Figure 5.1c). Based on our previous findings by 
Zhang et al., we suggest that ER then recruits PADI2 (Figure 5.1d), which 
subsequently citrullinates H3R26, further weakening the interaction and allowing for 
stable ER binding to nucleosomal ERE (Figure 5.1e). Future experiments in our lab  
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Figure 5.1: PADI2-mediated citrullination of histone H3 arginine 26 (H3R26) 
yields the citrulline modification (H3Cit26), which can have an effect on ER 
nucleosomal ERE binding. (a) Our working model predicts that acetylation of H3 
lysine 27 (H3K27) by p300 promotes PADI2-mediated citrullination of H3R26; thus, 
weakening H3 tail-DNA interaction and allowing for binding of ER to nucleosomal 
EREs. (b) H3 tail (red) blocks the ER binding to ERE. (c) ER recruits HAT to 
acetylate (Ac) H3K27, partially weakening H3 tail-DNA binding. (d) ER then recruits 
PADI2 to citrullinate H3R26 (Cit), further weakening interaction and allowing for 
stable ER binding to nucleosomal ERE (e). 
  
242 
 
 
  
243 
 
will help to elucidate whether HER2 expression may be regulated by “cross-talk” 
between PADI2-catalyzed histone citrullination and histone acetylation and/or 
phosphorylation via similar mechanisms. To examine whether p300-mediated H3K27 
acetylation is necessary for the H3Cit26 modification, we can perform estrogen (E2) 
stimulation experiments on MCF7 cells (and/or BT474 for HER2 studies) that have 
been stably transfected with shRNA targeting p300. Conversely, we can test whether 
we see an increase in H3Cit26 levels with H3R27ac by treating MCF7 cells with the 
HDAC inhibitor TSA, then measuring H3Cit26 levels in E2 stimulated cells versus 
control. As previously outlined, PADI2 can act as an ER co-activator via PADI-
mediated citrullination of H3R26, leading to the upregulation of ER-target genes 
(Figure 5.2a). Similarly, we predict that either ER, or potentially other ER co-factors 
such as AIB1 or SRC1, will recruit PADI2 to the downstream ERE, thus promoting 
activation of HER2 via the citrullination of H3R26 (Figure 5.2b). We can assess the 
relative importance of these genes by first performing standard siRNA experiments, or 
potentially shRNA for stable cell lines. Preliminary evidence suggests that siRNA of 
ER reduces PADI2 expression, but whether this has any effect on HER2 expression or 
H3Cit26 levels remains to be investigated. Alternatively, PADI2 may activate HER2 
expression by functioning as an ETS co-factor (e.g. PEA3), thereby enhancing HER2 
transcription. PEA3 is a well-known ETS co-factor and transcriptional activator of 
HER2 
24, 25
, and the primers used for detecting PADI2 at the HER2 promoter are 
within the known PEA3 binding site.               
We have shown conclusively using both molecular genetics (PADI2-KD) and 
pharmacological inhibition (BB-Cl-amidine), that the absence of PADI2 leads to 
decreased transcription of HER2, as well as downstream genes (Figure 5.2c). More 
work is needed to elucidate these mechanisms, including testing whether PADI2 
overexpression can drive HER2 expression using the HER2 promoter luciferase- 
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Figure 5.2: PADI2 appears to be a transcriptional co-activator of both ER target 
gene and HER2 expression using the same mechanism. (a) PADI2-mediated 
citrullination of H3R26 leads to the upregulation of ER-target genes. (b) It is predicted 
that either ER or additional ETS factors (e.g. PEA3) will recruit PADI2 to known ETS 
binding elements on the HER2 promoter, leading to H3Cit26 promoted acetylation and 
subsequent activation of HER2 transcription. (c) Using both the genetic knockdown 
and pharmacological inhibition of PADI2, we have shown that the absence of PADI2 
leads to decreased transcription of HER2, as well as downstream genes. 
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reporter plasmid (pNeuLite) 
26
. This should help clarify whether PADI2 binding to the 
promoter is sufficient to drive HER2 expression; however, previous evidence from 
studies of PEA3 indicates that these results might be contradictory 
26
. In addition, it 
would be interesting to identify additional genes that might serve as co-regulators of 
the PADI2-HER2 oncogenic loop using genomics based approaches. Based on our 
results presented here, and previous links between PADI2 and inflammation, 
cytokines IL6 and IL8 are great candidates. 
 
5.3 PADI2 involvement in inflammation and EMT  
As mentioned previously, numerous studies have documented the role of PADIs and 
increased citrullination in immune diseases characterized by inflammation (Chapter 
1). In addition, the PADI inhibitor Cl-amidine has also been shown to reduce the 
inflammatory symptoms in mouse models of colitis and RA 
27
. Recently, a new link 
between PADIs and inflammation has been established, implicating a role for PADI4 
and PADI2 in catalyzing histone tail hypercitrullination during NET formation and 
MET formation, respectively, in inflamed tissues 
28, 29
. PADIs also play a role in the 
citrullination of various genes involved in inflammatory diseases; for example, the 
citrullination of vimentin has been shown to correlate with the proliferation of 
fibroblast-like synoviocytes (from patients with RA), thereby stimulating TNFα and 
IL1 production in these cells 
30
. Interestingly, the citrullination of vimentin, in addition 
to promoting an inflammatory microenvironment, might also have implications in 
tumor cell migration. Increasing evidence supports a pro-tumorigenic role for immune 
cells and inflammatory processes, with tumor-promoting inflammation being defined 
as an emerging hallmark of cancer 
31, 32
. Many inflammatory mediators (e.g. 
cytokines/chemokines) are important for the growth and proliferation of pre-malignant 
cells 
33
. These mediators often activate oncogenic transcription factors, such as NFκB 
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and STAT3 
34-36
. Conversely, HER family signaling, and oncogenes such as Ras and 
Myc, can initiate an inflammatory response 
32, 37-39
. Downstream signaling from these 
various pathways leads to the induction of an inflammatory loop; thus, setting the 
stage for further recruitment of factors involved in cancer cell survival, proliferation, 
invasiveness (EMT), and eventual metastasis (Figure 5.3). PADI family members 
have previously been shown to promote the inflammatory microenvironment, as 
PADI2 can regulate cytokine signaling in macrophages via citrullination of IKKγ, 
which controls NFκB expression activity 40. Furthermore, PADI2 has also been shown 
to citrullinate CXCL8 (IL8) 
41
, again suggesting a role for regulating the inflammatory 
milieu of the cancer microenvironment.  
We have shown using MMTV-FLAG-PADI2 mice that Il6 and Il8 expression 
are both increased in the skin lesions of mice. This relationship between PADI2-driven 
tumors and IL6-IL8 upregulation was confirmed in the squamous cell carcinoma cell 
line, A431, that was stably transfected with FLAG-tagged PADI2 (A431-FP2). Both 
IL6 and IL8 have been shown to be important in the progression of cancer, having a 
critical role in tumor growth, angiogenesis, and EMT 
37-39, 42-48
. Further work is needed 
to identify exactly how PADI2 regulates the expression of these two inflammatory 
mediators. Future experiments will use ChIP to examine whether PADI2 binds to 
either gene’s promoter; in addition, co-immunoprecipitation (Co-IP) will help examine 
whether there are any protein-protein interactions.  Interestingly, while we see PADI2 
upregulation increases IL6 and IL8 transcription in skin cancer, we see the opposite 
effect in breast cancer cells. The highly invasive MCF10DCIS cell line and the 
luminal B BT474 cell line show the upregulation of both IL6 and IL8 transcription 
when PADI2 is stably knocked-downed via shRNA. However, this effect is less 
pronounced (or lost) when cell lines were treated with BB-Cl-amidine. Since BB-Cl-
amidine is a pan-PADI inhibitor, the targeting of additional PADIs might explain this  
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Figure 5.3: Tumor-promoting inflammation is an emerging hallmark of cancer. 
Inflammation may contribute to tumor initiation via the release of signaling molecules 
such as EGF, VEGF, and other proangiogenic factors. In addition, the production of 
cytokines and chemokines enhance the inflammatory state, which helps to facilitate 
cancer cell survival, proliferation, and invasiveness (via EMT). (Figure adapted from 
Genentech, via Grivennikov and Karin, Current. Opinion. in Gen. & Dev., 2010 
49
) 
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discrepancy. Supporting this hypothesis, we see a 2-fold induction of IL6 and IL8 in 
BT474 cells upon BB-Cl-amidine treatment, which might be explained by the fact that 
this cell line predominantly expresses the PADI2 isozyme (data not shown). In 
contrast, MCF10DCIS cells, which also express PADI1 and PADI3 (data not shown), 
show a reduction in IL6 and IL8 when we treat with BB-Cl-amidine. Previous studies 
have shown that activation of inflammatory loops can occur upon treatment with 
drugs, as the development of trastuzumab resistance often occurs as a result of the 
concomitant upregulation of IL6. In addition, the tumor drug taxol (paclitaxel), which 
has also been shown to be a moderate PADI inhibitor 
50
, leads to the transcriptional 
activation of IL8 in both human ovarian and lung carcinoma cell lines 
51-53
. 
Interestingly, Lee et al. show that this increase in IL8 actually plays a role in reducing 
the rate of tumor growth in vivo, most likely mediated by increased neutrophil 
infiltration 
54
. Further work is needed to elucidate the pathways involved in PADI2 
regulation of IL6 and IL8 expression. 
In the PADI2 overexpressing mice, we show that, in addition to increased Il6 
and Il8 expression, transgenic skin lesions also display markers of invasiveness and 
EMT. Furthermore, A431-FP2 cells show increased invasion through a collagen 
matrix when compared to control transfected cells. Cells undergoing EMT are often at 
the leading edge of invasive tumors that are epithelial in origin. EMT is an important 
process during normal development by which epithelial cells acquire mesenchymal, 
fibroblast-like properties, and show reduced intercellular adhesion and increased 
motility (Figure 5.4). Several oncogenic pathways have been implicated in EMT, 
including Src, Ras, Ets, Wnt/β-catenin, as well as signaling downstream from the 
PI3K-AKT-axis resulting from IGF1, as well as TGFβ, EGFR, and HER2 activation 
55, 56
. Recently, studies have suggested a variety of epigenetic mechanisms may also 
play a role in EMT 
57
. Nevertheless, the critical molecular feature of EMT is the  
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Figure 5.4: Overview of epithelial to mesenchymal transition (EMT). Epithelial-
to-mesenchymal transition (EMT) describes a series of molecular and morphologic 
changes that occur in epithelial cells. During EMT, normal polarized epithelial cells 
undergo a functional transition into more fibroblastic-like mobile/invasive 
mesenchymal cells. The common markers for each stage are listed. E-cadherin 
expression is usually the first to be downregulated during this transition, while 
Vimentin expression is upregulated. Snail and Slug, which bind to E-boxes in the 
promoter of E-cadherin leading to direct repression, are also upregulated. This process 
is usually accompanied by the loss/degradation of the basement membrane, allowing 
for distant site metastasis of tumor cells. 
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downregulation of E-cadherin, a cell adhesion molecular present in the plasma 
membrane of most normal epithelial cells. Reduced E-cadherin expression in breast 
cancer often correlates with poor differentiation, increased invasiveness, aggressive 
metastatic behavior, and an unfavorable prognosis 
58-60
. This is the earliest event in 
EMT, though as the cell progresses from epithelial-like to mesenchymal-like cells, 
they are often accompanied by the increased expression of Snail1 (Snai1) and 
Snail2/Slug (Slug), the intermediate filament vimentin, and the eventual degradation 
of the basement membrane by proteases (MMPs) 
61
. We show that Snail1 is 
upregulated in the skin lesions of MMTV-FLAG-PADI2 mice, E-cadherin is reduced, 
and that vimentin levels increase, all indicative of EMT. This molecular evidence 
matches well with the invasive histology of the lesions, as some lesions advance to 
highly invasive squamous cell carcinomas. Snail and Slug are inversely correlated 
with E-cadherin expression, as both have been shown to bind to E-boxes in the 
promoter of E-cadherin, directly repressing gene expression via various mechanisms 
62, 63
. The most established method of repression is via the recruitment of HDAC 
containing complexes to the E-cadherin promoter, such as the Sin3A/HDAC1/HDAC2 
complex 
64
. Further work will be needed to characterize the mechanism that PADI2 
regulates EMT. The first experiment should look at whether PADI2 directly binds the 
E-cadherin promoter to regulate transcription, in addition to looking at both Snail and 
Slug. The stable A431-FLAG-PADI2 (A431-FP2) cell line could be effectively used 
to analyze chromatin binding of PADI2, as well as H3Cit26, to see whether potential 
gene regulation occurs via the same mechanism as HER2 and ER-target genes. In 
addition, it would be interesting to evaluate the transcriptomic differences between 
these two cell lines, to gain a better idea of what genes are involved in PADI2-
mediated oncogenesis. With regard to PADI2 overexpression in breast cancer, various 
animal models could be used to analyze what effect PADI2 has on the invasiveness of 
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tumors in vivo. Stadler et al. have shown that PADI4 knockdown in xenografted 
MCF7 breast cancer cells leads to an increase in tumor invasiveness and associated 
EMT markers via the citrullination of GSK3β, which subsequently activates TGFβ 
signaling. Alternatively, we could use the MCF10DCIS cells, which are known to 
recapitulate invasive comedo-DCIS cancers when xenografted into nude mice. 
Preliminary evidence shows that when we knockdown PADI2, E-cadherin is 
upregulated and cellular migration is decreased in MCF10DCIS cells. Again, this 
suggests a direct relationship between PADI2 and E-cadherin expression. The 
xenografted MCF10DCIS tumors would provide a valuable model to further 
investigate this relationship. It would also be of interest to cross our MMTV-FLAG-
PADI2 mice, in addition to our recently acquired PADI2
-/- 
mice, to known mouse 
models of breast cancer (e.g. MMTV-neu) to see whether these tumors show 
increased/decreased invasiveness based on PADI2 gene dosage. While the MMTV-
FLAG-PADI2 mouse model is imperfect, genetic crosses might prove valuable in 
delineating a role for PADI2 in the progression of cancer.  
 
5.4 Reflections on PADI2 transgenic mouse – can it be improved? 
Genetic crosses can help to bring out phenotypes in transgenic mice that might not 
have been evident during the initial evaluation. However, generating double transgenic 
mice is both time consuming and expensive. The simplest method of evaluating 
modifying factors (i.e. your transgene of interest) in the study of molecular 
carcinogenesis is via chemical carcinogenesis. Mammary tumors in rodents can be 
produced following the administration of DMBA (7,12-dimethylbenz[a]anthracene) 
by oral gavage, which usually results in the activation of oncogenes, most frequently 
hRas 
65, 66
. Other genes have been shown to be upregulated upon treatment with 
DMBA, including the aryl hydrocarbon receptor (AhR), as well as cyclin D1 and c-
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Myc, and hyperphosphorylated pRb 
67
. Transgenic mice under control of the MMTV-
LTR promoter can often have low expression in the mammary gland, or only 
noticeable expression in the mammary glands of lactating or multi-parous mice 
68-70
. 
Another study has suggested that this is due to the MMTV promoter often becoming 
hypermethylated, and thus silenced 
71
. Interestingly, this study employed the chemical 
carcinogen normally used for generating mammary carcinomas in rats, NMU (N-
methyl-N-nitrosourea), to generate tumors in the MMTV-neu (unactivated) mouse. 
Since global hypomethylation is a normal event found in the early stage of breast 
cancer development 
72, it is possible this result was a “side-effect” of using the 
chemical carcinogen. However, this reinforces the value of chemical carcinogens in 
the promotion of tumors in genetically modified mouse models lacking an observable 
phenotype. We have currently started the DMBA treatment of MMTV-FLAG-PADI2 
mice via oral gavage using the experimental design detailed in Table 5.1. Preliminary 
results look promising; however, more time is needed to determine whether the 
transgenic mice have any increase in tumor burden or latency, or any change in 
morphology (e.g. increased clinically invasive features). 
 Research has shown that squamous cell carcinomas (SCCs), which are 
responsible for the majority of non-melanoma skin cancer related deaths, are the result 
of accumulating genetic alterations 
73
. Understanding the role these genetic lesions 
play in the etiology of skin cancer is essential for designing improved therapies for 
cancer treatment and prevention.  This is where the full potential of our MMTV-
FLAG-PADI2 mice, within which a subset of skin lesions develops to SCC, can be 
realized. However, the current problem is that only 20% of our mice show the 
phenotype of skin lesions, and only a proportion of those develop to fully invasive 
SCCs. The need to examine these tumors on an alternative background, whether 
genetic or chemically manipulated, cannot be understated. More than 50% of human 
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cutaneous SCCs carry mutations in the p53 gene, most of which are missense 
mutations resulting in the change of a single amino acid and expression of altered 
forms of p53 
74
. Transgenic mice with this mutant p53 allele have been shown to 
develop normally, without any obvious epidermal phenotype or development of 
spontaneous tumors. However, these mice demonstrate an increased susceptibility to 
the two-stage chemical carcinogenesis protocol, with both an increase in the rate and 
number of papillomas compared to wild-type controls 
75
. Since it is likely that the 
MMTV-FLAG-PADI2 mice need additional mutations to promote oncogenesis, 
crossbreeding experiments with mice such as the p53 mutant, or potentially mutant 
hRas and/or kRas mice, would offer a unique opportunity to test this hypothesis.  
Several mouse models have previously documented that overexpression of oncogenic 
hRas or kRas in the skin can induce tumor formation 
76-80
. The Ras oncogene is also 
often mutated in SCCs (10%–30% of human skin SCCs) 80, 81, and as previously 
mentioned, activating Ras mutations can be induced by DMBA, which is the initiating 
event of the two-step chemical carcinogenesis protocol. Mice subjected to chemical 
carcinogenesis protocols by initiation with DMBA and tumor promotion with 12-O-
tetradecanoylphorbol-13-acetate (TPA) develop skin tumors that exhibit hRas 
mutations in more than 90% of the cases 
82, 83
. Our MMTV-FLAG-PADI2 mice are on 
the FVB background, which is known to be highly sensitive to chemical induction 
with DMBA 
84
. A description of the general protocol can be found in Table 5.1, while 
an overview of the procedure and expected results is detailed in Figure 5.5. Briefly, 
the initiation stage occurs with the chemical carcinogen DMBA, which is applied 
topically to the mice. The hRas gene is the primary target of DMBA, with activating 
mutations (A182T transversion in codon 61 of the HRAS1 gene), detectable in mice as 
early as 3-4 weeks 
85, 86
. About 1-2 weeks after the initiation stage, the mutated cells 
are promoted with TPA to clonally expand the mutated cells. The topical application  
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Table 5.1: Challenge of MMTV-FLAG-PADI2 mice with DMBA or DMBA/TPA 
Experimental 
Groups 
Wild type and PADI2-Tg mice (n=20); Wild type and PADI2-
KO mice (n=20); Vehicle control (n=10).  
 
Method Mammary tumorigenesis – DMBA Oral gavage (1 mg/wk. for 6 
weeks), Tumors arise in 15-18 wks. after first treatment.  
(DMBA = 7,12-dimethylbenz[a]anthracene) 
 
Cutaneous tumorigenesis – DMBA/TPA treatment  
(DMBA - 200 nmol over 3X3 mm shaved area; TPA – 7 days 
post DMBA, 17 nmol, 3 times a week for 20 weeks). 
 
Evaluation Number of tumors developed (e.g. # papillomas from 
DMBA/TPA), size, histopathology features.  
 
Expected Results PADI2 transgenic mice will develop a higher tumor load with 
more invasive clinical features.  
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Figure 5.5: Two-stage model of skin carcinogenesis in mice. Initiation occurs with 
the topical application of a sub-carcinogenic dose of a mutagenic agent, in this case 
DMBA (7,12-dimethylbenz[a]anthracene). DMBA has been shown to induce 
mutations in target genes in keratinocyte stem cells (e.g. hRas and kRas). Following 
initiation (generally 1-2 weeks after), repeated topical application of a tumor 
promoting agent, such as the phorbol ester, 12-O-tetradecanoylphorbol-13-acetate 
(TPA) continue weekly (2-3X) until the end of the study, which is usually anywhere 
between 20-50 weeks after initiation. Papillomas begin to arise ~6-12 weeks of 
promotion with TPA, with a subset advancing to squamous cell carcinomas (SCC) 
after ~20 weeks. Representative H&E stained sections of normal and hyperplastic 
skin, a papilloma, and SCC. The two-stage skin carcinogenesis protocol allows for the 
evaluation of genes (e.g. PADI2) and cell-signaling pathways involved in the 
progression of tumors. (Figure obtained from Abel et al., Nat. Protocols, 2009 
87
) 
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of TPA leads to sustained epidermal hyperplasia, stimulating an increase in cellular 
signaling, production of growth factors, oxidative stress, and tissue inflammation 
88
. 
Papillomas generally appear in all of the mice within ~6-12 weeks following initiation, 
with a subset progressing to invasive SCCs in as early as 20 weeks. The percentage of 
mice that progress to SCC depends on a number of factors, including DMBA and TPA 
dosage, as well as genetic background 
84, 89
. Up to 50% of papillomas in mice on the 
FVB background may progress to SCC 
84
. This is especially important to our research, 
as we are interested in the role of PADI2 signaling in the progression of lesions to 
SCC, so the prediction is that we see an increase in the number of SCCs in the treated 
transgenic mice versus wild-type control. Preliminary results look promising, as we 
currently see a statistically significant increase in the number of papillomas in the 
treated transgenic mice compared to wild-type controls. However, more time will need 
to elapse before a full analysis of the data can confirm these initial results. The two-
stage skin carcinogenesis model is often cited as recapitulating the natural progression 
of cancer, where the slow accumulation of mutations occurs before tumor formation. 
While we are currently using this model to test whether PADI2 acts as a genetic 
modifier or proto-oncogene in tumor progression, it could potentially be used to 
evaluate the effectiveness of therapeutic agents, such as our PADI inhibitors. For 
example, previous research has shown that the mTOR inhibitor, rapamycin, was 
successful in causing the regression of carcinogen-induced skin tumor lesions 
90
.  
 Taken together, there are many available options, both genetically and 
experimentally, to improve upon our MMTV-FLAG-PADI2 transgenic mouse. We 
have postulated placing the FLAG-PADI2 gene under the control of different 
promoters, including the ubiquitous CAG (CMV early enhancer/chicken β-actin) 
promoter, to fully evaluate the potential role for PADI2 as an oncogene in all tissues. 
The current working plan was to clone FLAG-PADI2 into a two different bicistronic 
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vectors, both expressing a reporter construct containing the coding sequence for a 
either a membrane localized red fluorescent protein (Myr-TdTomato), or a nuclear 
localized green fluorescent protein (H2B-GFP), separated by a 2A sequence 
91
. The 
use of 2A peptides has emerged as an attractive alternative to the internal ribosomal 
entry site (IRES), resulting in the cotranslational 'cleavage' of the two proteins in a 
transgene, and leading to bicistronic expression of both proteins at equimolar levels. 
To gain a better view at tissue-specific expression of PADI2, and to further evaluate 
the role of PADI-driven carcinogenesis in the skin, we have planned to express PADI2 
under the control of promoters specific to the basal layer of epidermis in mice. The 
mammalian keratin-14 (K14) and keratin-4 (K5) promoters have been extensively 
used to drive expression of transgenes in the epidermis of mice 
92, 93
, and are both 
potential options. However, much more work on the DMBA treated mice is needed 
before we move onto this next stage. Regardless, we currently have an abundance of 
evidence linking PADI2 to the oncogenesis of mouse epidermis. 
 
5.5 Linking it all together – summary of PADI2 involvement in cancer 
The objective of these studies was to gain insight into the potential function of PADI2 
in the progression of breast cancer. This thesis has advanced our understanding of 
PADI2 biology, while establishing a role for PADI2 as a novel oncogene and 
therapeutic target of cancer therapy (an overview of the potential functions of PADI2 
in cancer, as described from experimental evidence offered in this thesis, is reviewed 
in Figure 5.6). We show here, for the first time, that PADI2 is capable of transforming 
epithelial cells both in vitro and in vivo. In addition, we have the ability to specifically 
block the growth of these transformed cells, in addition to other carcinomas, with 
PADI inhibitors. While previous work has shown that PADI2-mediated citrullination 
of H3R26 plays a pivotal role in ER-target gene activation, we show here that this co- 
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Figure 5.6: Overview of the potential role of PADI2 in cancer pathogenesis. This 
body of work has shown that PADI2 can play a role in the progression of breast cancer 
through regulation at gene promoters via the citrullination of H3 arginine 26 (H3R26). 
This leads to chromatin decondensation, and ultimately the upregulation of both ER-
target genes and HER2. These two pathways are known to be important in the 
neoplastic transformation of mammary epithelial tissue. Using the MMTV-FLAG-
PADI2 mouse, we have also shown PADI2 expression to have an effect on the tumor 
microenvironment, either through the upregulation of pro-inflammatory genes (e.g. 
IL6/IL8) or increased invasiveness due to the alteration of known EMT markers (e.g. 
E-cadherin). (Adapted from Qiagen) 
  
261 
 
 
  
262 
 
activator function extends to the HER2 oncogene via the same mechanism. Using 
molecular genetics, we have discovered that PADI2 operates both upstream and 
downstream of HER2 signaling, potentially functioning as part of an oncogenic 
positive-feedback loop. In addition, we show that the PADI inhibitor, BB-Cl-amidine, 
is a powerful next-generation small molecule drug that blocks tumor growth at near-
nanomolar levels. Furthermore, we show a synergistic effect for BB-Cl-amidine in the 
treatment of HER2-positive breast cancers when used in conjunction with the dual 
EGFR/HER2 inhibitor, lapatinib. Given the role of PADI2 in ER- and HER2-positive 
tumors, PADI2 inhibitors may have therapeutic value for over 85% of all breast 
cancers, thus potentially benefiting a large majority of patients. Lastly, we show 
evidence that PADI2 expression is sufficient to drive oncogenic transformation in the 
murine epidermis, as ~20% of MMTV-FLAG-PADI2 transgenic mice develop skin 
lesions. Moreover, a subset of these lesions expresses markers of inflammation and 
EMT, having progressed to highly invasive squamous cell carcinomas. The knowledge 
gained from MMTV-FLAG-PADI2 mice further extends the reach of PADI2 as an 
oncogene to additional organ systems, and paves the way for future studies.  
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